@NP	ÔªøOlfactory Ensheathing Cell Transplantation	1
@NP	a Complete Spinal Cord Transection	53
@NP	Neuroprotective and Immunomodulatory Mechanisms	97
@NP	Regeneration Multiple neural	159
@NP	Regeneration	159
@NP	peripheral cell types	193
@NP	tissue damage after spinal cord injury	234
@NP	tissue damage	234
@NP	spinal cord injury	254
@NP	a structurally and chemically inhibitory scar that limits axon regeneration	281
@NP	a structurally and chemically inhibitory scar	281
@NP	axon regeneration	339
@NP	Astrocytes	358
@NP	an astroglial scar	374
@NP	chondroitin sulfate proteoglycans -LRB- CSPGs -RRB-	405
@NP	chondroitin sulfate proteoglycans	405
@NP	CSPGs	440
@NP	microglia	457
@NP	blood-derived immune cells	480
@NP	the lesion for debris removal	510
@NP	the lesion	510
@NP	debris removal	525
@NP	One beneficial therapy	541
@NP	olfactory ensheathing cell -LRB- OEC -RRB- transplantation	565
@NP	olfactory ensheathing cell	565
@NP	OEC	593
@NP	transplantation	598
@NP	functional improvements	626
@NP	axon regeneration	663
@NP	spinal cord injury	687
@NP	The lack of an OEC-specific marker	707
@NP	The lack	707
@NP	an OEC-specific marker	719
@NP	the investigation of mechanisms underlying their proregenerative effects	764
@NP	the investigation	764
@NP	mechanisms underlying their proregenerative effects	785
@NP	mechanisms	785
@NP	their proregenerative effects	807
@NP	We	838
@NP	the effects of enhanced green fluorescent protein-labeled fibroblast	850
@NP	the effects	850
@NP	enhanced green fluorescent protein-labeled fibroblast	865
@NP	FB	920
@NP	OEC transplants	928
@NP	a complete low-thoracic spinal cord transection	958
@NP	the preservation	1031
@NP	neurons and serotonergic axons	1051
@NP	neurons	1051
@NP	serotonergic axons	1063
@NP	the levels of inhibitory CSPGs and myelin debris	1083
@NP	the levels	1083
@NP	inhibitory CSPGs and myelin debris	1097
@NP	inhibitory CSPGs	1097
@NP	myelin debris	1118
@NP	the extent of immune cell activation between 1 and 8	1137
@NP	the extent	1137
@NP	immune cell activation between 1 and 8	1151
@NP	immune cell activation	1151
@NP	1 and 8	1182
@NP	Our findings	1208
@NP	OECs	1235
@NP	FBs post-transplantation	1260
@NP	FBs	1260
@NP	axons and neurons	1295
@NP	inhibitory molecules	1325
@NP	the lesion core	1349
@NP	we	1380
@NP	OECs	1393
@NP	immune-cell activation and infiltration	1404
@NP	FBs	1453
@NP	astroglial scar formation and increase immune-cell infiltration	1463
@NP	concomitant secondary tissue damage	1531
@NP	Administration of cyclosporine-A to enhance graft survival	1568
@NP	Administration	1568
@NP	cyclosporine-A to enhance graft survival	1586
@NP	graft survival	1612
@NP	immune suppression	1645
@NP	OEC contact-mediated protection of axons and neurons	1676
@NP	OEC contact-mediated protection	1676
@NP	axons and neurons	1711
@NP	the first 2 weeks postinjury	1736
@NP	these data	1780
@NP	OECs	1804
@NP	neuroprotective and immunomodulatory mechanisms	1814
@NP	a supportive environment for neuronal survival and axon regeneration	1874
@NP	a supportive environment	1874
@NP	neuronal survival and axon regeneration	1903
@NP	spinal cord injury	1949
@NP	Significance Statement Spinal cord injury	1970
@NP	Significance Statement	1970
@NP	Spinal cord injury	1993
@NP	physical and chemical barriers	2020
@NP	a complete spinal cord transection model and olfactory ensheathing cell	2079
@NP	OEC	2152
@NP	fibroblast -LRB- FB ; control -RRB-	2160
@NP	fibroblast	2160
@NP	FB ; control	2172
@NP	FB	2172
@NP	control	2176
@NP	transplantation as a repair strategy	2185
@NP	transplantation	2185
@NP	a repair strategy	2204
@NP	OECs , but not FBs , intermingled with astrocytes ,	2223
@NP	OECs	2223
@NP	FBs , intermingled with astrocytes	2237
@NP	FBs	2237
@NP	astrocytes	2260
@NP	astroglial scar border formation and sequestered	2284
@NP	astroglial scar border formation	2284
@NP	sequestered	2321
@NP	peripheral cells	2342
@NP	OECs	2360
@NP	immune cell infiltration	2376
@NP	secondary tissue damage	2410
@NP	neurons and axons	2445
@NP	the lesion core	2466
@NP	clear myelin debris	2494
@NP	Immunosuppression	2515
@NP	survival of OECs and FBs	2542
@NP	survival	2542
@NP	OECs and FBs	2554
@NP	OEC transplantation	2577
@NP	scaffold formation	2606
@NP	the lesion site that facilitated axon regeneration and neuron preservation	2628
@NP	the lesion site	2628
@NP	axon regeneration and neuron preservation	2661
@NP	axon regeneration	2661
@NP	neuron preservation	2683
@NP	Introduction	2705
@NP	The regenerative capacity	2718
@NP	adult mammalian neurons	2747
@NP	injury	2777
@NP	astroglial scar formation	2798
@NP	inhibitory myelinassociated proteins	2825
@NP	chondroitin sulfate proteoglycan -LRB- CSPG -RRB- deposition	2863
@NP	chondroitin sulfate proteoglycan	2863
@NP	CSPG	2897
@NP	deposition	2903
@NP	inflammatory cell activation	2919
@NP	a nonpermissive environment and minimal functional recovery	2976
@NP	a nonpermissive environment	2976
@NP	minimal functional recovery	3008
@NP	Reier	3037
@NP	Houle , 1988	3047
@NP	Houle	3047
@NP	1988	3054
@NP	Fitch et al. , 1999	3060
@NP	Fitch	3060
@NP	et al. , 1999	3066
@NP	et al.	3066
@NP	1999	3074
@NP	Fitch and Silver , 2008	3080
@NP	Fitch and Silver	3080
@NP	2008	3098
@NP	Buss et al. , 2009 ; Hu et al. ,	3104
@NP	Buss	3104
@NP	et al. , 2009 ; Hu et al. ,	3109
@NP	et al.	3109
@NP	2009 ; Hu et al.	3117
@NP	2009	3117
@NP	Hu et al.	3123
@NP	Hu	3123
@NP	et al.	3126
@NP	2010	3134
@NP	axonal regeneration and subsequent synaptic connectivity	3155
@NP	axonal regeneration	3155
@NP	subsequent synaptic connectivity	3179
@NP	therapies	3213
@NP	these post-traumatic growth-inhibitory factors	3237
@NP	tissue preservation	3296
@NP	Examples of such therapies	3317
@NP	Examples	3317
@NP	such therapies	3329
@NP	the reduction of glial scar inhibition	3352
@NP	the reduction	3352
@NP	glial scar inhibition	3369
@NP	the removal of cellular debris	3392
@NP	the removal	3392
@NP	cellular debris	3407
@NP	the establishment of a permissive cellular bridge across the lesion site	3428
@NP	the establishment	3428
@NP	a permissive cellular bridge across the lesion site	3449
@NP	a permissive cellular bridge	3449
@NP	the lesion site	3485
@NP	treatments	3516
@NP	neurotrophic factors	3540
@NP	spared neurons and function in axonal guidance	3564
@NP	spared neurons and function	3564
@NP	axonal guidance	3595
@NP	the intrinsic capacity of injured neurons	3623
@NP	the intrinsic capacity	3623
@NP	injured neurons	3649
@NP	functional synaptic connections	3679
@NP	recovery	3724
@NP	an olfactory nerve injury	3740
@NP	olfactory ensheathing cells -LRB- OECs -RRB-	3767
@NP	olfactory ensheathing cells	3767
@NP	OECs	3796
@NP	the generation of new olfactory receptor neurons	3813
@NP	the generation	3813
@NP	new olfactory receptor neurons	3831
@NP	a conduit	3875
@NP	they	3918
@NP	their olfactory bulb targets	3934
@NP	Lipson	3964
@NP	et al. , 2003 ; Li et al. , 2005a	3971
@NP	et al.	3971
@NP	2003 ; Li et al.	3979
@NP	2003	3979
@NP	Li et al.	3985
@NP	Li	3985
@NP	et al.	3988
@NP	2005a	3996
@NP	OECs	4004
@NP	adhesion molecules involved in axonal outgrowth	4017
@NP	adhesion molecules	4017
@NP	axonal outgrowth	4048
@NP	trophic factors , such as brain derived	4074
@NP	trophic factors	4074
@NP	brain derived	4099
@NP	brain	4099
@NP	neurotrophic factor and ciliary neurotrophic factor	4113
@NP	CNTF	4166
@NP	ensheath growing axons to protect them from inhibitory molecules	4177
@NP	ensheath	4177
@NP	axons	4194
@NP	them	4211
@NP	inhibitory molecules	4221
@NP	the past decade	4248
@NP	many studies	4265
@NP	OECs	4292
@NP	axon regeneration	4305
@NP	a severe spinal cord injury	4334
@NP	rodents and humans	4365
@NP	Ramo ¬ ¥	4385
@NP	Ramo ¬	4385
@NP	¥	4390
@NP	n-Cueto	4392
@NP	et al.	4400
@NP	1998	4408
@NP	2000	4414
@NP	Lu	4420
@NP	et al. , 2002	4423
@NP	et al.	4423
@NP	2002	4431
@NP	Lo ¬ ¥ pez-Vales et al. , 2006	4437
@NP	Lo ¬ ¥ pez-Vales	4437
@NP	Lo	4437
@NP	¬ ¥ pez-Vales	4439
@NP	et al. , 2006	4452
@NP	et al.	4452
@NP	2006	4460
@NP	Kubasak et al. , 2008	4466
@NP	Kubasak	4466
@NP	et al. , 2008	4474
@NP	et al.	4474
@NP	2008	4482
@NP	Takeoka et al. , 2011	4488
@NP	Takeoka	4488
@NP	et al. , 2011	4496
@NP	et al.	4496
@NP	2011	4504
@NP	Ziegler et al. , 2011	4510
@NP	Ziegler	4510
@NP	et al. , 2011	4518
@NP	et al.	4518
@NP	2011	4526
@NP	Granger et al. , 2012	4532
@NP	Granger	4532
@NP	et al. , 2012	4540
@NP	et al.	4540
@NP	2012	4548
@NP	Tabakow et al.	4554
@NP	Tabakow	4554
@NP	et al.	4562
@NP	2014	4570
@NP	these studies	4590
@NP	anatomical	4619
@NP	behavioral evidence	4650
@NP	OEC transplantation	4675
@NP	the regeneration of corticospinal tract axons	4704
@NP	the regeneration	4704
@NP	corticospinal tract axons	4724
@NP	neurons and axons near the lesion site	4761
@NP	neurons and axons	4761
@NP	the lesion site	4784
@NP	the recovery of motor-evoked potentials	4811
@NP	the recovery	4811
@NP	motor-evoked potentials	4827
@NP	the hindlimb muscles	4854
@NP	grid climbing ability compared with media-treated controls	4905
@NP	grid climbing ability	4905
@NP	media-treated controls	4941
@NP	these functional improvements	4973
@NP	the lack of an OEC-specific marker	5004
@NP	the lack	5004
@NP	an OEC-specific marker	5016
@NP	the irrefutable identification of OEC transplants	5052
@NP	the irrefutable identification	5052
@NP	OEC transplants	5086
@NP	spinal cord injury studies	5105
@NP	the mechanisms	5142
@NP	OECs	5166
@NP	axon regeneration and functional recovery	5186
@NP	axon regeneration	5186
@NP	functional recovery	5208
@NP	acutely transplanted OECs	5266
@NP	the glial scar	5306
@NP	inhibitory environment	5337
@NP	a complete spinal cord transection	5366
@NP	we	5402
@NP	green fluorescent protein	5419
@NP	GFP	5446
@NP	control fibroblasts -LRB- FBs -RRB-	5459
@NP	control fibroblasts	5459
@NP	FBs	5480
@NP	OECs derived from GFP-transgenic rats -LRB- Perry et al. , 1999 -RRB-	5489
@NP	OECs	5489
@NP	GFP-transgenic rats -LRB- Perry et al. , 1999 -RRB-	5507
@NP	GFP-transgenic rats	5507
@NP	Perry	5528
@NP	et al. , 1999	5534
@NP	et al.	5534
@NP	1999	5542
@NP	the survival and engraftment	5559
@NP	we	5589
@NP	the volume of GFP-positive cells	5603
@NP	the volume	5603
@NP	GFP-positive cells	5617
@NP	the lesion core between 1 and 8 weeks postinjury	5639
@NP	the lesion core	5639
@NP	between 1 and 8 weeks	5655
@NP	OECs	5703
@NP	FBs	5736
@NP	we	5747
@NP	the presence of OECs	5764
@NP	the presence	5764
@NP	OECs	5780
@NP	neurons	5795
@NP	a permissive environment	5816
@NP	axons postinjury	5845
@NP	We	5863
@NP	neurons and axons	5877
@NP	the lesion core and fewer inhibitory molecules in OEC	5898
@NP	the lesion core	5898
@NP	fewer inhibitory molecules in OEC	5918
@NP	fewer inhibitory molecules	5918
@NP	OEC	5948
@NP	FB-transplanted spinal cords	5958
@NP	FBs and OECs	6009
@NP	their modification of the lesion site	6034
@NP	their modification	6034
@NP	the lesion site	6056
@NP	we	6073
@NP	astroglial scar formation	6085
@NP	the density of activated immune cells and their infiltration	6126
@NP	the density	6126
@NP	activated immune cells and their infiltration	6141
@NP	activated immune cells	6141
@NP	their infiltration	6168
@NP	the spinal cord stumps	6192
@NP	a second part of the study	6219
@NP	a second part	6219
@NP	the study	6236
@NP	we	6247
@NP	the pharmacological immunosuppressant , cyclosporine-A -LRB- CSA -RRB- ,	6264
@NP	the pharmacological immunosuppressant	6264
@NP	cyclosporine-A -LRB- CSA -RRB-	6303
@NP	cyclosporine-A	6303
@NP	CSA	6319
@NP	graft survival	6339
@NP	the beneficial effects of OECs	6366
@NP	the beneficial effects	6366
@NP	OECs	6392
@NP	CSA treatment	6398
@NP	both FB and OEC survival	6421
@NP	FB	6426
@NP	OEC survival	6433
@NP	OECs	6466
@NP	growth permissive cells that modulate the inhibitory environment	6492
@NP	growth permissive cells	6492
@NP	the inhibitory environment	6530
@NP	secondary tissue damage	6565
@NP	axon regeneration	6602
@NP	Materials and Methods Animals .	6622
@NP	Materials and Methods Animals	6622
@NP	Materials	6622
@NP	Methods Animals	6636
@NP	All animal experimental procedures	6653
@NP	All animal	6653
@NP	experimental procedures	6664
@NP	the Chancellor ` Äôs Animal Research Committee	6705
@NP	the Chancellor ` Äôs	6705
@NP	Animal Research Committee	6724
@NP	UCLA	6753
@NP	accordance	6775
@NP	the National Institutes of Health guidelines	6791
@NP	the National Institutes	6791
@NP	Health guidelines	6818
@NP	Animals	6837
@NP	standard conditions	6863
@NP	ad libitum access to food	6888
@NP	ad libitum access	6888
@NP	food	6909
@NP	a breeding colony	6938
@NP	GFP-expressing Sprague - Dawley rats -LRB- Perry et al. , 1999 -RRB-	6959
@NP	GFP-expressing Sprague	6959
@NP	Dawley rats	6983
@NP	Perry	6996
@NP	et al. , 1999	7002
@NP	et al.	7002
@NP	1999	7010
@NP	Homozygous and heterozygous rats	7017
@NP	PCR -LRB- Perry et al. , 1999 -RRB-	7084
@NP	PCR	7084
@NP	Perry	7089
@NP	et al. , 1999	7095
@NP	et al.	7095
@NP	1999	7103
@NP	rats 8 ` Äì10 weeks old were used to obtain GFP-labeled FBs and OECs	7113
@NP	rats	7113
@NP	8 ` Äì10 weeks old	7118
@NP	8 ` Äì10 weeks	7118
@NP	GFP-labeled FBs and OECs	7155
@NP	All cells transplanted into rats	7181
@NP	All cells	7181
@NP	rats	7209
@NP	FB or OEC	7259
@NP	the paper	7280
@NP	Wild-type postnatal day 8 rat pups	7291
@NP	cortical neurite outgrowth experiments	7339
@NP	An overdose of ketaminexylazine	7379
@NP	An overdose	7379
@NP	ketaminexylazine	7394
@NP	euthanasia	7424
@NP	the extraction	7442
@NP	the olfactory bulbs , cerebral hemispheres , or abdominal skin biopsies	7460
@NP	the olfactory bulbs	7460
@NP	cerebral hemispheres	7481
@NP	abdominal skin biopsies	7506
@NP	Sixty-one female Sprague-Dawley rats	7531
@NP	Charles River Laboratories	7569
@NP	10 ` Äì12 weeks of age	7598
@NP	10 ` Äì12 weeks	7598
@NP	age	7615
@NP	cell transplants	7629
@NP	a complete low-thoracic spinal cord transection	7661
@NP	1 , 2 , 4 , or 8 weeks postinjury -LRB- Table 1 -RRB-	7733
@NP	1	7733
@NP	2	7736
@NP	4	7739
@NP	8 weeks postinjury -LRB- Table 1 -RRB-	7745
@NP	8 weeks postinjury	7745
@NP	Table 1	7765
@NP	Olfactory bulb-derived OEC cultures .	7775
@NP	Olfactory bulb-derived OEC	7775
@NP	cultures	7802
@NP	Methods to prepare all OEC primary and immunopurified cultures	7812
@NP	all OEC	7831
@NP	primary and immunopurified cultures	7839
@NP	those of Ramo ¬ ¥ n - Cueto et al. -LRB- 2000 -RRB-	7891
@NP	those of Ramo ¬ ¥ n	7891
@NP	those of Ramo ¬	7891
@NP	those	7891
@NP	Ramo ¬	7900
@NP	¥ n	7905
@NP	Cueto et al. -LRB- 2000 -RRB-	7909
@NP	Cueto	7909
@NP	et al. -LRB- 2000 -RRB-	7915
@NP	et al.	7915
@NP	2000	7923
@NP	those recently reported -LRB- Khankan et al. , 2015 -RRB-	7946
@NP	those recently reported	7946
@NP	Khankan	7971
@NP	et al. , 2015	7979
@NP	et al.	7979
@NP	2015	7987
@NP	OEC dissection from the first two layers of the olfactory bulb	8000
@NP	OEC dissection	8000
@NP	the first two layers	8020
@NP	the olfactory bulb	8044
@NP	meninges and blood vessels	8064
@NP	fibroblast contamination	8114
@NP	Cells	8140
@NP	0.1 % trypsin -LRB- Invitrogen -RRB-	8166
@NP	0.1 % trypsin	8166
@NP	Invitrogen	8180
@NP	a mixture	8211
@NP	1:1 Dulbecco ` Äôs	8224
@NP	Eagle	8250
@NP	` Äôs/Ham ` Äôs F12 medium -LRB- D/F medium ; Invitrogen -RRB-	8255
@NP	` Äôs/Ham ` Äôs F12 medium	8255
@NP	` Äôs/Ham ` Äôs	8255
@NP	F12 medium	8268
@NP	D/F medium ; Invitrogen	8280
@NP	D/F medium	8280
@NP	Invitrogen	8292
@NP	10 % fetal bovine serum -LRB- FBS ; Hyclone -RRB-	8322
@NP	10 % fetal bovine serum	8322
@NP	FBS ; Hyclone	8346
@NP	FBS	8346
@NP	Hyclone	8351
@NP	1 % penicillin streptomycin -LRB- P/S ; Invitrogen ; D/F-FBS -RRB-	8364
@NP	1 % penicillin streptomycin	8364
@NP	P/S	8392
@NP	Invitrogen ; D/F-FBS	8397
@NP	Invitrogen	8397
@NP	D/F-FBS	8409
@NP	Medium	8419
@NP	every 2 d.	8438
@NP	OECs	8461
@NP	5 d	8495
@NP	p75-nerve growth factor receptor	8529
@NP	anti-p75-NGFR , 1:5 ; clone 192 ; Chandler et al. , 1984	8563
@NP	anti-p75-NGFR	8563
@NP	1:5 ; clone 192 ; Chandler et al.	8578
@NP	1:5 ; clone 192	8578
@NP	1:5	8578
@NP	clone 192	8583
@NP	Chandler et al.	8594
@NP	Chandler	8594
@NP	et al.	8603
@NP	1984	8611
@NP	OECs	8627
@NP	an additional 7 d	8661
@NP	D/F-FBS medium	8692
@NP	pituitary extract	8725
@NP	20 ¬ µg/ml ; Invitrogen	8744
@NP	20 ¬ µg/ml	8744
@NP	Invitrogen	8755
@NP	forskolin	8771
@NP	2 ¬ µM ; Sigma-Aldrich	8782
@NP	2 ¬ µM	8782
@NP	Sigma-Aldrich	8789
@NP	Mitogens	8805
@NP	cells 1 ` Äì2 d	8834
@NP	cells 1	8834
@NP	Äì2 d	8842
@NP	transplantation or use	8855
@NP	neurite outgrowth experiments	8881
@NP	Samples of OEC preparations	8912
@NP	Samples	8912
@NP	OEC preparations	8923
@NP	antibodies	8958
@NP	p75-NGFR -LRB- 1:5 ; clone 192 -RRB-	8977
@NP	p75-NGFR	8977
@NP	1:5 ; clone 192	8987
@NP	1:5	8987
@NP	clone 192	8992
@NP	S100 -LRB- 1:1000 ; Dako -RRB-	9004
@NP	S100	9004
@NP	1:1000 ; Dako	9010
@NP	1:1000	9010
@NP	Dako	9018
@NP	Sox10 -LRB- 1:100 ; R&D Systems -RRB-	9028
@NP	Sox10	9028
@NP	1:100 ; R&D Systems	9035
@NP	1:100	9035
@NP	R&D Systems	9042
@NP	Fibroblast cell cultures .	9056
@NP	Fibroblast	9056
@NP	cell cultures	9067
@NP	Skin biopsies from the abdominal wall	9082
@NP	Skin biopsies	9082
@NP	the abdominal wall	9101
@NP	fibroblast cultures	9142
@NP	Takashima	9178
@NP	2001	9189
@NP	The dermis	9196
@NP	the epidermis and hypodermis	9239
@NP	Dermal tissue	9269
@NP	0.3 %	9300
@NP	10 min at 37 ¬ ∞ C	9310
@NP	10 min	9310
@NP	37 ¬ ∞ C	9320
@NP	D/F-FBS medium	9343
@NP	Cells	9359
@NP	365µg for 5 min	9385
@NP	365µg	9385
@NP	5 min	9395
@NP	the pellet	9408
@NP	12.5 mg/ml collagenase -LRB- Invitrogen -RRB- for 1 h at 37 ¬ ∞	9452
@NP	12.5 mg/ml collagenase -LRB- Invitrogen -RRB-	9452
@NP	12.5 mg/ml collagenase	9452
@NP	Invitrogen	9476
@NP	1 h at 37 ¬ ∞	9492
@NP	1 h	9492
@NP	37 ¬ ∞	9499
@NP	C.	9503
@NP	The collagenase-cell mixture	9506
@NP	a cell strainer	9554
@NP	D/F-FBS supplemented with Primocin -LRB- 0.1 mg/ml ; InvivoGen -RRB-	9608
@NP	D/F-FBS	9608
@NP	Primocin -LRB- 0.1 mg/ml ; InvivoGen -RRB-	9634
@NP	Primocin	9634
@NP	0.1 mg/ml ; InvivoGen	9644
@NP	0.1 mg/ml	9644
@NP	InvivoGen	9655
@NP	Primary FBs	9667
@NP	culture flasks	9694
@NP	37 ¬	9724
@NP	∞ C with 5 % CO2	9727
@NP	∞ C	9727
@NP	5 % CO2	9735
@NP	the medium	9747
@NP	every 2 d.	9770
@NP	FBs	9781
@NP	one to two times	9799
@NP	cell transplantation -LRB- 12 ` Äì14 d in vitro -RRB-	9823
@NP	cell transplantation	9823
@NP	12 ` Äì14 d in vitro	9845
@NP	12 ` Äì14 d	9845
@NP	12	9845
@NP	Äì14 d	9848
@NP	vitro	9858
@NP	Cortical neurite outgrowth assay .	9866
@NP	Cortical neurite	9866
@NP	outgrowth assay	9883
@NP	neurite	9913
@NP	outgrowth experiments	9921
@NP	wild-type or GFP-labeled OECs	9944
@NP	a concentration	9995
@NP	32,000 ` Äì35 ,000 cells	10014
@NP	4-well glass slides	10041
@NP	poly-L-lysine -LRB- PLL ; 0.05 mg/ml ; Sigma-Aldrich -RRB- 5 d	10077
@NP	poly-L-lysine -LRB- PLL ; 0.05 mg/ml ; Sigma-Aldrich -RRB-	10077
@NP	poly-L-lysine	10077
@NP	PLL	10092
@NP	0.05 mg/ml ; Sigma-Aldrich	10097
@NP	0.05 mg/ml	10097
@NP	Sigma-Aldrich	10109
@NP	immunopurification	10134
@NP	48 h	10160
@NP	cortical neurons	10166
@NP	the center of each	10215
@NP	the center	10215
@NP	each	10229
@NP	Cortical neurons	10240
@NP	postnatal day 8 rat cerebral cortices	10276
@NP	postnatal day	10276
@NP	8 rat cerebral cortices	10290
@NP	removal of the leptomeninges	10321
@NP	removal	10321
@NP	the leptomeninges	10332
@NP	cerebral cortices	10351
@NP	Hibernate	10387
@NP	A medium -LRB- BrainBits -RRB-	10398
@NP	A medium	10398
@NP	BrainBits	10408
@NP	P/S	10424
@NP	L-glutamine -LRB- L-glu ; Invitrogen -RRB-	10429
@NP	L-glutamine	10429
@NP	L-glu ; Invitrogen	10442
@NP	L-glu	10442
@NP	Invitrogen	10449
@NP	B27 supplement -LRB- Invitrogen -RRB-	10466
@NP	B27 supplement	10466
@NP	Invitrogen	10482
@NP	Cortices	10495
@NP	warm papain -LRB- 2 mg/ml ; Worthington -RRB-	10535
@NP	warm papain	10535
@NP	2 mg/ml ; Worthington	10548
@NP	2 mg/ml	10548
@NP	Worthington	10557
@NP	Hibernate-A medium with P/S and L-glu	10573
@NP	Hibernate-A medium	10573
@NP	P/S and L-glu	10597
@NP	Neurons	10612
@NP	an OptiPrep step gradient -LRB- Axis - Shield -RRB-	10639
@NP	an OptiPrep step gradient	10639
@NP	Axis - Shield	10666
@NP	Axis	10666
@NP	Shield	10672
@NP	Neurobasal medium -LRB- Invitrogen -RRB-	10696
@NP	Neurobasal medium	10696
@NP	Invitrogen	10715
@NP	they	10747
@NP	the positive control	10766
@NP	pre-coated laminin PLL -LRB- Laminin 10µg/ml ; Invitrogen -RRB-	10788
@NP	pre-coated laminin PLL	10788
@NP	Laminin 10µg/ml ; Invitrogen	10814
@NP	Laminin 10µg/ml	10814
@NP	Invitrogen	10831
@NP	the neutral control	10844
@NP	PLL only -LRB- 0.05 mg/ml -RRB-	10865
@NP	PLL only	10865
@NP	0.05 mg/ml	10875
@NP	either wild-type or transgenic OECs	10891
@NP	PLL wells	10929
@NP	a concentration of 100,000 cells per well	10942
@NP	a concentration	10942
@NP	100,000 cells per well	10961
@NP	100,000 cells	10961
@NP	the cortical neurons	10999
@NP	cultures	11021
@NP	an additional 24 h.	11050
@NP	Cultures	11070
@NP	4 % paraformaldehyde for 15 min , washed with buffer	11093
@NP	4 % paraformaldehyde	11093
@NP	15 min	11117
@NP	buffer	11137
@NP	neurons	11149
@NP	anti- -3-tubulin -LRB- 1:1500 ; Covance -RRB-	11178
@NP	anti- -3-tubulin	11178
@NP	1:1500 ; Covance	11196
@NP	1:1500	11196
@NP	Covance	11204
@NP	Three independent culture experiments	11214
@NP	two wells per experiment per variable	11272
@NP	two wells	11272
@NP	experiment per variable	11286
@NP	experiment	11286
@NP	variable	11301
@NP	Approximately 10 randomly selected 0.1296 mm2 fields	11325
@NP	Approximately 10 randomly	11325
@NP	Approximately 10	11325
@NP	0.1296 mm2 fields	11360
@NP	a Zeiss LSM 510 confocal microscope for neurite outgrowth analysis	11407
@NP	a Zeiss LSM 510 confocal microscope	11407
@NP	neurite outgrowth analysis	11447
@NP	Neuronal cell bodies and all neurites	11475
@NP	Neuronal cell bodies	11475
@NP	all neurites	11500
@NP	Neurolucida software -LRB- v10 .31 , MicroBrightField -RRB-	11531
@NP	Neurolucida software	11531
@NP	v10 .31	11553
@NP	MicroBrightField	11561
@NP	individual neurite lengths and cell body details	11588
@NP	Microsoft Excel using Neurolucida Explorer 10.31	11654
@NP	Microsoft Excel	11654
@NP	Neurolucida Explorer 10.31	11676
@NP	Surgical procedures : spinal cord injury and cell transplantation .	11704
@NP	Surgical procedures	11704
@NP	spinal cord injury and cell transplantation	11725
@NP	All surgeries	11770
@NP	aseptic conditions with the rats deeply anesthetized	11805
@NP	aseptic conditions	11805
@NP	the rats deeply anesthetized	11829
@NP	the rats	11829
@NP	isoflurane gas administered via facemask	11863
@NP	isoflurane gas	11863
@NP	facemask	11895
@NP	A skin incision	11905
@NP	vertebral levels T6	11933
@NP	L1	11956
@NP	the paravertebral muscles	11960
@NP	partial laminectomies at T8 and T9	12006
@NP	partial laminectomies	12006
@NP	T8 and T9	12031
@NP	The dorsal dura	12057
@NP	both ends	12122
@NP	the spinal cord	12142
@NP	most of the lateral and ventral dura	12177
@NP	most	12177
@NP	the lateral and ventral dura	12185
@NP	The spinal cord	12222
@NP	spinal level T9 ` ÄìT10	12272
@NP	spinal level T9	12272
@NP	ÄìT10	12288
@NP	micro-scissors	12299
@NP	Two surgeons verified that the transection was complete.Atotal of 16 spinal rats	12315
@NP	Two surgeons	12315
@NP	the transection	12342
@NP	16 spinal rats	12381
@NP	CSA beginning 3 d	12423
@NP	CSA	12423
@NP	3 d	12437
@NP	the spinal cord transection and transplantation surgery	12448
@NP	the end of the study -LRB- Table 1 -RRB-	12524
@NP	the end	12524
@NP	the study -LRB- Table 1 -RRB-	12535
@NP	the study	12535
@NP	Table 1	12546
@NP	FBs and OECs	12556
@NP	a total of 12 ` Äì14 d	12590
@NP	a total	12590
@NP	12 ` Äì14 d	12601
@NP	12	12601
@NP	Äì14 d	12604
@NP	Cells were rinsed with HBSS without Ca2 +	12621
@NP	Cells	12621
@NP	HBSS	12644
@NP	Ca2	12657
@NP	+	12660
@NP	Mg2	12662
@NP	0.25 % trypsin-EDTA	12688
@NP	a medium rinse and centrifugation	12718
@NP	a medium rinse	12718
@NP	centrifugation	12737
@NP	cells	12753
@NP	a concentration of 100,000 cells per microliter	12779
@NP	a concentration	12779
@NP	100,000 cells per microliter	12798
@NP	100,000 cells	12798
@NP	microliter	12816
@NP	serumfree DMEM	12830
@NP	A fresh cell preparation	12846
@NP	each FB and OEC transplantation	12884
@NP	FBs -LRB- 29 rats -RRB- or OECs -LRB- 32 rats -RRB-	12917
@NP	FBs -LRB- 29 rats -RRB-	12917
@NP	FBs	12917
@NP	29 rats	12922
@NP	OECs -LRB- 32 rats -RRB-	12934
@NP	OECs	12934
@NP	32 rats	12940
@NP	the spinal cord 1 mm rostral and caudal	12985
@NP	the spinal cord 1 mm rostral	12985
@NP	caudal	13018
@NP	the lesion	13028
@NP	the spinal cord transection	13057
@NP	Approximately 50,000 cells	13086
@NP	four midline injection sites	13136
@NP	each spinal cord stump for a total of 200,000 cells per stump	13172
@NP	each spinal cord stump	13172
@NP	a total of 200,000 cells per stump	13199
@NP	a total	13199
@NP	200,000 cells per stump	13210
@NP	200,000 cells	13210
@NP	stump	13228
@NP	Rats	13235
@NP	an incubator	13255
@NP	Spinal rats	13321
@NP	manual bladder expression	13342
@NP	three times daily	13368
@NP	2 weeks and then twice daily	13390
@NP	2 weeks	13390
@NP	then twice daily	13402
@NP	12 h intervals	13433
@NP	All animals	13449
@NP	weight loss and dehydration	13486
@NP	Urine samples	13515
@NP	weekly	13541
@NP	Multistix	13554
@NP	10 SG reagent strips -LRB- Siemens -RRB-	13564
@NP	10 SG reagent strips	13564
@NP	Siemens	13586
@NP	Surgeons and investigators	13596
@NP	Surgeons	13596
@NP	investigators	13609
@NP	treatment group	13639
@NP	the time of transplantation	13660
@NP	the time	13660
@NP	transplantation	13672
@NP	the remainder of the study	13699
@NP	the remainder	13699
@NP	the study	13716
@NP	Tissue preparation .	13727
@NP	Tissue	13727
@NP	preparation	13734
@NP	Rats	13747
@NP	4 % paraformaldehyde	13803
@NP	2 h at 4 ¬ ∞	13841
@NP	2 h	13841
@NP	4 ¬ ∞	13848
@NP	C.	13851
@NP	Spinal cords	13854
@NP	30 % sucrose	13910
@NP	OCT compound -LRB- Tissue-Tek -RRB-	13939
@NP	OCT compound	13939
@NP	Tissue-Tek	13953
@NP	Spinal cords , including the injury site ,	13966
@NP	Spinal cords	13966
@NP	the injury site	13990
@NP	a thickness of 25 ¬ µm	14040
@NP	a thickness	14040
@NP	25 ¬ µm	14055
@NP	tissue sections	14062
@NP	series	14094
@NP	16 slides	14106
@NP	4 ¬ ∞ C in Millonigs buffer	14136
@NP	4 ¬ ∞ C	14136
@NP	Millonigs buffer	14144
@NP	azide	14166
@NP	Immunohistochemical procedures	14173
@NP	Sections	14839
@NP	species	14881
@NP	appropriate serum	14889
@NP	a presoak -LRB- donkey , Jackson ImmunoResearch ;	14910
@NP	a presoak	14910
@NP	donkey , Jackson ImmunoResearch	14921
@NP	donkey	14921
@NP	Jackson ImmunoResearch	14929
@NP	goat serum , Vector Laboratories	14956
@NP	goat serum	14956
@NP	Vector Laboratories	14968
@NP	incubation with primary antibodies overnight	14996
@NP	incubation	14996
@NP	primary antibodies overnight	15012
@NP	primary antibodies	15012
@NP	immunostaining	15055
@NP	species appropriate AlexaFluor 488 , 555 , 594 , or 647	15071
@NP	species	15071
@NP	AlexaFluor 488 , 555 , 594 , or 647	15091
@NP	AlexaFluor 488	15091
@NP	555 , 594 , or 647	15107
@NP	1:100	15125
@NP	` Äì500 ; Jackson ImmunoResearch	15131
@NP	` Äì500	15131
@NP	Jackson ImmunoResearch	15139
@NP	Nuclei	15173
@NP	Hoechst	15198
@NP	Sigma-Aldrich	15211
@NP	5 min and sections	15230
@NP	5 min	15230
@NP	sections	15240
@NP	Fluorogel -LRB- Electron Microscopy Sciences -RRB-	15272
@NP	Fluorogel	15272
@NP	Electron Microscopy Sciences	15283
@NP	Electron	15283
@NP	Microscopy Sciences	15292
@NP	Oil red and GFAP bright-field staining .	15314
@NP	Oil red and GFAP	15314
@NP	bright-field staining	15331
@NP	Slide-mounted sections	15354
@NP	ddH2O for 5 min	15394
@NP	ddH2O	15394
@NP	5 min	15404
@NP	70 % ethanol for 5 min	15426
@NP	70 % ethanol	15426
@NP	5 min	15442
@NP	Sections	15449
@NP	Oil RedOstain	15478
@NP	700 mg	15493
@NP	Oil Red powder	15503
@NP	100 ml of 70 % ethanol , filtered twice , Sigma-Aldrich	15531
@NP	100 ml	15531
@NP	70 % ethanol , filtered twice , Sigma-Aldrich	15541
@NP	70 % ethanol	15541
@NP	Sigma-Aldrich	15570
@NP	30 min	15589
@NP	ethanol for 1 min and ddH2Ofor 5 min -LRB- Ma et al. , 2002 -RRB-	15619
@NP	ethanol for 1 min	15619
@NP	ethanol	15619
@NP	1 min	15631
@NP	ddH2Ofor 5 min -LRB- Ma et al. , 2002 -RRB-	15641
@NP	ddH2Ofor	15641
@NP	5 min -LRB- Ma et al. , 2002 -RRB-	15650
@NP	Ma	15657
@NP	et al. , 2002	15660
@NP	et al.	15660
@NP	2002	15668
@NP	Sections	15675
@NP	0.1 M Tris	15701
@NP	1.4 % NaCl and 0.1 % BSA followed by 15 min in 0.1 % Triton detergent buffer	15723
@NP	1.4 % NaCl	15723
@NP	0.1 % BSA followed by 15 min in 0.1 % Triton detergent buffer	15737
@NP	0.1 % BSA	15737
@NP	15 min in 0.1 % Triton detergent buffer	15758
@NP	15 min	15758
@NP	0.1 % Triton detergent buffer	15768
@NP	0.1 %	15768
@NP	Triton detergent buffer	15773
@NP	Sections	15798
@NP	5 % donkey serum	15825
@NP	0.1 % Triton before incubation	15852
@NP	0.1 % Triton	15852
@NP	incubation	15871
@NP	anti-GFAP overnight	15887
@NP	Sections	15908
@NP	Tris buffer	15935
@NP	a	15952
@NP	rabbit secondary antibody , amplified by incubation with avidin-biotin complex ,	15967
@NP	rabbit secondary antibody	15967
@NP	incubation	16007
@NP	avidin-biotin complex	16023
@NP	diaminobenzidine -LRB- Dojindo Laboratories -RRB-	16067
@NP	diaminobenzidine	16067
@NP	Dojindo Laboratories	16085
@NP	Lesion site analyses .	16108
@NP	Lesion	16108
@NP	site analyses	16115
@NP	All anatomical analyses	16130
@NP	cell transplant type	16178
@NP	Photomicrographic montages of spinal cord sections	16200
@NP	Photomicrographic montages	16200
@NP	spinal cord sections	16230
@NP	an Olympus AX70 microscope	16267
@NP	Zen 2012 image capture software -LRB- Carl Zeiss -RRB-	16298
@NP	Zen 2012 image capture	16298
@NP	software -LRB- Carl Zeiss -RRB-	16321
@NP	software	16321
@NP	Carl Zeiss	16331
@NP	the panorama module	16348
@NP	Confocal images	16369
@NP	a Zeiss LSM 510 or 800 microscope and 25 or 63 oil objective	16404
@NP	a Zeiss LSM 510 or 800 microscope	16404
@NP	a Zeiss LSM	16404
@NP	510 or 800 microscope	16416
@NP	25 or 63 oil objective	16442
@NP	Analyses and 3D visualization	16468
@NP	Analyses	16468
@NP	3D visualization	16481
@NP	the Neurolucida and Neurolucida Explorer software	16518
@NP	v10 , MicroBrightField	16569
@NP	v10	16569
@NP	MicroBrightField	16574
@NP	the survival and migration of transplanted FBs and OECs	16606
@NP	the survival and migration	16606
@NP	transplanted FBs and OECs	16636
@NP	we	16663
@NP	the GFP-positive area	16673
@NP	the lesion core and stumps	16698
@NP	the lesion core	16698
@NP	stumps	16718
@NP	every eighth section	16728
@NP	The percentage of GFP-positive cells in the lesion core	16750
@NP	The percentage	16750
@NP	GFP-positive cells in the lesion core	16768
@NP	GFP-positive cells	16768
@NP	the lesion core	16790
@NP	the volume of GFP	16821
@NP	the volume	16821
@NP	GFP	16835
@NP	the lesion core	16842
@NP	the total volume of GFP	16869
@NP	the total volume	16869
@NP	GFP	16889
@NP	the lesion core plus stumps	16900
@NP	the lesion core	16900
@NP	stumps	16921
@NP	FB and OEC filling of the lesion core	16942
@NP	FB and OEC filling	16942
@NP	the lesion core	16964
@NP	the areas of GFP-labeled cells	16981
@NP	the areas	16981
@NP	GFP-labeled cells	16994
@NP	fibronectin-positive extracellular matrix in the lesion core	17016
@NP	fibronectin-positive extracellular matrix	17016
@NP	the lesion core	17061
@NP	every 16th section of the spinal cord	17094
@NP	every 16th section	17094
@NP	the spinal cord	17116
@NP	volumes	17145
@NP	Kubasak	17169
@NP	et al. -LRB- 2008 -RRB-	17177
@NP	et al.	17177
@NP	2008	17185
@NP	We	17192
@NP	the percentage of GFP-positive cells that fill the GFAPnegative lesion volume	17202
@NP	the percentage	17202
@NP	GFP-positive cells	17220
@NP	the GFAPnegative lesion volume	17249
@NP	the extent of neuronal preservation	17294
@NP	the extent	17294
@NP	neuronal preservation	17308
@NP	the length of the nonneuronal tissue	17331
@NP	the length	17331
@NP	the nonneuronal tissue	17345
@NP	Takeoka et al. -LRB- 2011 -RRB-	17389
@NP	Takeoka et al.	17389
@NP	Takeoka	17389
@NP	et al.	17397
@NP	2011	17405
@NP	every eighth section	17416
@NP	the distance	17438
@NP	the neuron closest to the rostral and caudal GFAP-positive stumps	17459
@NP	the neuron	17459
@NP	the rostral and caudal GFAP-positive stumps	17481
@NP	the rostral	17481
@NP	caudal GFAP-positive stumps	17497
@NP	the total distance of the non-neuronal tissue and lesion core	17549
@NP	the total distance	17549
@NP	the non-neuronal tissue and lesion core	17571
@NP	the preservation of axons postinjury	17625
@NP	the preservation	17625
@NP	axons postinjury	17645
@NP	we	17663
@NP	serotonergic axons	17675
@NP	the rostral stump associated with the GFAP border in every 16th section	17705
@NP	the rostral stump	17705
@NP	the GFAP border in every 16th section	17739
@NP	the GFAP border	17739
@NP	every 16th section	17758
@NP	Axon sparing	17778
@NP	Axon	17778
@NP	the number	17820
@NP	5-HT-positive axons that crossed the GFAP-positive border into the lesion core	17834
@NP	5-HT-positive axons	17834
@NP	the GFAP-positive border	17867
@NP	the lesion core	17897
@NP	the total area	17918
@NP	5-HT-labeled axons within the GFAP-negative lesion core	17936
@NP	5-HT-labeled axons	17936
@NP	the GFAP-negative lesion core	17962
@NP	the distance	18001
@NP	the rostral border to the most caudal 5-HT-labeled axon in the lesion core	18019
@NP	the rostral border	18019
@NP	the most caudal 5-HT-labeled axon in the lesion core	18041
@NP	the most caudal 5-HT-labeled axon	18041
@NP	the lesion core	18078
@NP	Axons that did not extend beyond the GFAP-positive border	18095
@NP	Axons	18095
@NP	the GFAP-positive border	18128
@NP	zero	18168
@NP	negative lengths	18191
@NP	changes	18222
@NP	immune cell activation , astrocyte reactivity , and CSPG deposition	18233
@NP	immune cell activation	18233
@NP	astrocyte reactivity	18257
@NP	CSPG deposition	18283
@NP	luminance measurements	18305
@NP	Iba-1 , GFAP , and CS-56 immunoreactivity	18332
@NP	images of every 16th section	18406
@NP	images	18406
@NP	every 16th section	18416
@NP	Images	18436
@NP	identical exposure conditions	18463
@NP	the mean pixel luminance	18514
@NP	individual channels using the Zen 2012 annotations/measurements feature	18544
@NP	individual channels	18544
@NP	the Zen 2012 annotations/measurements feature	18570
@NP	the Iba-1 analysis	18621
@NP	five zones	18641
@NP	rectangles -LRB- 500,000 m2 -RRB- on the image	18667
@NP	rectangles -LRB- 500,000 m2 -RRB-	18667
@NP	rectangles	18667
@NP	500,000 m2	18679
@NP	the image	18695
@NP	rostral stump , rostral border , lesion core , caudal border , or caudal stump	18729
@NP	rostral stump	18729
@NP	rostral border	18744
@NP	lesion core	18760
@NP	caudal border	18773
@NP	caudal stump	18791
@NP	Luminance measurements for the CS-56 analysis	18805
@NP	Luminance measurements	18805
@NP	the CS-56 analysis	18832
@NP	eight zones	18867
@NP	squares -LRB- 6500 m2 -RRB- within the GFAP-positive rostral	18889
@NP	squares -LRB- 6500 m2 -RRB-	18889
@NP	squares	18889
@NP	6500 m2	18899
@NP	the GFAP-positive rostral	18916
@NP	caudal borders and GFAPnegative lesion core	18946
@NP	caudal borders	18946
@NP	GFAPnegative lesion core	18965
@NP	Additional luminance measurements for CS-56	18991
@NP	Additional luminance measurements	18991
@NP	CS-56	19029
@NP	eight zones with GFP-FBs , GFP-OECs , and adjacent zones	19051
@NP	eight zones	19051
@NP	GFP-FBs , GFP-OECs , and adjacent zones	19068
@NP	GFP-FBs	19068
@NP	GFP-OECs	19077
@NP	adjacent zones	19091
@NP	GFP cells	19114
@NP	Rectangles	19125
@NP	the GFAP-positive border	19154
@NP	cysts	19183
@NP	a control	19206
@NP	the GFAP luminance	19217
@NP	the same Iba-1 and CS-56 zones	19257
@NP	the same Iba-1	19257
@NP	CS-56 zones	19276
@NP	Mean luminance intensity measurements	19289
@NP	Iba-1 , GFAP , and CS-56 immunoreactivity	19336
@NP	background auto-fluorescence of each sec - tion	19395
@NP	background auto-fluorescence	19395
@NP	each sec - tion	19427
@NP	Results	19443
@NP	a fold-change from background levels and luminance values	19468
@NP	a fold-change	19468
@NP	background levels and luminance values	19487
@NP	zones for each animal	19547
@NP	zones	19547
@NP	each animal	19557
@NP	Myelin phagocytosis assay .	19570
@NP	Myelin	19570
@NP	phagocytosis assay	19577
@NP	p75-NGFR-positive OECs	19606
@NP	a concentration of 25,000 cells	19644
@NP	a concentration	19644
@NP	25,000 cells	19663
@NP	PLL-coated 15-mm-round coverslips	19681
@NP	overnight	19734
@NP	OECs	19745
@NP	Cell - Tracker Green CMFDA -LRB- 7 ¬ µM ; Invitrogen -RRB-	19771
@NP	Cell	19771
@NP	Tracker Green CMFDA	19777
@NP	7 ¬ µM ; Invitrogen	19798
@NP	7 ¬ µM	19798
@NP	Invitrogen	19805
@NP	24 h.	19844
@NP	Myelin	19850
@NP	Colman et al. , 1982 ; Zheng et al. , 2003 ; Runyan and Phelps , 2009	19895
@NP	Colman	19895
@NP	et al. , 1982 ; Zheng et al. , 2003 ; Runyan and Phelps , 2009	19902
@NP	et al. , 1982	19902
@NP	et al.	19902
@NP	1982	19910
@NP	Zheng et al. , 2003	19916
@NP	Zheng	19916
@NP	et al. , 2003	19922
@NP	et al.	19922
@NP	2003	19930
@NP	Runyan and Phelps , 2009	19936
@NP	Runyan and Phelps	19936
@NP	2009	19955
@NP	Myelin	19962
@NP	D/F-FBS media	19984
@NP	OEC-coated coverslips	20008
@NP	a final concentration of 0.1 mg/ml	20033
@NP	a final concentration	20033
@NP	0.1 mg/ml	20058
@NP	37 ¬ ∞ C for 1 h.	20093
@NP	37 ¬ ∞ C	20093
@NP	1 h.	20103
@NP	Coverslips	20108
@NP	media	20136
@NP	excess	20152
@NP	4 % paraformaldehyde for 30 min	20178
@NP	4 % paraformaldehyde	20178
@NP	30 min	20202
@NP	three times	20221
@NP	PBS	20238
@NP	immunocytochemical staining	20249
@NP	OECs	20278
@NP	5 %	20308
@NP	Triton X-100 solution -LRB- Sigma-Aldrich -RRB- ,	20311
@NP	Triton X-100 solution	20311
@NP	Sigma-Aldrich	20334
@NP	normal donkey serum	20363
@NP	overnight with anti-myelin basic protein -LRB- MBP ; 1:250 ; Millipore -RRB-	20398
@NP	overnight	20398
@NP	anti-myelin basic protein -LRB- MBP ; 1:250 ; Millipore -RRB-	20413
@NP	anti-myelin basic protein	20413
@NP	MBP	20440
@NP	1:250 ; Millipore	20445
@NP	1:250	20445
@NP	Millipore	20452
@NP	immunostaining	20477
@NP	cells	20493
@NP	donkey	20519
@NP	IgY-Rhodamine -LRB- 1:500 , Jackson ImmunoResearch -RRB- for 1 h.	20538
@NP	IgY-Rhodamine -LRB- 1:500 , Jackson ImmunoResearch -RRB-	20538
@NP	IgY-Rhodamine	20538
@NP	1:500	20553
@NP	Jackson ImmunoResearch	20560
@NP	1 h.	20588
@NP	Coverslips	20593
@NP	glass slides	20622
@NP	Fluorogel	20640
@NP	Images	20651
@NP	a Zeiss LSM 510 confocal microscope and 63 objective	20678
@NP	a Zeiss LSM 510 confocal microscope	20678
@NP	63 objective	20718
@NP	Statistical analyses	20733
@NP	Measurements from each analysis	20755
@NP	Measurements	20755
@NP	each analysis	20773
@NP	a mean for each animal	20811
@NP	a mean	20811
@NP	each animal	20822
@NP	The mean values for each rat	20835
@NP	The mean values	20835
@NP	each rat	20855
@NP	a group	20883
@NP	each time point	20900
@NP	mean ¬ ± SEM	20932
@NP	All statistical comparisons	20945
@NP	JMP Software -LRB- v10 .0.0 for Microsoft Windows , SAS Institute -RRB- orR	20993
@NP	JMP Software -LRB- v10 .0.0 for Microsoft Windows , SAS Institute -RRB-	20993
@NP	JMP Software	20993
@NP	v10 .0.0 for Microsoft Windows , SAS Institute	21007
@NP	v10 .0.0	21007
@NP	Microsoft Windows , SAS Institute	21019
@NP	Microsoft Windows	21019
@NP	SAS Institute	21038
@NP	3.2.2	21057
@NP	RCore Team , 2015	21063
@NP	RCore Team	21063
@NP	2015	21075
@NP	A two-way ANOVA	21082
@NP	the pooled effects of time and cell transplant groups	21123
@NP	the pooled effects	21123
@NP	time and cell transplant groups	21145
@NP	group	21189
@NP	time pointsMANOVAfollowed by a two-wayANOVAwas used	21208
@NP	time	21208
@NP	a two-wayANOVAwas used	21237
@NP	a two-wayANOVAwas	21237
@NP	Post hoc tests -LRB- Student ` Äôs t tests -RRB-	21261
@NP	Post hoc tests	21261
@NP	Post	21261
@NP	hoc	21266
@NP	tests	21270
@NP	Student ` Äôs t tests	21277
@NP	Student ` Äôs	21277
@NP	Student	21277
@NP	Äôs	21285
@NP	t tests	21289
@NP	interactions	21318
@NP	the case where the sample size was small	21349
@NP	the case	21349
@NP	the sample size	21364
@NP	95 % confidence intervals	21391
@NP	Monte Carlo	21434
@NP	simulation and significance	21446
@NP	nonparametric , Bootstrap approximation of a two-way repeatedmeasures ANOVA	21488
@NP	Bootstrap approximation of a two-way repeatedmeasures	21503
@NP	Bootstrap approximation	21503
@NP	a two-way repeatedmeasures	21530
@NP	Statistical significance	21564
@NP	p <	21608
@NP	p	21608
@NP	<	21610
@NP	0.05 , ** p < 0.01 , and *** p <	21611
@NP	0.05 , ** p < 0.01 ,	21611
@NP	0.05	21611
@NP	p <	21619
@NP	p	21619
@NP	<	21621
@NP	0.01	21622
@NP	*** p <	21632
@NP	*** p	21632
@NP	0.001	21638
@NP	Results Figure 1 .	21646
@NP	Results	21646
@NP	Figure 1	21654
@NP	Survival and migration of transplanted cells .	21664
@NP	Survival and migration	21664
@NP	transplanted cells	21690
@NP	A ` ÄìF , GFP-labeled FBs -LRB- A , C , E -RRB- or OECs -LRB- B , D , F -RRB-	21710
@NP	A ` ÄìF	21710
@NP	GFP-labeled FBs -LRB- A , C , E -RRB- or OECs -LRB- B , D , F -RRB-	21717
@NP	GFP-labeled FBs -LRB- A , C , E -RRB-	21717
@NP	GFP-labeled FBs	21717
@NP	A , C , E	21734
@NP	OECs -LRB- B , D , F -RRB-	21746
@NP	OECs	21746
@NP	B , D , F	21752
@NP	the lesion core -LRB- asterisks -RRB-	21782
@NP	the lesion core	21782
@NP	asterisks	21799
@NP	GFAP-positive -LRB- cyan -RRB- rostral and caudal stumps between 1 and 4 weeks	21817
@NP	GFAP-positive -LRB- cyan -RRB- rostral	21817
@NP	caudal stumps between 1 and 4 weeks	21850
@NP	caudal stumps	21850
@NP	between 1 and 4 weeks	21864
@NP	spinal cord transection and cell transplantation	21892
@NP	Anti-GFP immunolabeling	21942
@NP	large numbers	21977
@NP	FBs and OECs	22004
@NP	the lesion core -LRB- white arrowheads -RRB- and stumps -LRB- white arrows -RRB-	22020
@NP	the lesion core	22020
@NP	white arrowheads	22037
@NP	stumps	22059
@NP	white arrows	22067
@NP	1 week post-transplant -LRB- A , B -RRB-	22084
@NP	1 week	22084
@NP	A , B	22108
@NP	A	22108
@NP	B	22111
@NP	2 weeks	22118
@NP	neither FBs nor OECs	22127
@NP	FBs	22135
@NP	OECs	22143
@NP	the lesion core	22160
@NP	GFP-positive cells	22181
@NP	the stumps	22215
@NP	white arrows	22233
@NP	4 weeks	22251
@NP	no FBs	22259
@NP	-LRB- E -RRB-	22275
@NP	OECs	22288
@NP	the lesion core	22308
@NP	white arrowhead	22325
@NP	stumps	22346
@NP	F , white arrow	22354
@NP	F	22354
@NP	white arrow	22357
@NP	Neither FBs nor OECs	22371
@NP	FBs	22379
@NP	OECs	22387
@NP	8 weeks -LRB- data not shown -RRB-	22404
@NP	8 weeks	22404
@NP	data not shown	22413
@NP	data	22413
@NP	Confocal images	22436
@NP	FBs -LRB- G -RRB-	22467
@NP	FBs	22467
@NP	G	22472
@NP	dense sheets of cells -LRB- yellow arrowheads -RRB-	22478
@NP	dense sheets	22478
@NP	cells -LRB- yellow arrowheads -RRB-	22494
@NP	cells	22494
@NP	yellow arrowheads	22501
@NP	OECs -LRB- H -RRB-	22529
@NP	OECs	22529
@NP	H	22535
@NP	thin tubular tracks of cells -LRB- yellow arrows -RRB-	22545
@NP	thin tubular tracks	22545
@NP	cells -LRB- yellow arrows -RRB-	22568
@NP	cells	22568
@NP	yellow arrows	22575
@NP	I	22591
@NP	Confocal image	22594
@NP	intermingled spindle-shaped OECs -LRB- inset -RRB-	22615
@NP	intermingled spindle-shaped OECs	22615
@NP	4 weeks	22659
@NP	postinjury	22667
@NP	a trabecular network	22685
@NP	fibronectin-positive -LRB- red -RRB- extracellular matrix	22709
@NP	the lesion core	22760
@NP	J	22777
@NP	OECs	22780
@NP	more	22804
@NP	the lesion core relative to the total GFP volume than FBs at 4 weeks postinjury	22812
@NP	the lesion core	22812
@NP	the total GFP volume than FBs at 4 weeks	22840
@NP	the total GFP volume	22840
@NP	FBs at 4 weeks	22866
@NP	FBs	22866
@NP	4 weeks	22873
@NP	other time points	22914
@NP	Circles	22933
@NP	individual animals and group	22951
@NP	individual animals	22951
@NP	group	22974
@NP	± SEM values	22985
@NP	black for FBs	23010
@NP	black	23010
@NP	FBs	23020
@NP	OECs in this and subsequent figures	23038
@NP	OECs	23038
@NP	this and subsequent figures	23046
@NP	this	23046
@NP	subsequent figures	23055
@NP	All sagittal spinal cord images	23075
@NP	rostral to the left and dorsal to the top	23125
@NP	rostral	23125
@NP	the left and dorsal to the top	23136
@NP	the left and dorsal	23136
@NP	the top	23159
@NP	Scale bars : A ` ÄìF , 1 mm ; G , H , 50 ¬ µm ; I , 200 ¬ µm .	23168
@NP	Scale bars	23168
@NP	A ` ÄìF , 1 mm	23180
@NP	A ` ÄìF	23180
@NP	1 mm	23187
@NP	G , H , 50 ¬ µm	23193
@NP	G	23193
@NP	H , 50 ¬ µm	23196
@NP	H	23196
@NP	50 ¬ µm	23199
@NP	I , 200 ¬ µm	23206
@NP	I	23206
@NP	200 ¬ µm	23209
@NP	Figure 2 .	23218
@NP	Figure	23218
@NP	2	23225
@NP	OECs	23228
@NP	neuronal degeneration	23240
@NP	A , At 2 weeks	23263
@NP	2	23269
@NP	an OEC-transplanted spinal cord	23288
@NP	the astroglial scar border identified with GFAP -LRB- cyan -RRB-	23324
@NP	the astroglial scar border identified with GFAP	23324
@NP	the astroglial scar border	23324
@NP	GFAP	23367
@NP	cyan	23373
@NP	neurons -LRB- yellow arrows -RRB- marked with NeuN -LRB- red -RRB-	23383
@NP	neurons -LRB- yellow arrows -RRB- marked with NeuN	23383
@NP	neurons -LRB- yellow arrows -RRB-	23383
@NP	neurons	23383
@NP	yellow arrows	23392
@NP	NeuN	23419
@NP	red	23425
@NP	No OECs	23431
@NP	this section	23455
@NP	The distance	23469
@NP	neurons	23490
@NP	yellow arrows	23499
@NP	the nearest astrocyte scar border	23518
@NP	c	23553
@NP	the total distance between rostral and caudal neurons	23560
@NP	the total distance	23560
@NP	rostral and caudal neurons	23587
@NP	d	23615
@NP	measured.B	23623
@NP	Confocal image near the rostral scar border	23635
@NP	Confocal image	23635
@NP	the rostral scar border	23655
@NP	neurons	23688
@NP	white arrows	23697
@NP	OECs	23725
@NP	A , c	23825
@NP	A	23825
@NP	c	23827
@NP	andthetotaldistancebetweentheneuronsofthe rostral	23829
@NP	caudal stumps -LRB- A , d -RRB-	23883
@NP	caudal stumps	23883
@NP	A , d	23898
@NP	A	23898
@NP	d	23901
@NP	FB	23920
@NP	OEC-treated rats at 1 and 2 weeks postinjury	23929
@NP	OEC-treated rats	23929
@NP	1 and 2 weeks postinjury	23949
@NP	Scale bars : A , 500 ¬ µm ; B , 50 ¬ µm .	23975
@NP	Scale bars	23975
@NP	A , 500 ¬ µm	23987
@NP	A	23987
@NP	500 ¬ µm	23990
@NP	B , 50 ¬ µm	23997
@NP	B	23997
@NP	50 ¬ µm	24000
@NP	Figure 3 .	24008
@NP	Figure	24008
@NP	3	24015
@NP	OECs	24018
@NP	serotonergic axonal dieback	24030
@NP	A ` ÄìD	24059
@NP	Representative images -LRB- A , C -RRB- and enlargements -LRB- B , D -RRB-	24066
@NP	Representative images -LRB- A , C -RRB-	24066
@NP	Representative images	24066
@NP	A , C	24089
@NP	A	24089
@NP	C	24092
@NP	enlargements -LRB- B , D -RRB-	24099
@NP	enlargements	24099
@NP	B , D	24113
@NP	B	24113
@NP	D	24116
@NP	serotonergic axons	24124
@NP	5-HT , red	24144
@NP	5-HT	24144
@NP	red	24150
@NP	yellow arrowheads	24175
@NP	the GFAP-positive rostral	24194
@NP	border	24220
@NP	the lesion core -LRB- * , yellow arrows -RRB- in FB	24236
@NP	the lesion core -LRB- * , yellow arrows -RRB-	24236
@NP	the lesion core	24236
@NP	* , yellow arrows	24253
@NP	*	24253
@NP	yellow arrows	24256
@NP	FB	24274
@NP	A , B	24279
@NP	A	24279
@NP	B	24282
@NP	OEC-transplanted -LRB- C , D -RRB- spinal cords	24289
@NP	E , Confocal image	24327
@NP	5-HT axons	24356
@NP	the astroglial scar border -LRB- white arrowheads -RRB-	24390
@NP	the astroglial scar border	24390
@NP	white arrowheads	24418
@NP	OECs -LRB- white arrows -RRB-	24448
@NP	OECs	24448
@NP	white arrows	24454
@NP	the GFAP-negative lesion core -LRB- inset -RRB-	24485
@NP	the GFAP-negative lesion core	24485
@NP	inset	24516
@NP	F	24524
@NP	Groups	24527
@NP	OECs	24537
@NP	bundles of NF-H-positive axons -LRB- red -RRB- and astrocytes -LRB- cyan -RRB-	24567
@NP	bundles	24567
@NP	NF-H-positive axons -LRB- red -RRB- and astrocytes -LRB- cyan -RRB-	24578
@NP	NF-H-positive axons	24578
@NP	red	24599
@NP	astrocytes	24608
@NP	cyan	24620
@NP	scaffolds	24635
@NP	OECs and axons	24649
@NP	the scar border -LRB- white arrowheads -RRB-	24681
@NP	the scar border	24681
@NP	white arrowheads	24698
@NP	average	24726
@NP	more 5-HT-labeled axon bundles	24735
@NP	the rostral border in OEC	24772
@NP	the rostral border	24772
@NP	OEC	24794
@NP	FB-treated rats at 1 and 2 weeks postinjury -LRB- G -RRB-	24804
@NP	FB-treated rats	24804
@NP	1 and 2 weeks postinjury -LRB- G -RRB-	24823
@NP	1 and 2 weeks postinjury	24823
@NP	1 and 2 weeks	24823
@NP	G	24849
@NP	The distance between the scar border and the most caudally extending 5-HT axon	24853
@NP	The distance	24853
@NP	the scar border and the most caudally extending 5-HT axon	24874
@NP	the scar border	24874
@NP	the most caudally extending 5-HT axon	24894
@NP	the most	24894
@NP	5-HT axon	24922
@NP	greater in OEC	24936
@NP	greater	24936
@NP	OEC	24947
@NP	FB-treated rats at 2 weeks -LRB- H -RRB-	24957
@NP	FB-treated rats	24957
@NP	2 weeks -LRB- H -RRB-	24976
@NP	2 weeks	24976
@NP	H	24985
@NP	Scale bars : A , C , 200 ¬ µm ; B , D ` ÄìF , 50 ¬ µm .	24989
@NP	Scale bars	24989
@NP	A	25001
@NP	C	25004
@NP	200 ¬ µm ; B , D ` ÄìF	25007
@NP	200 ¬ µm	25007
@NP	B , D ` ÄìF	25015
@NP	B	25015
@NP	D ` ÄìF	25018
@NP	D	25018
@NP	ÄìF	25020
@NP	50 ¬ µm	25025
@NP	Figure 4 .	25033
@NP	Figure	25033
@NP	4	25040
@NP	OECs	25043
@NP	inhibitory CSPGs	25055
@NP	the lesion core	25075
@NP	astrocyte border formation	25106
@NP	A , B , The spinal cord injury site and caudal stump border	25134
@NP	B	25136
@NP	The spinal cord injury site and caudal stump border	25139
@NP	astrocytes -LRB- GFAP , cyan -RRB-	25207
@NP	astrocytes	25207
@NP	GFAP , cyan	25219
@NP	GFAP	25219
@NP	cyan	25225
@NP	CSPGs -LRB- CS-56 , red -RRB-	25232
@NP	CSPGs	25232
@NP	CS-56	25239
@NP	red	25246
@NP	FBs -LRB- A , green -RRB-	25256
@NP	FBs	25256
@NP	A , green	25261
@NP	A	25261
@NP	green	25264
@NP	OECs -LRB- B , green -RRB- at 2 weeks postinjury	25274
@NP	OECs -LRB- B , green -RRB-	25274
@NP	OECs	25274
@NP	B , green	25280
@NP	B	25280
@NP	green	25283
@NP	2 weeks postinjury	25293
@NP	FBs -LRB- A , white arrows -RRB-	25313
@NP	FBs	25313
@NP	A , white arrows	25318
@NP	A	25318
@NP	white arrows	25321
@NP	high levels of CSPG	25348
@NP	high levels	25348
@NP	CSPG	25363
@NP	OECs -LRB- B , yellow arrows -RRB-	25376
@NP	OECs	25376
@NP	B , yellow arrows	25382
@NP	B	25382
@NP	yellow arrows	25385
@NP	the inverse	25405
@NP	Astrocyte processes in OEC-treated spinal cords	25418
@NP	Astrocyte processes	25418
@NP	OEC-treated spinal cords	25441
@NP	CSPG-positive cells -LRB- B , yellow arrowheads -RRB-	25475
@NP	CSPG-positive cells	25475
@NP	B , yellow arrowheads	25496
@NP	B	25496
@NP	yellow arrowheads	25499
@NP	a function	25519
@NP	FB-treated rats -LRB- A , white arrowheads -RRB-	25543
@NP	FB-treated rats	25543
@NP	A , white arrowheads	25560
@NP	A	25560
@NP	white arrowheads	25563
@NP	Individual channels of the entire image	25582
@NP	Individual channels	25582
@NP	the entire image	25605
@NP	the right	25639
@NP	distribution of each antibody	25657
@NP	distribution	25657
@NP	each antibody	25673
@NP	The mean luminance of CSPGs	25694
@NP	The mean luminance	25694
@NP	CSPGs	25716
@NP	the lesion core -LRB- C -RRB- and the rostral	25737
@NP	the lesion core -LRB- C -RRB-	25737
@NP	the lesion core	25737
@NP	C	25754
@NP	the rostral	25761
@NP	caudal stumps -LRB- D -RRB- of FB -LRB- black -RRB-	25777
@NP	caudal stumps -LRB- D -RRB-	25777
@NP	caudal stumps	25777
@NP	D	25792
@NP	FB -LRB- black -RRB-	25798
@NP	FB	25798
@NP	of OEC -LRB- green -RRB- transplanted spinal cords at 2 , 4 ,	25814
@NP	OEC -LRB- green -RRB-	25817
@NP	OEC	25817
@NP	transplanted spinal cords	25829
@NP	2 , 4 ,	25858
@NP	2	25858
@NP	4	25861
@NP	8 weeks postinjury	25868
@NP	8 weeks	25868
@NP	postinjury	25876
@NP	E , F , Astrocyte morphology at the lesion border ,	25888
@NP	E	25888
@NP	F	25891
@NP	Astrocyte morphology at the lesion border	25894
@NP	Astrocyte morphology	25894
@NP	the lesion border	25918
@NP	combined Aquaporin 4	25946
@NP	AQP4 , cyan	25968
@NP	AQP4	25968
@NP	cyan	25974
@NP	GFAP -LRB- cyan -RRB- staining ,	25984
@NP	GFAP	25984
@NP	cyan	25990
@NP	staining	25996
@NP	FB - -LRB- E -RRB- but not OEC-treated -LRB- F -RRB- spinal cords	26020
@NP	FB	26020
@NP	-LRB- E -RRB- but not OEC-treated -LRB- F -RRB- spinal cords	26024
@NP	-LRB- E -RRB-	26024
@NP	not OEC-treated -LRB- F -RRB- spinal cords	26032
@NP	F	26049
@NP	2 weeks postinjury	26069
@NP	Astrocytic processes	26089
@NP	a palisading arrangement	26115
@NP	OECs -LRB- F , yellow arrowheads -RRB-	26161
@NP	OECs	26161
@NP	F , yellow arrowheads	26167
@NP	F	26167
@NP	yellow arrowheads	26170
@NP	FBs -LRB- E , white arrowheads -RRB-	26233
@NP	FBs	26233
@NP	E , white arrowheads	26238
@NP	E	26238
@NP	white arrowheads	26241
@NP	High levels of fibronectin -LRB- red -RRB-	26260
@NP	High levels of fibronectin	26260
@NP	High levels	26260
@NP	fibronectin	26275
@NP	red	26288
@NP	FBs -LRB- E , individual channels -RRB-	26313
@NP	FBs	26313
@NP	E , individual channels	26318
@NP	E	26318
@NP	individual channels	26321
@NP	fibronectin-positive cells	26351
@NP	F , individual channels	26395
@NP	F	26395
@NP	individual channels	26398
@NP	astrocytes -LRB- yellow arrowheads -RRB-	26422
@NP	astrocytes	26422
@NP	yellow arrowheads	26434
@NP	OEC-treated rats	26456
@NP	Scale bars : A , B , E , F , 200 ¬ µm .	26474
@NP	Scale bars	26474
@NP	A , B , E , F , 200 ¬ µm	26486
@NP	A , B , E , F ,	26486
@NP	200 ¬ µm	26498
@NP	Figure 5 .	26507
@NP	Figure	26507
@NP	5	26514
@NP	OECs	26517
@NP	myelin debris	26529
@NP	2 , 4 , and 8 weeks postinjury	26546
@NP	2	26546
@NP	4	26549
@NP	8 weeks postinjury	26556
@NP	8 weeks	26556
@NP	postinjury	26564
@NP	Distribution of Oil Red O-labeled myelin debris -LRB- red puncta -RRB-	26576
@NP	Distribution	26576
@NP	Oil Red O-labeled myelin debris	26592
@NP	red puncta	26625
@NP	the lesion core -LRB- * -RRB- and stumps of FB -	26640
@NP	the lesion core -LRB- * -RRB-	26640
@NP	the lesion core	26640
@NP	stumps of FB	26664
@NP	stumps	26664
@NP	FB	26674
@NP	A , C , E	26679
@NP	OEC-treated spinal cords -LRB- B , D , F -RRB-	26692
@NP	OEC-treated spinal cords	26692
@NP	B , D , F	26718
@NP	The astroglial scar border	26738
@NP	GFAP -LRB- brown -RRB- immunostaining	26780
@NP	GFAP	26780
@NP	-LRB- brown -RRB- immunostaining	26785
@NP	A , B , At 2 weeks postinjury myelin debris -LRB- black arrows -RRB-	26809
@NP	A , B , At 2 weeks postinjury myelin debris	26809
@NP	A , B , At 2 weeks	26809
@NP	B	26812
@NP	2 weeks	26818
@NP	postinjury myelin debris	26826
@NP	black arrows	26852
@NP	the lesion border	26882
@NP	the stumps	26909
@NP	FB-treated -LRB- A -RRB- rats	26923
@NP	A	26935
@NP	less	26952
@NP	OEC-transplanted -LRB- B -RRB- rats	26970
@NP	B	26988
@NP	C ` ÄìF , Oil Red O-positive staining	26997
@NP	C	26997
@NP	ÄìF	26999
@NP	Oil Red O-positive staining	27004
@NP	the lesion site of FB	27054
@NP	the lesion site	27054
@NP	FB	27073
@NP	C , E	27078
@NP	C	27078
@NP	E	27081
@NP	not OEC-treated -LRB- D , F -RRB- spinal cords at 4 and 8 weeks	27088
@NP	not OEC-treated -LRB- D , F -RRB- spinal cords	27088
@NP	D , F	27105
@NP	D	27105
@NP	F	27108
@NP	at 4 and 8 weeks	27125
@NP	a ` Äìf	27154
@NP	Enlarged images	27161
@NP	the	27180
@NP	areas -LRB- insets -RRB- in A ` ÄìF show more red punctate	27190
@NP	areas -LRB- insets -RRB- in A ` ÄìF show	27190
@NP	areas -LRB- insets -RRB-	27190
@NP	areas	27190
@NP	insets	27197
@NP	A ` ÄìF show	27208
@NP	myelin debris -LRB- arrowheads -RRB-	27237
@NP	myelin debris	27237
@NP	arrowheads	27252
@NP	FB	27267
@NP	OEC-treated rats	27276
@NP	Scale bars : A ` ÄìF , 1 mm ; a ` Äìf , 100 ¬ µm .	27294
@NP	Scale bars	27294
@NP	A ` ÄìF , 1 mm	27306
@NP	A ` ÄìF	27306
@NP	1 mm	27313
@NP	a ` Äìf , 100 ¬ µm	27319
@NP	a ` Äìf	27319
@NP	100 ¬ µm	27326
@NP	Figure 6 .	27335
@NP	Figure	27335
@NP	6	27342
@NP	OECs	27345
@NP	immune cell activation	27357
@NP	the first 2 weeks postinjury	27387
@NP	A , Lesion site of an OEC-transplanted spinal cord 2 weeks postinjury	27417
@NP	A , Lesion site of an OEC-transplanted spinal cord	27417
@NP	Lesion site	27420
@NP	an OEC-transplanted	27435
@NP	2 weeks	27467
@NP	microglia/macrophages	27498
@NP	Iba-1 , red	27521
@NP	Iba-1	27521
@NP	red	27528
@NP	astrocytes	27537
@NP	GFAP , cyan	27549
@NP	GFAP	27549
@NP	cyan	27555
@NP	OECs	27562
@NP	this section	27587
@NP	White boxes	27601
@NP	the zones in which Iba-1 and GFAP immunofluorescence intensities were measured	27623
@NP	the zones	27623
@NP	Iba-1 and GFAP immunofluorescence intensities	27642
@NP	B ` ÄìE	27703
@NP	B	27703
@NP	ÄìE	27705
@NP	Graphical representation	27710
@NP	the mean Iba-1 luminance	27738
@NP	the rostral border -LRB- B -RRB-	27766
@NP	the rostral border	27766
@NP	B	27786
@NP	caudal border -LRB- C -RRB-	27790
@NP	caudal border	27790
@NP	C	27805
@NP	rostral stump -LRB- D -RRB-	27809
@NP	rostral stump	27809
@NP	D	27824
@NP	caudal stump -LRB- E -RRB-	27832
@NP	caudal stump	27832
@NP	E	27846
@NP	2 weeks	27853
@NP	Iba-1 intensities	27862
@NP	greater in FB	27885
@NP	greater	27885
@NP	FB	27896
@NP	OEC-treated spinal cords	27905
@NP	Scale bar : A , 500 ¬ µm .	27931
@NP	Scale bar	27931
@NP	A , 500 ¬ µm	27942
@NP	A	27942
@NP	500 ¬ µm	27945
@NP	Figure 7 .	27954
@NP	Figure	27954
@NP	7	27961
@NP	OECs	27964
@NP	immune cell infiltration	27976
@NP	the spinal cord stumps	28006
@NP	A ` ÄìD	28030
@NP	the rostral -LRB- A , B -RRB- and caudal border -LRB- C , D -RRB- zones	28044
@NP	the rostral -LRB- A , B -RRB-	28044
@NP	the rostral	28044
@NP	A , B	28057
@NP	A	28057
@NP	B	28060
@NP	caudal border -LRB- C , D -RRB- zones	28067
@NP	astrocytes -LRB- GFAP , cyan -RRB-	28095
@NP	astrocytes	28095
@NP	GFAP , cyan	28107
@NP	GFAP	28107
@NP	cyan	28113
@NP	activated macrophages / microglia -LRB- Iba-1 , red -RRB- are immunolabeled	28123
@NP	activated macrophages	28123
@NP	microglia -LRB- Iba-1 , red -RRB-	28146
@NP	microglia	28146
@NP	Iba-1 , red	28157
@NP	Iba-1	28157
@NP	red	28164
@NP	nuclei	28191
@NP	Hoechst	28211
@NP	yellow	28220
@NP	These images from FB - -LRB- A , C -RRB-	28229
@NP	These images	28229
@NP	FB	28247
@NP	A , C	28252
@NP	A	28252
@NP	C	28255
@NP	OEC-treated -LRB- B , D -RRB- lesion sites	28262
@NP	B , D	28275
@NP	B	28275
@NP	D	28278
@NP	2 -LRB- A , B -RRB- and 4 weeks -LRB- C , D -RRB- postinjury	28298
@NP	2 -LRB- A , B -RRB-	28298
@NP	2	28298
@NP	A , B	28301
@NP	A	28301
@NP	B	28304
@NP	4 weeks -LRB- C , D -RRB-	28311
@NP	postinjury	28326
@NP	Individual channels of the entire image	28338
@NP	Individual channels	28338
@NP	the entire image	28361
@NP	the left	28395
@NP	The GFAP scar border -LRB- cyan image -RRB-	28405
@NP	The GFAP scar border	28405
@NP	cyan image	28427
@NP	A ` ÄìD	28459
@NP	The distribution	28467
@NP	Iba-1-positive immune cells -LRB- red image -RRB-	28487
@NP	Iba-1-positive immune cells	28487
@NP	red image	28516
@NP	the GFAP-positive scar border and the lesion core	28535
@NP	the GFAP-positive scar border	28535
@NP	the lesion core	28569
@NP	the FB -LRB- A , C -RRB- versus OEC -LRB- B , D -RRB- sections	28600
@NP	the FB -LRB- A , C -RRB-	28600
@NP	the FB	28600
@NP	A , C	28608
@NP	A	28608
@NP	C	28611
@NP	OEC -LRB- B , D -RRB- sections	28621
@NP	OEC -LRB- B , D -RRB-	28621
@NP	OEC	28621
@NP	B , D	28626
@NP	B	28626
@NP	D	28629
@NP	sections	28632
@NP	Spherical Iba-1 immune cells	28642
@NP	distinct zones	28706
@NP	yellow arrows	28722
@NP	astrocyte processes in OEC - -LRB- B , D -RRB- but not FB-treated rats	28751
@NP	astrocyte processes in OEC - -LRB- B , D -RRB-	28751
@NP	astrocyte processes in OEC -	28751
@NP	astrocyte processes	28751
@NP	OEC	28774
@NP	B , D	28780
@NP	B	28780
@NP	D	28783
@NP	FB-treated rats	28794
@NP	A , C	28811
@NP	A	28811
@NP	C	28814
@NP	Astrocyte processes in FB-treated rats bundle together tightly and are oriented	28818
@NP	Astrocyte processes	28818
@NP	FB-treated rats bundle together tightly and are oriented	28841
@NP	FB-treated rats	28841
@NP	parallel -LRB- white arrowheads -RRB-	28898
@NP	parallel	28898
@NP	white arrowheads	28908
@NP	the scar border	28929
@NP	they	28953
@NP	yellow arrowheads	28994
@NP	OEC-treated rats	29016
@NP	Hoechst nuclear staining -LRB- yellow image -RRB-	29034
@NP	Hoechst nuclear staining	29034
@NP	yellow image	29060
@NP	an even	29080
@NP	Figure legend	29089
@NP	Figure 8 .	29116
@NP	Figure	29116
@NP	8	29123
@NP	CSA administration	29126
@NP	graft survival	29154
@NP	2 and 8 weeks postinjury	29172
@NP	A ` ÄìD	29198
@NP	CSA immunosuppression both FB -LRB- A , C -RRB- and OEC -LRB- B , D -RRB-	29210
@NP	CSA immunosuppression both FB	29210
@NP	A , C	29241
@NP	A	29241
@NP	C	29244
@NP	OEC	29251
@NP	B , D	29256
@NP	B	29256
@NP	D	29259
@NP	transplanted cells	29262
@NP	the lesion core -LRB- * -RRB-	29308
@NP	the lesion core	29308
@NP	2 weeks	29331
@NP	A , B	29340
@NP	A	29340
@NP	B	29343
@NP	8 weeks -LRB- C , D -RRB-	29369
@NP	8 weeks	29369
@NP	postinjury	29384
@NP	GFP-labeled cells	29396
@NP	the stumps -LRB- white arrows -RRB- and lesion core -LRB- white arrowheads -RRB-	29428
@NP	the stumps	29428
@NP	white arrows	29440
@NP	lesion core	29458
@NP	white arrowheads	29471
@NP	OEC-treated rats	29505
@NP	E	29523
@NP	Comparison	29526
@NP	the percentage of GFP in the lesion core of FB - -LRB- left , black -RRB-	29540
@NP	the percentage	29540
@NP	GFP in the lesion core of FB -	29558
@NP	GFP	29558
@NP	the lesion core	29565
@NP	FB	29584
@NP	black	29595
@NP	OEC	29606
@NP	green	29619
@NP	rats	29634
@NP	CSA -LRB- FB+CSA , orange ; OEC+CSA , purple -RRB-	29655
@NP	CSA	29655
@NP	FB+CSA , orange ; OEC+CSA , purple	29660
@NP	FB+CSA	29660
@NP	orange ; OEC+CSA	29668
@NP	orange	29668
@NP	OEC+CSA	29676
@NP	purple	29685
@NP	The volume of FBs and OECs in the lesion core	29694
@NP	The volume	29694
@NP	FBs and OECs in the lesion core	29708
@NP	FBs and OECs	29708
@NP	the lesion core	29724
@NP	CSA administration	29769
@NP	F , The difference in Iba-1 luminance in the stumps	29789
@NP	F	29789
@NP	The difference in Iba-1 luminance in the stumps	29792
@NP	The difference	29792
@NP	Iba-1 luminance in the stumps	29810
@NP	Iba-1 luminance	29810
@NP	the stumps	29829
@NP	the lesion core	29852
@NP	immune cell infiltration	29886
@NP	2 week CSA+FB	29924
@NP	non-CSA FB-treated rats	29947
@NP	The group	29972
@NP	Iba-l luminance	29991
@NP	OEC-treated rats	30010
@NP	CSA treatment	30047
@NP	Scale bars : A ` ÄìD , 1 mm .	30062
@NP	Scale bars	30062
@NP	A ` ÄìD , 1 mm	30074
@NP	A ` ÄìD	30074
@NP	1 mm	30081
@NP	Figure 9 .	30088
@NP	Figure	30088
@NP	9	30095
@NP	OEC survival in CSA-treated rats	30098
@NP	OEC survival	30098
@NP	CSA-treated rats	30114
@NP	neuronal degeneration	30139
@NP	serotonergic axonal preservation	30174
@NP	A , B , The same section	30208
@NP	B	30210
@NP	The same section	30213
@NP	A -LRB- red neurons and cyan GFAP scar border -RRB- andB	30248
@NP	A -LRB- red neurons and cyan GFAP scar border -RRB-	30248
@NP	A	30248
@NP	red neurons and cyan GFAP scar border	30251
@NP	red neurons	30251
@NP	cyan GFAP scar border	30267
@NP	red neurons and green OECs	30295
@NP	red neurons	30295
@NP	green OECs	30311
@NP	CSA and OEC treatment	30338
@NP	neurons -LRB- white arrows -RRB-	30361
@NP	neurons	30361
@NP	white arrows	30370
@NP	the astrocyte scar border -LRB- cyan -RRB-	30406
@NP	the astrocyte scar border	30406
@NP	cyan	30433
@NP	2weeks postinjury -LRB- A -RRB-	30442
@NP	2weeks postinjury	30442
@NP	A	30461
@NP	Neurons marked with white arrowheads -LRB- A , B -RRB-	30465
@NP	Neurons	30465
@NP	white arrowheads	30485
@NP	A , B	30503
@NP	A	30503
@NP	B	30506
@NP	the lesion core -LRB- * -RRB-	30521
@NP	the lesion core	30521
@NP	OECs -LRB- B , inset -RRB-	30563
@NP	OECs	30563
@NP	C	30580
@NP	Confocal 3D visualization	30583
@NP	neurofilament-labeled axons -LRB- red -RRB-	30612
@NP	neurofilament-labeled axons	30612
@NP	red	30641
@NP	the lesion core	30653
@NP	OECs in horizontal -LRB- white arrows -RRB-	30693
@NP	OECs	30693
@NP	horizontal -LRB- white arrows -RRB-	30701
@NP	horizontal	30701
@NP	white arrows	30713
@NP	cross-sectional -LRB- white arrowhead -RRB- orientation at 8 weeks postinjury	30731
@NP	cross-sectional -LRB- white arrowhead -RRB- orientation	30731
@NP	white arrowhead	30748
@NP	8 weeks postinjury	30780
@NP	an OEC+CSA	30802
@NP	rat.D , E ,	30821
@NP	rat.D	30821
@NP	E	30828
@NP	non-CSA-treated rats	30843
@NP	the number of 5-HT axons crossing the scar border	30865
@NP	the number	30865
@NP	5-HT axons crossing the scar border	30879
@NP	5-HT axons	30879
@NP	the scar border	30899
@NP	the area of 5-HT in the lesion core	30931
@NP	the area	30931
@NP	5-HT in the lesion core	30943
@NP	5-HT	30943
@NP	the lesion core	30951
@NP	FB+CSA - and OEC+CSA	30980
@NP	rats	31008
@NP	2 weeks	31016
@NP	F	31025
@NP	The average distance	31028
@NP	the furthest extending 5-HT axon and the scar border	31057
@NP	the furthest	31057
@NP	5-HT axon and the scar border	31080
@NP	5-HT axon	31080
@NP	the scar border	31094
@NP	8-week OEC+CSA	31125
@NP	rats	31148
@NP	any other treatment group -LRB- FB , FB+CSA , OEC -RRB-	31158
@NP	any other treatment group	31158
@NP	FB , FB+CSA , OEC	31185
@NP	The mean luminance of CSPGs	31207
@NP	The mean luminance	31207
@NP	CSPGs	31229
@NP	the lesion core -LRB- G -RRB-	31250
@NP	the lesion core	31250
@NP	G	31267
@NP	stumps -LRB- H -RRB- of FB+CSA -LRB- orange -RRB-	31274
@NP	stumps -LRB- H -RRB-	31274
@NP	stumps	31274
@NP	H	31282
@NP	FB+CSA -LRB- orange -RRB-	31288
@NP	FB+CSA	31288
@NP	orange	31296
@NP	OEC+CSA -LRB- purple -RRB-	31312
@NP	OEC+CSA	31312
@NP	purple	31321
@NP	spinal cords	31337
@NP	2 and 8 weeks postinjury	31353
@NP	the lesion core -LRB- G -RRB-	31386
@NP	the lesion core	31386
@NP	G	31403
@NP	FB-treated rats	31407
@NP	levels of CSPGs with versus without CSA administration	31435
@NP	levels	31435
@NP	CSPGs with versus without CSA administration	31445
@NP	CSPGs	31445
@NP	CSA administration	31471
@NP	8 weeks	31493
@NP	OEC-treated rats	31510
@NP	lower levels of CSPGs	31531
@NP	lower levels	31531
@NP	CSPGs	31547
@NP	OEC+CSA	31558
@NP	rats	31574
@NP	2 weeks	31582
@NP	postinjury	31590
@NP	Scale bars : A , B , 500 ¬ µm ; inset , 50 ¬ µm ; C , 5 ¬ µm .	31602
@NP	Scale bars	31602
@NP	A , B , 500 ¬ µm ; inset , 50 ¬ µm ; C , 5 ¬ µm	31614
@NP	A , B , 500 ¬ µm ; inset	31614
@NP	A , B , 500 ¬ µm ;	31614
@NP	A	31614
@NP	B	31616
@NP	500 ¬ µm	31619
@NP	500 ¬	31619
@NP	µm	31623
@NP	50 ¬ µm	31634
@NP	50 ¬	31634
@NP	µm	31637
@NP	C , 5 ¬ µm	31641
@NP	C	31641
@NP	5 ¬ µm	31644
@NP	Figure 10 .	31651
@NP	Figure	31651
@NP	10	31658
@NP	CSA treatment	31662
@NP	OEC-mediated myelin uptake at 2 and 8 weeks postinjury	31685
@NP	OEC-mediated myelin uptake	31685
@NP	2 and 8 weeks postinjury	31715
@NP	Oil	31746
@NP	Red O-labeled myelin debris -LRB- red spheres -RRB-	31750
@NP	Red O-labeled myelin debris	31750
@NP	red spheres	31779
@NP	the lesion core -LRB- * -RRB-	31807
@NP	the lesion core	31807
@NP	stumps -LRB- brown , GFAP -RRB-	31831
@NP	stumps	31831
@NP	brown , GFAP	31839
@NP	brown	31839
@NP	GFAP	31846
@NP	FB+CSA -LRB- A , C -RRB- than OEC+CSA - treated spinal cords -LRB- B , D -RRB-	31855
@NP	FB+CSA -LRB- A , C -RRB-	31855
@NP	FB+CSA	31855
@NP	A , C	31863
@NP	A	31863
@NP	C	31866
@NP	OEC+CSA - treated spinal cords	31874
@NP	OEC+CSA	31874
@NP	spinal cords	31890
@NP	B , D	31904
@NP	B	31904
@NP	D	31907
@NP	A , B , Myelin debris -LRB- black arrows -RRB-	31911
@NP	A , B , Myelin debris	31911
@NP	B	31914
@NP	black arrows	31932
@NP	the stumps and lesion core	31966
@NP	FB+CSA	31996
@NP	OEC	32015
@NP	CSA-treated spinal cords	32020
@NP	2 weeks postinjury	32048
@NP	8 weeks	32077
@NP	rats treated with FB+CSA	32097
@NP	rats	32097
@NP	FB+CSA	32115
@NP	more myelin debris present in the stumps	32126
@NP	more myelin debris	32126
@NP	the stumps	32156
@NP	those treated with OEC+CSA	32172
@NP	those	32172
@NP	OEC+CSA	32191
@NP	a ` Äìd	32200
@NP	Enlarged images	32207
@NP	the	32226
@NP	areas -LRB- insets -RRB- in A ` ÄìD	32236
@NP	areas -LRB- insets -RRB-	32236
@NP	areas	32236
@NP	insets	32243
@NP	A ` ÄìD	32254
@NP	more red punctate	32265
@NP	Oil Red O-staining in FB+CSA than OEC+CSA	32283
@NP	Oil Red O-staining	32283
@NP	FB+CSA than OEC+CSA	32305
@NP	FB+CSA	32305
@NP	OEC+CSA	32317
@NP	spinal cords	32333
@NP	E , Orthogonal view of a Cell	32347
@NP	E , Orthogonal view	32347
@NP	a Cell	32369
@NP	Tracker Green-labeled OEC -LRB- green -RRB-	32376
@NP	Tracker Green-labeled OEC	32376
@NP	MBP-positive myelin debris -LRB- red , white arrowheads -RRB-	32424
@NP	MBP-positive myelin debris	32424
@NP	red , white arrowheads	32452
@NP	red	32452
@NP	white arrowheads	32457
@NP	Scale bars : A ` ÄìD , 1 mm ; a ` Äìd , 100 ¬ µm ; E , 5 ¬ µm .	32485
@NP	Scale bars	32485
@NP	A ` ÄìD , 1 mm	32497
@NP	A ` ÄìD	32497
@NP	1 mm	32504
@NP	a ` Äìd , 100 ¬ µm	32510
@NP	a ` Äìd	32510
@NP	100 ¬ µm	32517
@NP	E , 5 ¬ µm	32525
@NP	E	32525
@NP	5 ¬ µm	32528
@NP	Wild-type and GFP-OECs	32535
@NP	Wild-type	32535
@NP	GFP-OECs	32549
@NP	similar growth promoting abilities OECs are unique glia of the olfactory system	32563
@NP	similar growth	32563
@NP	abilities OECs are unique glia of the olfactory system	32588
@NP	abilities	32588
@NP	OECs	32598
@NP	unique glia of the olfactory system	32607
@NP	unique glia	32607
@NP	the olfactory system	32622
@NP	they	32648
@NP	markers	32661
@NP	astrocytes , oligodendrocytes , and Schwann cells	32679
@NP	No OEC-specific marker	32728
@NP	transplanted cells in this study	32787
@NP	transplanted cells	32787
@NP	this study	32809
@NP	we	32821
@NP	OECs	32832
@NP	GFPlabeled rats generated by random transgene integration into the genome	32842
@NP	GFPlabeled rats	32842
@NP	random transgene integration	32871
@NP	the genome	32905
@NP	OECs cultured from GFP-expressing rats -LRB- GFP-OECs -RRB-	32935
@NP	OECs	32935
@NP	GFP-expressing rats	32954
@NP	GFP-OECs	32975
@NP	those derived from wild-type nontransgenic rats	32999
@NP	those	32999
@NP	wild-type nontransgenic rats	33018
@NP	we	33048
@NP	GFP-OECs	33060
@NP	expression of typical markers	33073
@NP	expression	33073
@NP	typical markers	33087
@NP	Most GFP-OECs	33104
@NP	established OEC markers -LRB- 89 % p-75-NGFR ; 96 % S100 ; 100 % Sox10 -RRB-	33128
@NP	established OEC markers	33128
@NP	89 % p-75-NGFR ; 96 % S100 ; 100 % Sox10	33153
@NP	89 % p-75-NGFR	33153
@NP	96 % S100 ; 100 % Sox10	33168
@NP	96 % S100	33168
@NP	100 % Sox10	33178
@NP	We	33191
@NP	the growth	33208
@NP	abilities of wild-type OECs	33229
@NP	abilities	33229
@NP	wild-type OECs	33242
@NP	GFP-OECs	33262
@NP	We	33272
@NP	postnatal cortical neurons on	33284
@NP	postnatal cortical neurons	33284
@NP	-LRB- positive control -RRB-	33327
@NP	PLL	33351
@NP	-LRB- neutral substrate -RRB- ,	33355
@NP	-LRB- neutral substrate -RRB-	33355
@NP	-LRB- 3 -RRB- PLL and OEC , and -LRB- 4 -RRB- PLL and GFP-OEC	33376
@NP	-LRB- 3 -RRB- PLL and OEC	33376
@NP	PLL	33380
@NP	OEC	33388
@NP	-LRB- 4 -RRB- PLL and GFP-OEC	33397
@NP	PLL	33401
@NP	GFP-OEC	33409
@NP	Neurites	33418
@NP	processes	33437
@NP	laminin	33464
@NP	outgrowth on the PLL substrate	33489
@NP	outgrowth	33489
@NP	the PLL substrate	33502
@NP	neurite length	33532
@NP	: laminin 146 ¬ ± 31 ¬ µm ; PLL 54 ¬ ± 9 ¬ µm ; p = 0.0014	33549
@NP	laminin 146 ¬ ± 31 ¬ µm	33551
@NP	laminin 146 ¬	33551
@NP	± 31 ¬ µm	33564
@NP	PLL 54 ¬ ± 9 ¬ µm	33574
@NP	PLL 54	33574
@NP	¬ ± 9 ¬ µm	33581
@NP	¬ ±	33581
@NP	9 ¬ µm	33584
@NP	p = 0.0014	33591
@NP	p	33591
@NP	0.0014	33595
@NP	The addition of OECs or GFP-OECs	33604
@NP	The addition	33604
@NP	OECs or GFP-OECs	33620
@NP	neurite outgrowth	33660
@NP	PLL alone	33692
@NP	OEC 117 ¬ ± 19 ¬ µm , p = 0.0114 ; GFP-OECs 118 ¬ ± 29 ¬ µm , p = 0.0111	33703
@NP	OEC 117 ¬ ± 19 ¬ µm	33703
@NP	OEC 117 ¬	33703
@NP	± 19 ¬ µm	33712
@NP	p = 0.0114 ; GFP-OECs 118 ¬ ± 29 ¬ µm	33722
@NP	p = 0.0114	33722
@NP	p	33722
@NP	0.0114	33726
@NP	GFP-OECs 118 ¬ ± 29 ¬ µm	33734
@NP	GFP-OECs 118 ¬	33734
@NP	± 29 ¬ µm	33748
@NP	p = 0.0111	33758
@NP	p	33758
@NP	0.0111	33762
@NP	neurite outgrowth	33779
@NP	OECs and GFP-OECs -LRB- p = 0.986 -RRB-	33820
@NP	OECs and GFP-OECs	33820
@NP	p	33839
@NP	0.986	33843
@NP	the random GFP gene insertion	33850
@NP	the growth promoting effects of OECs	33905
@NP	the growth	33905
@NP	effects of OECs	33926
@NP	effects	33926
@NP	OECs	33937
@NP	OECs	33943
@NP	FBs	33968
@NP	transplantation Transplanted FBs and OECs	33978
@NP	the GFAP-positive rostral	34047
@NP	caudal stumps	34080
@NP	the lesion core	34099
@NP	the first week postinjury -LRB- Fig. 1A , B ; Table 1 -RRB-	34122
@NP	the first week postinjury	34122
@NP	Fig. 1A , B ; Table 1	34149
@NP	Fig. 1A	34149
@NP	B ; Table 1	34157
@NP	B	34157
@NP	Table 1	34160
@NP	week 1	34177
@NP	the transplanted cells	34185
@NP	their differences	34240
@NP	size and cellular morphology	34261
@NP	size	34261
@NP	cellular morphology	34270
@NP	Fig. 1G , H	34291
@NP	Fig. 1G	34291
@NP	H	34299
@NP	Ovoid-shaped FBs	34303
@NP	a contiguous carpet-like arrangement	34327
@NP	a larger area	34375
@NP	spindle-shaped OECs that aligned into tubular networks -LRB- Fig. 1G , H -RRB-	34394
@NP	spindle-shaped OECs	34394
@NP	tubular networks	34432
@NP	Fig. 1G , H	34450
@NP	Fig. 1G	34450
@NP	H	34458
@NP	2 weeks	34465
@NP	there	34474
@NP	a clear loss of cells in the lesion core	34484
@NP	a clear loss	34484
@NP	cells in the lesion core	34500
@NP	cells	34500
@NP	the lesion core	34509
@NP	FBs and OECs	34528
@NP	the spinal cord stumps	34567
@NP	Fig. 1C , D	34591
@NP	Fig. 1C	34591
@NP	D	34599
@NP	GFPpositive debris	34617
@NP	the lesion core and the stumps	34649
@NP	the lesion core	34649
@NP	the stumps	34669
@NP	2 and 4 weeks postinjury , consistent	34683
@NP	2 and 4 weeks	34683
@NP	graft cell death	34725
@NP	4 weeks	34746
@NP	none of the rats transplanted with FBs	34755
@NP	none	34755
@NP	the rats transplanted with FBs	34763
@NP	the rats	34763
@NP	FBs	34790
@NP	GFP-labeled cells	34798
@NP	OECs	34825
@NP	five of eight rats -LRB- Fig. 1E , F -RRB-	34842
@NP	five	34842
@NP	eight rats -LRB- Fig. 1E , F -RRB-	34850
@NP	eight rats	34850
@NP	Fig. 1E , F	34862
@NP	Fig. 1E	34862
@NP	F	34870
@NP	those five rats with OECs	34877
@NP	those five rats	34877
@NP	OECs	34898
@NP	two rats	34904
@NP	OECs in the rostral	34917
@NP	OECs	34917
@NP	the rostral	34925
@NP	caudal stumps and three	34941
@NP	caudal stumps	34941
@NP	three	34959
@NP	the majority of OECs in the lesion core -LRB- Fig. 1F -RRB-	34969
@NP	the majority	34969
@NP	OECs in the lesion core -LRB- Fig. 1F -RRB-	34985
@NP	OECs	34985
@NP	the lesion core -LRB- Fig. 1F -RRB-	34993
@NP	the lesion core	34993
@NP	Fig. 1F	35010
@NP	more OECs	35035
@NP	the lesion core	35057
@NP	4 than at 2 weeks -LRB- Fig. 1 , compare D , F -RRB-	35076
@NP	4 than at 2 weeks	35076
@NP	Fig. 1 , compare D , F	35095
@NP	Fig. 1	35095
@NP	D , F	35111
@NP	D	35111
@NP	F	35114
@NP	a few OECs	35127
@NP	the stumps	35156
@NP	none	35172
@NP	the lesion core	35189
@NP	8 weeks -LRB- data not shown -RRB-	35208
@NP	8 weeks	35208
@NP	data not shown	35217
@NP	data	35217
@NP	These data	35234
@NP	OECs	35258
@NP	FBs	35283
@NP	transplantation	35293
@NP	FB and OEC survival and migration	35322
@NP	FB and OEC survival	35322
@NP	migration	35346
@NP	the volume	35357
@NP	GFP-labeled cells	35371
@NP	the lesion core divided by the total volume of GFP in the spinal cord	35392
@NP	the lesion core	35392
@NP	the total volume of GFP	35419
@NP	the total volume	35419
@NP	GFP	35439
@NP	the spinal cord	35446
@NP	a percentage	35478
@NP	1	35495
@NP	week	35497
@NP	a large percentage of the GFP-labeled cells	35502
@NP	a large percentage	35502
@NP	the GFP-labeled cells	35524
@NP	the lesion core -LRB- Fig. 1J ; FB 72 ¬ ± 5 % vs OEC 79 ¬ ± 4 % -RRB-	35560
@NP	the lesion core	35560
@NP	Fig. 1J ; FB 72 ¬ ± 5 % vs OEC 79 ¬ ± 4 %	35577
@NP	Fig. 1J	35577
@NP	FB 72 ¬ ± 5 % vs OEC 79 ¬ ± 4 %	35586
@NP	FB 72 ¬ ± 5 %	35586
@NP	FB 72 ¬	35586
@NP	± 5 %	35593
@NP	OEC 79 ¬ ± 4 %	35601
@NP	OEC 79 ¬	35601
@NP	± 4 %	35609
@NP	The decrease in survival of transplanted cells in the lesion core at 2 weeks	35616
@NP	The decrease	35616
@NP	survival of transplanted cells in the lesion core at 2 weeks	35632
@NP	survival	35632
@NP	transplanted cells in the lesion core at 2 weeks	35644
@NP	transplanted cells	35644
@NP	the lesion core	35666
@NP	at 2 weeks	35682
@NP	Fig. 1J ; FB 3 ¬ ± 3 % vs OEC 14 ¬ ± 7 %	35709
@NP	Fig. 1J	35709
@NP	FB 3 ¬ ± 3 % vs OEC 14 ¬ ± 7 %	35718
@NP	FB 3 ¬ ± 3 %	35718
@NP	FB 3 ¬	35718
@NP	± 3 %	35724
@NP	OEC 14 ¬ ± 7 %	35732
@NP	OEC	35732
@NP	14 ¬ ± 7 %	35736
@NP	14 ¬ ±	35736
@NP	4 weeks	35750
@NP	GFP-labeled cells	35759
@NP	the lesion core	35796
@NP	OECtreated rats -LRB- Fig. 1J ; FB 0 % vs OEC 23 ¬ ± 14 % ; p = 0.0381 -RRB-	35815
@NP	OECtreated rats	35815
@NP	Fig. 1J ; FB 0 % vs OEC 23 ¬ ± 14 % ; p = 0.0381	35832
@NP	Fig. 1J	35832
@NP	FB 0 % vs OEC 23 ¬ ± 14 % ; p = 0.0381	35841
@NP	FB 0 %	35841
@NP	FB	35841
@NP	0 %	35844
@NP	OEC 23 ¬ ± 14 % ; p = 0.0381	35850
@NP	OEC 23 ¬ ± 14 %	35850
@NP	OEC 23 ¬	35850
@NP	± 14 %	35858
@NP	p = 0.0381	35865
@NP	p	35865
@NP	0.0381	35869
@NP	This finding	35878
@NP	OECs	35906
@NP	the lesion core between 2 and 4 weeks	35936
@NP	the lesion core	35936
@NP	2 and 4 weeks	35960
@NP	the lesion core	35983
@NP	FBs	36000
@NP	a continuous sheet of cells	36011
@NP	a continuous sheet	36011
@NP	cells	36033
@NP	OECs	36048
@NP	delicate trabecular-like networks -LRB- Fig. 1G ` ÄìI -RRB-	36067
@NP	delicate trabecular-like networks	36067
@NP	Fig. 1G ` ÄìI	36102
@NP	Fig. 1G	36102
@NP	` ÄìI	36109
@NP	the extent	36128
@NP	FBs and OECs	36144
@NP	the lesion core	36164
@NP	the volume of GFP-labeled cells	36181
@NP	the volume	36181
@NP	GFP-labeled cells	36195
@NP	the volume of the fibronectin-positive extracellular matrix in the lesion core	36228
@NP	the volume	36228
@NP	the fibronectin-positive extracellular matrix in the lesion core	36242
@NP	the fibronectin-positive extracellular matrix	36242
@NP	the lesion core	36291
@NP	a percentage	36323
@NP	FBs	36337
@NP	âà83	36349
@NP	17 %	36356
@NP	the lesion at 1	36363
@NP	the lesion	36363
@NP	1	36377
@NP	week	36379
@NP	2 weeks	36392
@NP	few FBs	36400
@NP	3 * 3 %	36418
@NP	3 * 3	36418
@NP	3	36418
@NP	3	36421
@NP	%	36422
@NP	OECs	36426
@NP	34	36438
@NP	6 % of the lesion volume	36441
@NP	6 %	36441
@NP	the lesion volume	36447
@NP	1 week	36468
@NP	2 weeks	36483
@NP	âà1 % of the lesion volume	36498
@NP	âà1 %	36498
@NP	the lesion volume	36506
@NP	OECs	36534
@NP	Interestingly , by 4 weeks OECs likely	36540
@NP	Interestingly , by 4 weeks OECs	36540
@NP	4 weeks	36558
@NP	the stumps	36592
@NP	the lesion core	36608
@NP	they	36627
@NP	8 ¬	36643
@NP	± 5 % of the lesion volume	36646
@NP	± 5 %	36646
@NP	the lesion volume	36654
@NP	These data	36673
@NP	FBs	36697
@NP	more of the lesion core	36716
@NP	more	36716
@NP	the lesion core	36724
@NP	OECs	36745
@NP	this difference	36755
@NP	time	36794
@NP	OECs	36800
@NP	neuronal degeneration	36812
@NP	a spinal cord transection	36840
@NP	We	36866
@NP	OEC transplantation	36888
@NP	long lasting effects on neuronal survival	36912
@NP	long lasting effects	36912
@NP	neuronal survival	36936
@NP	OECs	36976
@NP	neurons	36995
@NP	we	37004
@NP	the shortest distance	37016
@NP	the astroglial scar border and NeuN-labeled neuronal cell bodies	37046
@NP	the astroglial scar border	37046
@NP	NeuN-labeled neuronal cell bodies	37077
@NP	the rostral and caudal stumps -LRB- Fig. 2A -RRB-	37114
@NP	the rostral	37114
@NP	caudal stumps -LRB- Fig. 2A -RRB-	37130
@NP	caudal stumps	37130
@NP	Fig. 2A	37145
@NP	The distance between the GFAP border and the nearest neuron	37155
@NP	The distance	37155
@NP	the GFAP border and the nearest neuron	37176
@NP	the GFAP border	37176
@NP	the nearest neuron	37196
@NP	the rostral and caudal stumps	37238
@NP	the rostral	37238
@NP	caudal stumps	37254
@NP	values from the two stumps	37277
@NP	values	37277
@NP	the two stumps	37289
@NP	the average neuron-free distance	37328
@NP	the stumps	37364
@NP	Neuronal cell bodies	37376
@NP	the astroglial scar border in OEC - than in FB-transplanted rats	37420
@NP	the astroglial scar border	37420
@NP	OEC	37450
@NP	FB-transplanted rats	37463
@NP	1 and 2 weeks	37487
@NP	Fig. 2C ; 1 week FB 1.2 ¬ ± 0.1 vs OEC 0.5 ¬ ± 0.1 mm	37502
@NP	Fig. 2C	37502
@NP	1 week FB 1.2 ¬ ± 0.1 vs OEC 0.5 ¬ ± 0.1 mm	37511
@NP	1 week FB	37511
@NP	1.2 ¬ ± 0.1 vs OEC 0.5 ¬ ± 0.1 mm	37521
@NP	1.2 ¬ ± 0.1	37521
@NP	1.2 ¬	37521
@NP	± 0.1	37526
@NP	OEC 0.5 ¬ ± 0.1 mm	37535
@NP	OEC 0.5 ¬	37535
@NP	± 0.1 mm	37544
@NP	p = 0.0502 ; 2 week FB 1.9 ¬ ± 0.5 vs OEC 0.6 ¬ ± 0.2 mm	37554
@NP	p = 0.0502	37554
@NP	p	37554
@NP	0.0502	37558
@NP	2 week FB 1.9 ¬ ± 0.5 vs OEC 0.6 ¬ ± 0.2 mm	37566
@NP	2 week FB	37566
@NP	1.9 ¬ ± 0.5 vs OEC 0.6 ¬ ± 0.2 mm	37576
@NP	1.9 ¬ ± 0.5	37576
@NP	1.9 ¬	37576
@NP	± 0.5	37581
@NP	OEC 0.6 ¬ ± 0.2 mm	37590
@NP	OEC 0.6 ¬	37590
@NP	± 0.2 mm	37599
@NP	p = 0.0004	37609
@NP	p	37609
@NP	0.0004	37613
@NP	addition	37625
@NP	the first 2 weeks	37642
@NP	the total distance between the closest rostral and caudal stump neurons	37660
@NP	the total distance	37660
@NP	the closest rostral and caudal stump neurons	37687
@NP	the closest rostral	37687
@NP	caudal stump neurons	37711
@NP	FB-treated spinal cords	37764
@NP	Fig. 2D ; 1 week FB 7.2 ¬ ± 0.3 vs OEC 5.2 ¬ ± 0.3 mm	37789
@NP	Fig. 2D	37789
@NP	1 week FB 7.2 ¬ ± 0.3 vs OEC 5.2 ¬ ± 0.3 mm	37798
@NP	1 week FB 7.2 ¬ ± 0.3	37798
@NP	1 week FB	37798
@NP	7.2 ¬	37808
@NP	± 0.3	37812
@NP	OEC 5.2 ¬ ± 0.3 mm	37821
@NP	OEC 5.2 ¬	37821
@NP	± 0.3 mm	37829
@NP	p = 0.0024 ; 2 week FB 7.4 ¬ ± 1 vs OEC 4.1 ¬ ± 0.6 mm	37838
@NP	p = 0.0024	37838
@NP	p	37838
@NP	0.0024	37840
@NP	2 week FB 7.4 ¬ ± 1 vs OEC 4.1 ¬ ± 0.6 mm	37848
@NP	2 week FB	37848
@NP	7.4 ¬ ± 1 vs OEC 4.1 ¬ ± 0.6 mm	37858
@NP	7.4 ¬ ± 1	37858
@NP	7.4 ¬	37858
@NP	± 1	37862
@NP	OEC 4.1 ¬ ± 0.6 mm	37868
@NP	OEC 4.1 ¬	37868
@NP	± 0.6 mm	37877
@NP	p = 0.0272	37887
@NP	p	37887
@NP	0.0272	37891
@NP	the extent of neuronal survival	37909
@NP	the extent	37909
@NP	neuronal survival	37923
@NP	transplant groups	37964
@NP	4 weeks	37985
@NP	we	37994
@NP	spinal cord neurons ensheathed by GFP-positive OECs	38006
@NP	spinal cord neurons	38006
@NP	GFP-positive OECs	38040
@NP	FBs in the lesion core -LRB- Fig. 2B -RRB-	38066
@NP	FBs	38066
@NP	the lesion core -LRB- Fig. 2B -RRB-	38073
@NP	the lesion core	38073
@NP	Fig. 2B	38090
@NP	OEC transplantation	38106
@NP	neuronal survival	38135
@NP	the stumps	38156
@NP	the surviving neurons	38180
@NP	the lesion core	38209
@NP	OEC transplants	38226
@NP	axonal dieback	38249
@NP	a spinal cord transection	38270
@NP	a spinal cord injury	38314
@NP	astrocytes	38336
@NP	their processes to seal off the lesion	38374
@NP	the lesion	38402
@NP	the ` Äúpathways	38431
@NP	Äù	38447
@NP	routes for regenerating axons	38482
@NP	routes	38482
@NP	regenerating axons	38493
@NP	Li	38513
@NP	et al. , 2005b	38516
@NP	et al.	38516
@NP	2005b	38524
@NP	OEC transplantation	38557
@NP	axons	38592
@NP	we	38598
@NP	the raphespinal tract	38612
@NP	ie , descending serotonergic -LRB- 5-HT -RRB- axons	38635
@NP	serotonergic -LRB- 5-HT -RRB- axons	38650
@NP	5-HT	38664
@NP	locomotion	38690
@NP	FB	38705
@NP	OEC-treated spinal cords	38713
@NP	we	38750
@NP	5-HT axons	38764
@NP	the rostral stump	38789
@NP	the lesion core	38812
@NP	a complete spinal cord transection	38834
@NP	the raphespinal tract thanintraspinal5-HTneurons	38893
@NP	Takeokaet	38942
@NP	al. , 2011	38952
@NP	al.	38952
@NP	2011	38957
@NP	OEC treatment	38974
@NP	multiple 5-HT axons	38989
@NP	astrocytes at the GFAP-positive border -LRB- Fig. 3C , D -RRB-	39037
@NP	astrocytes	39037
@NP	the GFAP-positive border -LRB- Fig. 3C , D -RRB-	39051
@NP	the GFAP-positive border	39051
@NP	Fig. 3C , D	39077
@NP	Fig. 3C	39077
@NP	D	39085
@NP	These 5-HT bundles	39089
@NP	astrocytes	39119
@NP	processes that effectively provide ` Äúpathways ` Äù	39167
@NP	processes	39167
@NP	Äúpathways ` Äù	39203
@NP	Äúpathways	39203
@NP	Äù	39214
@NP	severed axonstoregenerate -LRB- Fig. 3C , D -RRB-	39221
@NP	severed axonstoregenerate	39221
@NP	Fig. 3C , D	39247
@NP	Fig. 3C	39247
@NP	D	39254
@NP	FB-treated spinal cords	39271
@NP	astrocytic processes	39295
@NP	the rostrocaudal axis	39346
@NP	the extension of 5-HT axons	39389
@NP	the extension	39389
@NP	5-HT axons	39406
@NP	the lesion core -LRB- Fig. 3A , B -RRB-	39422
@NP	the lesion core	39422
@NP	Fig. 3A , B	39439
@NP	Fig. 3A	39439
@NP	B	39447
@NP	We	39451
@NP	the total number	39465
@NP	5-HT axons	39485
@NP	astrocytes	39514
@NP	the scar border	39537
@NP	fewer axons	39563
@NP	FB	39578
@NP	OEC groups	39586
@NP	all time points -LRB- FB 8 ¬ ± 7 vs OEC 31 ¬ ± 14 axons , p = 0.0045 -RRB-	39613
@NP	all time points	39613
@NP	FB 8 ¬ ± 7 vs OEC 31 ¬ ± 14 axons , p = 0.0045	39630
@NP	FB 8 ¬ ±	39630
@NP	7 vs OEC 31 ¬ ± 14 axons , p = 0.0045	39636
@NP	7	39636
@NP	OEC 31 ¬ ± 14 axons , p = 0.0045	39641
@NP	OEC 31 ¬ ± 14 axons	39641
@NP	OEC 31 ¬	39641
@NP	± 14 axons	39648
@NP	p = 0.0045	39659
@NP	p	39659
@NP	0.0045	39662
@NP	the first week	39674
@NP	the total number of 5-HTaxons	39689
@NP	the total number	39689
@NP	5-HTaxons	39709
@NP	twofold greater inOEC-than FB-treated rats	39723
@NP	Fig. 3G ; FB 29 ¬ ± 9 vs OEC 72 ¬ ± 22 axons , p 0.0045	39767
@NP	Fig. 3G	39767
@NP	FB 29 ¬ ± 9 vs OEC 72 ¬ ± 22 axons , p 0.0045	39776
@NP	FB 29 ¬ ± 9	39776
@NP	FB 29 ¬	39776
@NP	± 9	39783
@NP	OEC 72 ¬ ± 22 axons , p 0.0045	39790
@NP	OEC 72 ¬ ± 22 axons	39790
@NP	OEC 72 ¬	39790
@NP	± 22 axons	39797
@NP	p 0.0045	39808
@NP	axons	39824
@NP	the rostral border in OEC - than FBtreated rats	39843
@NP	the rostral border	39843
@NP	OEC	39865
@NP	FBtreated rats	39875
@NP	2 weeks -LRB- Fig. 3G ; FB 1 ¬ ± 1 vs OEC 32 ¬ ± 6 axons , p = 0.0231 -RRB-	39893
@NP	2 weeks	39893
@NP	Fig. 3G ; FB 1 ¬ ± 1 vs OEC 32 ¬ ± 6 axons , p = 0.0231	39902
@NP	Fig. 3G	39902
@NP	FB 1 ¬ ± 1 vs OEC 32 ¬ ± 6 axons , p = 0.0231	39911
@NP	FB	39911
@NP	1 ¬ ± 1 vs OEC 32 ¬ ± 6 axons , p = 0.0231	39914
@NP	1 ¬ ± 1	39914
@NP	1 ¬	39914
@NP	± 1	39917
@NP	OEC 32 ¬ ± 6 axons , p = 0.0231	39924
@NP	OEC 32 ¬ ± 6 axons	39924
@NP	OEC 32 ¬	39924
@NP	± 6 axons	39931
@NP	p = 0.0231	39941
@NP	p	39941
@NP	0.0231	39943
@NP	This finding	39952
@NP	OECs	39979
@NP	5-HT axons	39993
@NP	the configuration of astrocytes at the scar border	40020
@NP	the configuration	40020
@NP	astrocytes at the scar border	40041
@NP	astrocytes	40041
@NP	the scar border	40055
@NP	the extension of 5-HT axons	40082
@NP	the extension	40082
@NP	5-HT axons	40099
@NP	the lesion core	40115
@NP	addition to the number of 5-HT axons that crossed the astrocyte border	40135
@NP	addition	40135
@NP	the number of 5-HT axons that crossed the astrocyte border	40147
@NP	the number	40147
@NP	5-HT axons	40161
@NP	the astrocyte border	40185
@NP	we	40207
@NP	more 5-HT axons	40229
@NP	the lesion core of OEC	40259
@NP	the lesion core	40259
@NP	OEC	40278
@NP	FBtreated rats	40288
@NP	individual 5-HT axons	40312
@NP	we	40370
@NP	the area of the lesion core that contained 5-HT axons	40382
@NP	the area	40382
@NP	the lesion core	40394
@NP	5-HT axons	40425
@NP	Larger areas of the OEC than the FB lesion cores	40437
@NP	Larger areas	40437
@NP	the OEC than the FB lesion cores	40453
@NP	the OEC	40453
@NP	the FB lesion cores	40466
@NP	5-HTpositive axons	40490
@NP	2 weeks	40512
@NP	Fig. 3A , B ; FB 781 ¬ ± 641 vs OEC 12,020 ¬ ± 5342 ¬ µm2 , p = 0.0267	40521
@NP	Fig. 3A	40521
@NP	Fig.	40521
@NP	3A	40526
@NP	B ; FB 781 ¬ ± 641 vs OEC 12,020 ¬ ± 5342 ¬ µm2	40529
@NP	B	40529
@NP	FB 781 ¬ ± 641 vs OEC 12,020 ¬ ± 5342 ¬ µm2	40532
@NP	FB 781 ¬ ± 641	40532
@NP	FB 781 ¬ ±	40532
@NP	641	40542
@NP	OEC 12,020 ¬ ± 5342 ¬ µm2	40549
@NP	OEC 12,020 ¬ ±	40549
@NP	OEC 12,020	40549
@NP	¬ ±	40560
@NP	5342 ¬ µm2	40563
@NP	p = 0.0267	40574
@NP	p	40574
@NP	0.0267	40576
@NP	Wealso	40584
@NP	the lesion core	40613
@NP	the 5-HT axons	40629
@NP	We	40655
@NP	the distance between the most caudal 5-HT axon and the rostral GFAP-border	40667
@NP	the distance	40667
@NP	the most caudal 5-HT axon and the rostral GFAP-border	40688
@NP	the most caudal 5-HT axon	40688
@NP	the rostral GFAP-border	40718
@NP	average	40746
@NP	5-HT axons	40755
@NP	the lesion core of OEC	40797
@NP	the lesion core	40797
@NP	OEC	40816
@NP	FBtreated cords	40835
@NP	1 week -LRB- Fig. 3H ; FB 173 ¬ ± 38 vs OEC 438 ¬ ± 172 ¬ µm , p = 0.0757 -RRB-	40854
@NP	1 week	40854
@NP	Fig. 3H ; FB 173 ¬ ± 38 vs OEC 438 ¬ ± 172 ¬ µm , p = 0.0757	40862
@NP	Fig. 3H	40862
@NP	FB 173 ¬ ± 38 vs OEC 438 ¬ ± 172 ¬ µm , p = 0.0757	40871
@NP	FB 173 ¬ ± 38	40871
@NP	FB 173 ¬	40871
@NP	± 38	40879
@NP	OEC 438 ¬ ± 172 ¬ µm , p = 0.0757	40887
@NP	OEC 438 ¬ ± 172 ¬ µm	40887
@NP	OEC 438 ¬ ±	40887
@NP	172 ¬ µm	40898
@NP	p = 0.0757	40907
@NP	p	40907
@NP	0.0757	40911
@NP	2 weeks	40923
@NP	the 5-HT axons in FB-treated rats	40932
@NP	the 5-HT axons	40932
@NP	FB-treated rats	40950
@NP	dieback	40976
@NP	the rostral stump	40989
@NP	a negative value	41023
@NP	they	41049
@NP	the lesion core of OEC-treated rats	41076
@NP	the lesion core	41076
@NP	OEC-treated rats	41095
@NP	Fig. 3H ; FB 371 ¬ ± 161 vs OEC 227 ¬ ± 76 ¬ µm , p = 0.0001	41113
@NP	Fig. 3H	41113
@NP	FB 371 ¬ ± 161 vs OEC 227 ¬ ± 76 ¬ µm , p = 0.0001	41122
@NP	FB 371 ¬ ± 161	41122
@NP	FB 371 ¬ ±	41122
@NP	161	41130
@NP	OEC 227 ¬ ± 76 ¬ µm , p = 0.0001	41137
@NP	OEC 227 ¬	41137
@NP	± 76 ¬ µm , p = 0.0001	41145
@NP	± 76 ¬ µm , p	41145
@NP	0.0001	41157
@NP	4 weeks	41169
@NP	the 5-HT axons that extended beyond the astroglial scar border	41178
@NP	the 5-HT axons	41178
@NP	the astroglial scar border	41214
@NP	OECs -LRB- Fig. 3E -RRB-	41254
@NP	OECs	41254
@NP	Fig. 3E	41260
@NP	We	41270
@NP	anti-NF-H	41283
@NP	axons	41305
@NP	the injury site	41314
@NP	groups of OECs	41345
@NP	groups	41345
@NP	OECs	41355
@NP	bundles	41377
@NP	axons that extended past the rostral scar border at 4 weeks -LRB- Fig. 3F -RRB-	41388
@NP	axons	41388
@NP	the rostral scar border	41413
@NP	4 weeks -LRB- Fig. 3F -RRB-	41440
@NP	4 weeks	41440
@NP	Fig. 3F	41449
@NP	reactive scar-forming astrocytes	41473
@NP	scaffolds	41515
@NP	OECs and axons	41529
@NP	the lesion core -LRB- Fig. 3F -RRB-	41564
@NP	the lesion core	41564
@NP	Fig. 3F	41581
@NP	sum	41594
@NP	these data	41599
@NP	OECs	41623
@NP	axons	41642
@NP	the lesion core	41651
@NP	axonal dieback	41675
@NP	FBs	41704
@NP	extensions of astrocytes	41718
@NP	extensions	41718
@NP	astrocytes	41732
@NP	the scar border to provide pathways for axons to enter the lesion core	41746
@NP	pathways for axons	41773
@NP	pathways	41773
@NP	axons	41786
@NP	the lesion core	41801
@NP	OECs	41818
@NP	inhibitory factors	41830
@NP	the injury site	41852
@NP	OECs	41889
@NP	the inhibitory environment of the injury site	41901
@NP	the inhibitory environment	41901
@NP	the injury site	41931
@NP	we	41948
@NP	they	41960
@NP	inhibitory factors , such as CSPGs and myelin debris	41978
@NP	inhibitory factors	41978
@NP	CSPGs and myelin debris	42006
@NP	CSPGs	42006
@NP	myelin debris	42016
@NP	We	42031
@NP	CS-56 immunofluorescence	42043
@NP	CSPGs in the lesion core	42082
@NP	CSPGs	42082
@NP	the lesion core	42091
@NP	adjacent astroglial scar border in FB	42111
@NP	adjacent astroglial scar border	42111
@NP	FB	42146
@NP	OEC-treated spinal cords	42154
@NP	the lesion core	42191
@NP	the mean CS-56 luminance	42208
@NP	greater in FB	42237
@NP	greater	42237
@NP	FB	42248
@NP	OEC-treated rats	42257
@NP	all time-points -LRB- FB 3.2 ¬ ± 0.2 vs OEC 1.6 ¬ ± 0.1 , p = 0.0001 -RRB-	42281
@NP	all time-points	42281
@NP	FB 3.2 ¬ ± 0.2 vs OEC 1.6 ¬ ± 0.1 , p = 0.0001	42298
@NP	FB	42298
@NP	3.2 ¬ ± 0.2 vs OEC 1.6 ¬ ± 0.1 , p = 0.0001	42301
@NP	3.2 ¬ ± 0.2	42301
@NP	3.2 ¬	42301
@NP	± 0.2	42305
@NP	OEC 1.6 ¬ ± 0.1 , p = 0.0001	42313
@NP	OEC 1.6 ¬ ± 0.1	42313
@NP	OEC 1.6 ¬	42313
@NP	± 0.1	42322
@NP	p = 0.0001	42329
@NP	p	42329
@NP	0.0001	42333
@NP	Measurements of the mean CS-56 values	42342
@NP	Measurements	42342
@NP	the mean CS-56 values	42358
@NP	a similar cell transplant effect	42388
@NP	the rostral	42424
@NP	caudal stumps -LRB- FB 2.2 ¬ ± 0.1 vs OEC 1.2 ¬ ± 0.1 , p = 0.0001 -RRB-	42440
@NP	caudal stumps	42440
@NP	FB 2.2 ¬ ± 0.1 vs OEC 1.2 ¬ ± 0.1 , p = 0.0001	42455
@NP	FB	42455
@NP	2.2 ¬ ± 0.1 vs OEC 1.2 ¬ ± 0.1 , p = 0.0001	42458
@NP	2.2 ¬ ± 0.1	42458
@NP	2.2 ¬	42458
@NP	± 0.1	42463
@NP	OEC 1.2 ¬ ± 0.1 , p = 0.0001	42472
@NP	OEC 1.2 ¬ ± 0.1	42472
@NP	OEC 1.2 ¬	42472
@NP	± 0.1	42481
@NP	p = 0.0001	42488
@NP	p	42488
@NP	0.0001	42492
@NP	the difference in CSPG expression	42512
@NP	the difference	42512
@NP	CSPG expression	42530
@NP	time	42551
@NP	we	42557
@NP	CS-56 immunoreactivity	42569
@NP	different time-points	42595
@NP	The mean CS-56 luminance	42618
@NP	the lesion core	42658
@NP	FBversus OEC-treated spinal cords at 2 -LRB- Fig. 4A ` ÄìC -RRB- , 4 ,	42677
@NP	FBversus OEC-treated spinal cords at 2	42677
@NP	FBversus	42677
@NP	OEC-treated spinal cords at 2	42686
@NP	OEC-treated spinal cords	42686
@NP	2	42714
@NP	Fig. 4A ` ÄìC	42717
@NP	Fig. 4A	42717
@NP	` ÄìC	42724
@NP	4	42731
@NP	8 weeks	42738
@NP	Fig. 4C ; 2 week FB 3.2 ¬ ± 0.1 vs OEC 1.2 ¬ ± 0.1	42758
@NP	Fig. 4C	42758
@NP	2 week FB 3.2 ¬ ± 0.1 vs OEC 1.2 ¬ ± 0.1	42767
@NP	2 week FB	42767
@NP	3.2 ¬ ± 0.1 vs OEC 1.2 ¬ ± 0.1	42777
@NP	3.2 ¬ ± 0.1	42777
@NP	3.2 ¬	42777
@NP	± 0.1	42782
@NP	OEC 1.2 ¬ ± 0.1	42791
@NP	OEC 1.2 ¬	42791
@NP	± 0.1	42800
@NP	p = 0.0001	42807
@NP	p	42807
@NP	0.0001	42811
@NP	4 week FB 2.7 ¬ ± 0.3 vs OEC 1.9 ¬ ± 0.1 , p = 0.0218	42819
@NP	4 week FB 2.7 ¬ ± 0.3	42819
@NP	4 week FB	42819
@NP	2.7 ¬	42829
@NP	± 0.3	42833
@NP	OEC 1.9 ¬ ± 0.1 , p = 0.0218	42841
@NP	OEC 1.9 ¬ ± 0.1	42841
@NP	OEC 1.9 ¬	42841
@NP	± 0.1	42849
@NP	p = 0.0218	42855
@NP	p	42855
@NP	0.0218	42857
@NP	8 week FB 3.9 0.5 vs OEC 1.4 ¬ ± 0.2	42865
@NP	8 week FB 3.9 0.5	42865
@NP	8 week FB	42865
@NP	OEC 1.4 ¬ ± 0.2	42888
@NP	OEC 1.4 ¬	42888
@NP	± 0.2	42897
@NP	p ` â † 0.0013	42904
@NP	p ` â †	42904
@NP	0.0013	42910
@NP	The lesion core	42919
@NP	more CS-56 immunoreactivity	42945
@NP	the spinal cord stumps	42978
@NP	the rostral and caudal stump borders	43014
@NP	the rostral	43014
@NP	caudal stump borders	43030
@NP	CSPG levels	43052
@NP	higher in FB	43069
@NP	higher	43069
@NP	FB	43079
@NP	OEC-treated spinal cords	43088
@NP	2 and 4 weeks	43116
@NP	Fig. 4A , B	43131
@NP	Fig. 4A	43131
@NP	B	43139
@NP	D ; 2 week FB 2.7 ¬ ± 0.1 vs OEC 1.2 ¬ ± 0.1	43141
@NP	D	43141
@NP	2 week FB 2.7 ¬ ± 0.1 vs OEC 1.2 ¬ ± 0.1	43144
@NP	2 week FB	43144
@NP	2.7 ¬ ± 0.1 vs OEC 1.2 ¬ ± 0.1	43154
@NP	2.7 ¬ ± 0.1	43154
@NP	2.7 ¬	43154
@NP	± 0.1	43158
@NP	OEC 1.2 ¬ ± 0.1	43166
@NP	OEC 1.2 ¬	43166
@NP	± 0.1	43174
@NP	p = 0.0001 ; 4 week FB 2.1 ¬ ± 0.3 vs OEC 1.3 ¬ ± 0.1	43180
@NP	p = 0.0001	43180
@NP	p	43180
@NP	0.0001	43183
@NP	4 week FB 2.1 ¬ ± 0.3 vs OEC 1.3 ¬ ± 0.1	43191
@NP	4 week FB 2.1 ¬ ± 0.3	43191
@NP	4 week FB	43191
@NP	2.1 ¬	43201
@NP	± 0.3	43206
@NP	OEC 1.3 ¬ ± 0.1	43215
@NP	OEC 1.3 ¬	43215
@NP	± 0.1	43224
@NP	p = 0.0002	43231
@NP	p	43231
@NP	0.0002	43235
@NP	a control	43247
@NP	GFAP luminance	43258
@NP	the same regions in each section	43291
@NP	the same regions	43291
@NP	each section	43311
@NP	FB and OEC groups -LRB- data not shown -RRB-	43351
@NP	FB and OEC groups	43351
@NP	data not shown	43370
@NP	data	43370
@NP	luminance intensity	43398
@NP	a reliable measure	43432
@NP	differences in CSPG levels between FB and OEC transplanted rats	43469
@NP	differences	43469
@NP	CSPG levels between FB and OEC transplanted rats	43484
@NP	CSPG levels	43484
@NP	FB and OEC transplanted rats	43504
@NP	FB	43504
@NP	OEC transplanted rats	43511
@NP	we	43539
@NP	the areas	43554
@NP	transplanted FBs or OECs	43576
@NP	different levels of CSPG luminance	43608
@NP	different levels	43608
@NP	CSPG luminance	43628
@NP	the lesion core and stumps	43646
@NP	the lesion core	43646
@NP	stumps	43666
@NP	2 weeks	43677
@NP	we	43686
@NP	a 50 % reduction in CS-56 luminance	43695
@NP	a 50 % reduction	43695
@NP	CS-56 luminance	43714
@NP	areas directly occupied	43733
@NP	areas	43733
@NP	OECs	43760
@NP	those	43773
@NP	FBs	43795
@NP	Fig. 4A	43800
@NP	B , red channel	43808
@NP	B	43808
@NP	red channel	43811
@NP	lesion core	43824
@NP	lesion	43824
@NP	core	43831
@NP	FB 1.1 0.2 vs OEC 0.5 ¬ ± 0 , p = 0.0415	43837
@NP	FB 1.1 0.2	43837
@NP	FB	43837
@NP	1.1 0.2	43840
@NP	OEC 0.5 ¬ ± 0 , p = 0.0415	43853
@NP	OEC 0.5 ¬	43853
@NP	± 0 , p = 0.0415	43862
@NP	± 0	43862
@NP	p = 0.0415	43867
@NP	p	43867
@NP	0.0415	43871
@NP	stumps : FB 1.1 ¬ ± 0.1 vs OEC 0.49 ¬ ± 0.01	43879
@NP	stumps	43879
@NP	FB 1.1 ¬ ± 0.1 vs OEC 0.49 ¬ ± 0.01	43887
@NP	FB 1.1 ¬ ± 0.1	43887
@NP	FB 1.1 ¬	43887
@NP	± 0.1	43895
@NP	OEC 0.49 ¬ ± 0.01	43904
@NP	OEC 0.49 ¬	43904
@NP	± 0.01	43914
@NP	p 0.0398	43922
@NP	the astrocytic border	43950
@NP	FB-transplanted rats	43989
@NP	higher levels of CSPG-labeling	44014
@NP	higher levels	44014
@NP	CSPG-labeling	44031
@NP	the presence of FBs	44061
@NP	the presence	44061
@NP	FBs	44077
@NP	OECs -LRB- Fig. 4A , B -RRB-	44086
@NP	OECs	44086
@NP	Fig. 4A , B	44092
@NP	Fig. 4A	44092
@NP	B	44100
@NP	the stumps of OEC-treated spinal cords	44107
@NP	the stumps	44107
@NP	OEC-treated spinal cords	44121
@NP	astrocyte processes	44147
@NP	CSPG-labeled cells	44193
@NP	cavities	44219
@NP	Fig. 4B , yellow arrowheads	44229
@NP	Fig. 4B	44229
@NP	yellow arrowheads	44238
@NP	OECs	44264
@NP	inhibitory CSPGs at the injury site	44276
@NP	inhibitory CSPGs	44276
@NP	the injury site	44296
@NP	FBs	44326
@NP	The altered astrocyte border formation seen in FB-treated rats	44331
@NP	The altered astrocyte border formation	44331
@NP	FB-treated rats	44378
@NP	the comparison of astrocyte orientation and arrangement	44403
@NP	the comparison	44403
@NP	astrocyte orientation and arrangement	44421
@NP	the transplant groups	44467
@NP	A closer examination	44490
@NP	astrocytes	44514
@NP	both AQP4 and GFAP -LRB- Wanner et al. , 2013 -RRB-	44542
@NP	AQP4	44547
@NP	GFAP -LRB- Wanner et al. , 2013 -RRB-	44556
@NP	GFAP	44556
@NP	Wanner	44562
@NP	et al. , 2013	44569
@NP	et al.	44569
@NP	2013	44577
@NP	GFP-labeled cells at the scar borders	44588
@NP	GFP-labeled cells	44588
@NP	the scar borders	44609
@NP	astrocytic processes	44640
@NP	direct contact with FBs compared with OECs -LRB- Fig. 4E , F -RRB-	44692
@NP	direct contact	44692
@NP	FBs compared with OECs -LRB- Fig. 4E , F -RRB-	44712
@NP	FBs	44712
@NP	OECs -LRB- Fig. 4E , F -RRB-	44730
@NP	OECs	44730
@NP	Fig. 4E , F	44736
@NP	Fig. 4E	44736
@NP	F	44744
@NP	OEC-treated spinal cords	44751
@NP	astrocytic processes	44776
@NP	a palisading arrangement	44802
@NP	OECs -LRB- Fig. 4F -RRB-	44848
@NP	OECs	44848
@NP	Fig. 4F	44854
@NP	The disorganized astrocytes that interact with FBs	44864
@NP	The disorganized astrocytes	44864
@NP	FBs	44911
@NP	highly fibronectinpositive areas -LRB- Fig. 4E -RRB-	44928
@NP	highly fibronectinpositive areas	44928
@NP	Fig. 4E	44962
@NP	Low levels of fibronectin - or CSPG-positive cells	44972
@NP	Low levels	44972
@NP	fibronectin - or CSPG-positive cells	44986
@NP	sequestered inOEC-but	45031
@NP	FB-treated spinal cords -LRB- Fig. 4A , B , E , F -RRB-	45057
@NP	FB-treated spinal cords	45057
@NP	Fig. 4A	45082
@NP	B , E , F	45090
@NP	These data	45098
@NP	the astroglial scar border forms	45120
@NP	FB transplantation	45170
@NP	OECs	45211
@NP	the presence of myelin debris	45228
@NP	the presence	45228
@NP	myelin debris	45244
@NP	the injury site	45272
@NP	we	45289
@NP	Oil Red O , a histological	45297
@NP	Oil Red O	45297
@NP	a histological	45308
@NP	neutral lipids including myelin debris	45345
@NP	neutral lipids	45345
@NP	myelin debris	45370
@NP	we	45399
@NP	more punctate Oil Red O-staining in FB - than OEC-treated rats	45408
@NP	more punctate Oil Red O-staining	45408
@NP	FB	45444
@NP	OEC-treated rats	45453
@NP	Myelin debris	45471
@NP	the rostral and caudal stumps of FB	45507
@NP	the rostral	45507
@NP	caudal stumps of FB	45523
@NP	caudal stumps	45523
@NP	FB	45540
@NP	OEC-treated spinal cords	45549
@NP	2 weeks -LRB- Fig. 5A , B -RRB-	45577
@NP	2 weeks	45577
@NP	Fig. 5A , B	45586
@NP	Fig. 5A	45586
@NP	B	45594
@NP	Oil Red O particulates	45598
@NP	the stumps	45647
@NP	the lesion core of FB	45682
@NP	the lesion core	45682
@NP	FB	45701
@NP	OEC-treated rats -LRB- Fig. 5a , b -RRB-	45719
@NP	OEC-treated rats	45719
@NP	Fig. 5a , b	45737
@NP	Fig. 5a	45737
@NP	b	45745
@NP	Myelin debris	45749
@NP	FB	45776
@NP	OEC-treated spinal cords	45788
@NP	4 and 8 weeks	45816
@NP	Fig. 5C ` ÄìF	45831
@NP	Fig. 5C	45831
@NP	` ÄìF	45838
@NP	more demyelination	45861
@NP	FB	45883
@NP	OEC-treated spinal cords	45892
@NP	combination	45921
@NP	OEC transplantation	45934
@NP	two components of the inhibitory environment	45965
@NP	two components	45965
@NP	the inhibitory environment	45983
@NP	the lesion site , CSPGs and myelin debris	46013
@NP	the lesion site	46013
@NP	CSPGs	46030
@NP	myelin debris	46040
@NP	OECs	46055
@NP	immune cell activation and infiltration	46067
@NP	a complete spinal cord transection	46113
@NP	Our results	46148
@NP	OECs	46173
@NP	the survival of neurons and limit dieback of 5-HT axons	46186
@NP	the survival	46186
@NP	neurons and limit dieback	46202
@NP	5-HT axons	46231
@NP	yet very few OECs	46243
@NP	8 weeks	46269
@NP	injury	46283
@NP	Cell transplantation therapies	46291
@NP	the immune response	46348
@NP	1 and 8 weeks after a spinal cord injury -LRB- Beck et al. , 2010 -RRB-	46382
@NP	1 and 8 weeks	46382
@NP	a spinal cord injury -LRB- Beck et al. , 2010 -RRB-	46402
@NP	a spinal cord injury	46402
@NP	Beck	46424
@NP	et al. , 2010	46429
@NP	et al.	46429
@NP	2010	46437
@NP	the interactions between transplant survival	46456
@NP	the interactions	46456
@NP	transplant survival	46481
@NP	macrophages and astrocytes	46527
@NP	antibodies	46555
@NP	calciumbinding adaptor molecule-1 -LRB- Iba-1 -RRB- and a GFAP control	46582
@NP	calciumbinding adaptor molecule-1 -LRB- Iba-1 -RRB-	46582
@NP	calciumbinding adaptor molecule-1	46582
@NP	Iba-1	46617
@NP	a GFAP control	46628
@NP	We	46658
@NP	the mean Iba-1 and GFAP luminance in five zones	46670
@NP	the mean Iba-1 and GFAP luminance	46670
@NP	five zones	46707
@NP	the rostral and caudal scar borders and stumps	46719
@NP	the rostral	46719
@NP	caudal scar borders and stumps	46735
@NP	the lesion core -LRB- Fig. 6A -RRB-	46771
@NP	the lesion core	46771
@NP	Fig. 6A	46788
@NP	Iba-1 levels in the lesion core	46798
@NP	Iba-1 levels	46798
@NP	the lesion core	46814
@NP	between FB	46845
@NP	OEC-transplanted rats	46861
@NP	1 , 2 , 4 , and 8 weeks -LRB- data not shown -RRB-	46886
@NP	1 , 2 , 4 , and 8 weeks	46886
@NP	1	46886
@NP	2	46889
@NP	4	46892
@NP	8 weeks	46899
@NP	data not shown	46908
@NP	data	46908
@NP	A sharp increase in Iba-1 luminance	46925
@NP	A sharp increase	46925
@NP	Iba-1 luminance	46945
@NP	the rostral border and stump of FB	46987
@NP	the rostral border and stump	46987
@NP	FB	47019
@NP	OEC-treated rats	47037
@NP	2 weeks	47057
@NP	Fig. 6B	47066
@NP	D	47074
@NP	border FB 3.1 0.6 vs OEC 1.3 0.3 , p 0.0106 ; stump FB 3.1 0.6 vs OEC 1.3 0.3	47077
@NP	border FB 3.1 0.6	47077
@NP	border FB	47077
@NP	3.1 0.6	47087
@NP	OEC 1.3 0.3 , p 0.0106 ; stump FB 3.1 0.6 vs OEC 1.3 0.3	47100
@NP	OEC 1.3 0.3 , p 0.0106	47100
@NP	OEC 1.3 0.3	47100
@NP	OEC	47100
@NP	p 0.0106	47115
@NP	stump FB 3.1 0.6 vs OEC 1.3 0.3	47127
@NP	stump FB 3.1 0.6	47127
@NP	stump FB	47127
@NP	3.1 0.6	47136
@NP	OEC 1.3 0.3	47149
@NP	OEC	47149
@NP	p 0.0039	47164
@NP	Iba-1 levels	47177
@NP	the caudal stump of FB	47211
@NP	the caudal stump	47211
@NP	FB	47231
@NP	OEC-treated rats	47249
@NP	2 weeks -LRB- Fig. 6E ; stump FB 3.0 0.4 vs OEC 1.8 0.3 , p 0.0318 -RRB-	47269
@NP	2 weeks	47269
@NP	Fig. 6E ; stump FB 3.0 0.4 vs OEC 1.8 0.3 , p 0.0318	47278
@NP	Fig. 6E	47278
@NP	stump FB 3.0 0.4 vs OEC 1.8 0.3 , p 0.0318	47287
@NP	stump FB 3.0 0.4	47287
@NP	stump FB	47287
@NP	3.0 0.4	47296
@NP	OEC 1.8 0.3 , p 0.0318	47309
@NP	OEC 1.8 0.3	47309
@NP	OEC	47309
@NP	p 0.0318	47324
@NP	OEC-transplanted spinal cords	47340
@NP	the increase in Iba-1 levels	47370
@NP	the increase	47370
@NP	Iba-1 levels	47386
@NP	1 and 2 weeks in the rostral	47419
@NP	1 and 2 weeks	47419
@NP	the rostral	47436
@NP	not the caudal border and stump -LRB- Fig. 6 ,	47453
@NP	not the caudal border	47453
@NP	stump -LRB- Fig. 6 ,	47479
@NP	stump	47479
@NP	Fig. 6	47486
@NP	Fig.	47486
@NP	6	47491
@NP	slopes in B , D to C , E -RRB-	47502
@NP	slopes	47502
@NP	B , D to C , E -RRB-	47512
@NP	B	47512
@NP	E	47521
@NP	4 and 8 weeks	47528
@NP	the Iba-1 levels in the borders and stumps	47542
@NP	the Iba-1 levels	47542
@NP	the borders and stumps	47562
@NP	the FB andOECgroups	47606
@NP	Fig. 6B ` ÄìE	47627
@NP	Fig. 6B	47627
@NP	` ÄìE	47634
@NP	a control	47644
@NP	GFAP luminance	47655
@NP	the same five zones	47688
@NP	Figure 6A	47722
@NP	FB and OEC groups	47759
@NP	data not shown	47778
@NP	data	47778
@NP	These trends	47795
@NP	OECs delay	47821
@NP	the initial activation of Iba-1-positive immune cells	47843
@NP	the initial activation	47843
@NP	Iba-1-positive immune cells	47869
@NP	GFAP luminance measurements	47907
@NP	FB or OEC transplantation	47953
@NP	a close examination of the scar borders	47980
@NP	a close examination	47980
@NP	the scar borders	48003
@NP	differences	48029
@NP	The astroglial scar border	48042
@NP	2 weeks postinjury	48089
@NP	all transplanted rats	48111
@NP	the orientation and arrangement of astrocytic processes	48138
@NP	the orientation and arrangement	48138
@NP	astrocytic processes	48173
@NP	transplant group	48204
@NP	Fig. 7A ` ÄìD	48222
@NP	Fig. 7A	48222
@NP	` ÄìD	48229
@NP	FB-treated rats	48239
@NP	astrocytic processes	48256
@NP	peripheral cells	48330
@NP	more diffuse globoid Iba-1-positive cells	48361
@NP	the GFAP-positive scar	48410
@NP	Fig. 7A , C	48441
@NP	Fig. 7A	48441
@NP	C	48449
@NP	contrast	48456
@NP	astrocyte processes	48466
@NP	a distinctive barrier	48493
@NP	globoid Iba-1-positive immune cells	48546
@NP	OEC-treated spinal cords -LRB- Fig. 7B , D -RRB-	48585
@NP	OEC-treated spinal cords	48585
@NP	Fig. 7B , D	48611
@NP	Fig. 7B	48611
@NP	D	48619
@NP	Hoechst nuclear staining	48623
@NP	the astrocytic border formation	48671
@NP	FB	48720
@NP	OEC-treated rats -LRB- Fig. 7A ` ÄìD , individual channel images -RRB-	48738
@NP	OEC-treated rats	48738
@NP	Fig. 7A	48756
@NP	` ÄìD , individual channel images	48763
@NP	` ÄìD	48763
@NP	individual channel images	48769
@NP	immune cell infiltration	48825
@NP	cell transplantation type	48860
@NP	we	48887
@NP	the differences	48899
@NP	mean Iba-1 and GFAP luminance	48918
@NP	the stumps relative to the lesion core	48951
@NP	the stumps	48951
@NP	the lesion core	48974
@NP	FB-treated spinal cords	48991
@NP	2 weeks	49015
@NP	postinjury	49023
@NP	a greater difference in mean Iba-1 luminance	49038
@NP	a greater difference	49038
@NP	mean Iba-1 luminance	49062
@NP	OEC-treated spinal cords	49088
@NP	a finding	49114
@NP	higher levels of immune cell infiltration	49140
@NP	higher levels	49140
@NP	immune cell infiltration	49157
@NP	the stumps of FB-treated rats	49187
@NP	the stumps	49187
@NP	FB-treated rats	49201
@NP	Fig. 7E ; FB 1.9 0.5 vs OEC 0.5 0.3 , p 0.0031	49218
@NP	Fig. 7E	49218
@NP	FB 1.9 0.5 vs OEC 0.5 0.3 , p 0.0031	49227
@NP	FB 1.9 0.5	49227
@NP	FB	49227
@NP	1.9 0.5	49230
@NP	OEC 0.5 0.3 , p 0.0031	49241
@NP	OEC 0.5 0.3	49241
@NP	OEC	49241
@NP	p 0.0031	49256
@NP	the Iba-1 luminance	49284
@NP	differences in mean GFAP luminance	49305
@NP	differences	49305
@NP	mean GFAP luminance	49320
@NP	FB - and OEC-treated rats	49376
@NP	FB	49376
@NP	OEC-treated rats	49384
@NP	Fig. 7F	49417
@NP	Our findings	49427
@NP	the relationship between scar border formation and immune cell infiltration	49450
@NP	the relationship	49450
@NP	scar border formation and immune cell infiltration	49475
@NP	scar border formation	49475
@NP	immune cell infiltration	49501
@NP	We	49527
@NP	OECs	49540
@NP	the astroglial scar	49565
@NP	immune cell activation and infiltration	49596
@NP	immune cell activation	49596
@NP	infiltration	49623
@NP	FBs	49650
@NP	Immunosuppression using cyclosporine-A	49655
@NP	Immunosuppression	49655
@NP	cyclosporine-A	49679
@NP	graft cell survival	49703
@NP	We	49723
@NP	OECs	49736
@NP	the host immune response at 2 but not 8 weeks postinjury and suspect	49750
@NP	the host immune response at 2	49750
@NP	the host immune response	49750
@NP	2	49778
@NP	8 weeks postinjury and suspect	49788
@NP	8 weeks	49788
@NP	this loss at 8 weeks	49824
@NP	this loss	49824
@NP	8 weeks	49837
@NP	immune-mediated rejection of the transplanted cells	49855
@NP	immune-mediated rejection	49855
@NP	the transplanted cells	49884
@NP	immunosuppression	49929
@NP	OEC survival	49961
@NP	CSA	49975
@NP	the rats	49999
@NP	the study	50030
@NP	CSA treatment	50041
@NP	the survival of both FBs and OECs	50064
@NP	the survival	50064
@NP	both FBs and OECs	50080
@NP	2 and 8 weeks -LRB- Table 1 -RRB-	50101
@NP	2 and 8 weeks	50101
@NP	Table 1	50116
@NP	More transplanted cells in CSA-treated rats	50126
@NP	More transplanted cells	50126
@NP	CSA-treated rats	50153
@NP	the lesion core at 2 weeks	50184
@NP	the lesion core	50184
@NP	2 weeks	50203
@NP	our findings	50225
@NP	non-immunosuppressed rats	50241
@NP	Figs. 8A , B , 1C , D	50276
@NP	Figs. 8A	50276
@NP	B	50285
@NP	1C	50288
@NP	D	50291
@NP	2 weeks	50298
@NP	FBs and OECs in CSA-treated -LRB- FB CSA ; OEC CSA -RRB- rats	50307
@NP	FBs and OECs	50307
@NP	CSA-treated -LRB- FB CSA ; OEC CSA -RRB- rats	50323
@NP	FB CSA ; OEC CSA	50336
@NP	FB CSA	50336
@NP	OEC CSA	50344
@NP	the lesion core -LRB- Fig. 8E ; FB84 10 % , OEC75 4 % -RRB-	50372
@NP	the lesion core	50372
@NP	Fig. 8E ; FB84 10 % , OEC75 4 %	50389
@NP	Fig. 8E	50389
@NP	FB84 10 % , OEC75 4 %	50398
@NP	FB84 10 %	50398
@NP	FB84	50398
@NP	OEC75 4 %	50407
@NP	OEC75	50407
@NP	The CSA treatment	50418
@NP	the percentage	50460
@NP	the lesion volume	50478
@NP	FBs -LRB- 29 12 % -RRB- and OECs -LRB- 41 8 % -RRB-	50506
@NP	FBs	50506
@NP	29 12 %	50511
@NP	OECs	50525
@NP	41 8 %	50531
@NP	non-CSA-treated rats	50554
@NP	2 weeks -LRB- FB 3 3 % , p 0.0131 ; OECs1 0.1 % , p 0.0007 -RRB-	50578
@NP	2 weeks	50578
@NP	FB 3 3 % , p 0.0131 ; OECs1 0.1 % , p 0.0007	50587
@NP	FB 3 3 %	50587
@NP	FB	50587
@NP	p 0.0131 ; OECs1 0.1 %	50596
@NP	p 0.0131	50596
@NP	OECs1 0.1 %	50606
@NP	OECs1	50606
@NP	p 0.0007	50618
@NP	p	50618
@NP	0.0007	50620
@NP	8 weeks	50632
@NP	postinjury CSA-treated rats	50640
@NP	both cell types	50678
@NP	the lesion core	50707
@NP	Table 1 ; Fig. 8C , D , E ; FB48 27 % , OEC14 8 % , p 0.0241	50724
@NP	Table 1 ; Fig. 8C , D , E ; FB48 27 %	50724
@NP	Table 1	50724
@NP	Table	50724
@NP	1	50730
@NP	Fig. 8C , D , E	50733
@NP	Fig. 8C	50733
@NP	D	50741
@NP	E	50743
@NP	FB48 27 %	50746
@NP	FB48	50746
@NP	27 %	50751
@NP	OEC14 8 %	50755
@NP	OEC14	50755
@NP	p 0.0241	50765
@NP	p	50765
@NP	0.0241	50767
@NP	both	50780
@NP	bridges between the rostralandcaudal stumps -LRB- Fig. 8C , D -RRB-	50792
@NP	bridges	50792
@NP	the rostralandcaudal stumps -LRB- Fig. 8C , D -RRB-	50808
@NP	the rostralandcaudal stumps	50808
@NP	Fig. 8C , D	50837
@NP	Fig. 8C	50837
@NP	D	50845
@NP	the non-CSA-treated rats at 8 weeks	50861
@NP	the non-CSA-treated rats	50861
@NP	8 weeks	50889
@NP	CSA treatment	50898
@NP	a limited percentage	50922
@NP	transplanted cells in the lesion core -LRB- FB 8 9 % ; OEC 4 3 % -RRB-	50946
@NP	transplanted cells	50946
@NP	the lesion core -LRB- FB 8 9 % ; OEC 4 3 % -RRB-	50968
@NP	the lesion core	50968
@NP	FB 8 9 % ; OEC 4 3 %	50985
@NP	FB	50985
@NP	8 9 % ; OEC 4 3 %	50988
@NP	8 9 %	50988
@NP	OEC 4 3 %	50995
@NP	OEC	50995
@NP	enhanced cell survival	51021
@NP	suppression of the innate immune response	51055
@NP	suppression	51055
@NP	the innate immune response	51070
@NP	CSA administration	51103
@NP	we	51123
@NP	Iba-1 luminance levels	51135
@NP	Figure 6A	51164
@NP	CSA	51175
@NP	Iba-1 levels	51187
@NP	both transplant groups	51203
@NP	2 and 8 weeks postinjury , with a greater reduction in FB -	51229
@NP	2 and 8 weeks	51229
@NP	postinjury	51243
@NP	a greater reduction in FB	51260
@NP	a greater reduction	51260
@NP	FB	51283
@NP	OEC-treated rats	51292
@NP	We	51310
@NP	immune cell infiltration	51327
@NP	the difference in mean Iba-1 luminance	51365
@NP	the difference	51365
@NP	mean Iba-1 luminance	51383
@NP	the stumps and lesion core of transplanted rats	51407
@NP	the stumps and lesion core	51407
@NP	transplanted rats	51437
@NP	both cell transplants	51459
@NP	immune cell infiltration	51482
@NP	CSA treatment at 2	51534
@NP	CSA treatment	51534
@NP	2	51551
@NP	8 weeks	51565
@NP	Fig. 8F	51574
@NP	2 week FB CSA 0.6 0.1	51583
@NP	2 week FB CSA	51583
@NP	0.6 0.1	51599
@NP	OEC CSA 0.2 0.1 ; 8 week FB CSA 0.6 0.4 vs OEC CSA 0.2 0.1	51612
@NP	OEC CSA 0.2 0.1	51612
@NP	OEC CSA	51612
@NP	8 week FB CSA 0.6 0.4 vs OEC CSA 0.2 0.1	51634
@NP	8 week FB CSA 0.6 0.4	51634
@NP	8 week FB CSA	51634
@NP	0.6 0.4	51650
@NP	OEC CSA 0.2 0.1	51663
@NP	OEC CSA	51663
@NP	CSA treatment	51700
@NP	Iba-1 luminance levels of FB	51722
@NP	Iba-1 luminance levels	51722
@NP	FB	51748
@NP	not OEC-treated rats	51756
@NP	their non-CSA controls	51791
@NP	Fig. 8F ; FB 1.9 0.5 vs FB CSA 0.6 0.1 , p 0.0121	51815
@NP	Fig. 8F	51815
@NP	FB 1.9 0.5 vs FB CSA 0.6 0.1 , p 0.0121	51824
@NP	FB 1.9 0.5	51824
@NP	FB	51824
@NP	1.9 0.5	51827
@NP	FB CSA 0.6 0.1 , p 0.0121	51838
@NP	FB CSA	51838
@NP	0.6 0.1 , p 0.0121	51845
@NP	0.6 0.1	51845
@NP	p 0.0121	51854
@NP	These results	51865
@NP	CSA administration	51892
@NP	the innate immune response	51919
@NP	spinal cord transection	51952
@NP	the survival of both FBs and OECs	51990
@NP	the survival	51990
@NP	both FBs and OECs	52006
@NP	the 2-week time point	52027
@NP	Enhanced-OEC survival	52050
@NP	preservation of neurons and axons	52081
@NP	preservation	52081
@NP	neurons and axons	52097
@NP	CSA-enhanced OEC survival	52136
@NP	a beneficial response	52171
@NP	we	52194
@NP	neuronal preservation	52212
@NP	2 weeks	52238
@NP	neurons	52246
@NP	the astroglial scar border	52274
@NP	CSA treatment -LRB- Fig. 9A -RRB-	52307
@NP	CSA treatment	52307
@NP	Fig. 9A	52322
@NP	The neuron-free distance	52332
@NP	the total distance between rostral and caudal stump neurons	52361
@NP	the total distance	52361
@NP	rostral and caudal stump neurons	52388
@NP	the FB and OEC groups	52440
@NP	CSA administration	52468
@NP	both 2 and 8 weeks -LRB- CSA data not shown -RRB-	52490
@NP	both 2 and 8 weeks	52490
@NP	CSA data not shown	52510
@NP	CSA data	52510
@NP	the extent of tissue preservation in the stumps	52540
@NP	the extent	52540
@NP	tissue preservation in the stumps	52554
@NP	tissue preservation	52554
@NP	the stumps	52577
@NP	CSAenhanced OEC survival	52608
@NP	neurons now	52634
@NP	neurons	52634
@NP	the GFAPnegative lesion core of OEC	52658
@NP	the GFAPnegative lesion core	52658
@NP	OEC	52690
@NP	CSA-treated rats at 2	52694
@NP	CSA-treated rats	52694
@NP	2	52714
@NP	4 weeks in non-CSA-treated rats -LRB- compare Figs. 9B , 2B -RRB-	52728
@NP	4 weeks	52728
@NP	non-CSA-treated rats	52739
@NP	Figs. 9B , 2B	52769
@NP	Figs. 9B	52769
@NP	2B	52779
@NP	we	52789
@NP	axons	52801
@NP	the lesion core	52825
@NP	OECs	52850
@NP	8 weeks	52867
@NP	injury and CSA treatment	52881
@NP	Bundles of OECs	52907
@NP	Bundles	52907
@NP	OECs	52918
@NP	neurofilament-labeled axons	52934
@NP	the scar border	52981
@NP	our 4-week observation -LRB- Fig. 3F -RRB-	53013
@NP	our 4-week observation	53013
@NP	Fig. 3F	53037
@NP	axons	53059
@NP	OECs in the lesion core	53101
@NP	OECs	53101
@NP	the lesion core	53109
@NP	8 weeks -LRB- Fig. 9C -RRB-	53128
@NP	8 weeks	53128
@NP	Fig. 9C	53137
@NP	Confocal 3D visualization	53147
@NP	OECs	53179
@NP	axons	53207
@NP	both horizontal -LRB- Fig. 9C , white arrows -RRB-	53216
@NP	both horizontal	53216
@NP	Fig. 9C , white arrows	53233
@NP	Fig. 9C	53233
@NP	white arrows	53242
@NP	cross-sectional -LRB- Fig. 9C , white arrowhead -RRB- orientation	53260
@NP	Fig. 9C	53277
@NP	white arrowhead	53286
@NP	It	53316
@NP	OECs	53346
@NP	a bridge for axons to grow into the lesion core ,	53368
@NP	a bridge	53368
@NP	axons to grow into the lesion core ,	53381
@NP	the lesion core	53400
@NP	some functionally supportive role	53435
@NP	the lesion core	53476
@NP	OEC CSA treatment	53493
@NP	5-HT axon protection	53520
@NP	dieback	53546
@NP	enhanced FB or OEC survival due to CSA treatment	53572
@NP	enhanced FB or OEC survival	53572
@NP	CSA treatment	53607
@NP	axons	53636
@NP	axon regeneration	53654
@NP	we	53673
@NP	raphespinal tract axons	53687
@NP	-LRB- 1 -RRB- the number of axons that crossed the border	53725
@NP	the number	53729
@NP	axons that crossed the border	53743
@NP	axons	53743
@NP	the border	53762
@NP	-LRB- 2 -RRB- the area in the lesion core that contains 5-HT axons	53774
@NP	the area	53778
@NP	the lesion core that contains 5-HT axons	53790
@NP	the lesion core	53790
@NP	5-HT axons	53820
@NP	the distance	53840
@NP	the rostral border to the furthest extending 5-HT axon	53858
@NP	the rostral border	53858
@NP	the furthest extending 5-HT axon	53880
@NP	the furthest	53880
@NP	5-HT axon	53903
@NP	Fig. 9D ` ÄìF	53914
@NP	Fig. 9D	53914
@NP	` ÄìF	53921
@NP	non-immunosuppressed rats	53940
@NP	CSA treatment	53967
@NP	the number	53990
@NP	5-HT axons	54004
@NP	the rostral astrocyte scar border	54028
@NP	FB - and OEC-treated rats	54065
@NP	2 weeks	54093
@NP	Fig. 9D ; FB + CSA 34 ¬ ± 21 , p = 0.0314 ; OEC+CSA 86 ¬ ± 9 axons , p = 0.0023	54102
@NP	Fig. 9D ; FB + CSA 34 ¬ ± 21	54102
@NP	Fig. 9D	54102
@NP	FB + CSA 34 ¬ ± 21	54111
@NP	FB	54111
@NP	CSA 34 ¬ ± 21	54116
@NP	CSA 34 ¬	54116
@NP	± 21	54123
@NP	p = 0.0314 ; OEC+CSA 86 ¬ ± 9 axons	54128
@NP	p = 0.0314	54128
@NP	p	54128
@NP	0.0314	54130
@NP	OEC+CSA 86 ¬ ± 9 axons	54138
@NP	OEC+CSA 86	54138
@NP	¬ ± 9 axons	54148
@NP	p = 0.0023	54159
@NP	p	54159
@NP	0.0023	54161
@NP	8 weeks	54173
@NP	CSA + OEC treatment	54182
@NP	CSA	54182
@NP	OEC treatment	54188
@NP	a twofold greater number	54211
@NP	5-HT axons	54239
@NP	the border	54263
@NP	OEC-treatment	54288
@NP	Fig. 9D ; OEC + CSA 46 ¬ ± 18 , p = 0.0487	54309
@NP	Fig. 9D	54309
@NP	OEC + CSA 46 ¬ ± 18 , p = 0.0487	54318
@NP	OEC	54318
@NP	CSA 46 ¬ ± 18 , p = 0.0487	54324
@NP	CSA 46 ¬ ± 18	54324
@NP	CSA 46 ¬	54324
@NP	± 18	54332
@NP	p = 0.0487	54338
@NP	p	54338
@NP	0.0487	54342
@NP	We	54351
@NP	larger areas of 5-HT-positive axons in the lesion core of CSA	54360
@NP	larger areas	54360
@NP	5-HT-positive axons in the lesion core of CSA	54376
@NP	5-HT-positive axons	54376
@NP	the lesion core of CSA	54399
@NP	the lesion core	54399
@NP	CSA	54418
@NP	non-CSA-treated rats in both transplant groups	54427
@NP	non-CSA-treated rats	54427
@NP	both transplant groups	54451
@NP	2 weeks	54477
@NP	Fig. 9E ; FB + CSA 19,718 ¬ ± 5707 ¬ µm2	54486
@NP	Fig. 9E	54486
@NP	FB + CSA 19,718 ¬ ± 5707 ¬ µm2	54495
@NP	FB	54495
@NP	CSA 19,718 ¬ ± 5707 ¬ µm2	54500
@NP	CSA 19,718 ¬ ±	54500
@NP	CSA 19,718	54500
@NP	¬ ±	54511
@NP	5707 ¬ µm2	54514
@NP	p = 0.0020 ; OEC + CSA 33,013 ¬ ± 8295 ¬ µm2	54525
@NP	p = 0.0020	54525
@NP	p	54525
@NP	0.0020	54529
@NP	OEC + CSA 33,013 ¬ ± 8295 ¬ µm2	54537
@NP	OEC	54537
@NP	CSA 33,013 ¬ ± 8295 ¬ µm2	54543
@NP	CSA 33,013 ¬ ±	54543
@NP	CSA 33,013	54543
@NP	¬ ±	54554
@NP	8295 ¬ µm2	54557
@NP	p = 0.0018	54568
@NP	p	54568
@NP	0.0018	54572
@NP	Surpris	54581
@NP	the distance	54597
@NP	the furthest	54613
@NP	5-HT axon increased in the FB - but not OEC-treated rats at 2 weeks	54636
@NP	5-HT axon increased in the FB	54636
@NP	5-HT axon	54636
@NP	the FB	54659
@NP	OEC-treated rats at 2 weeks	54675
@NP	OEC-treated rats	54675
@NP	2 weeks	54695
@NP	CSA administration	54708
@NP	Fig. 9F ; FB 371 ¬ ± 161 vs FB+CSA 146 ¬ ± 84 ¬ µm , p = 0.0018	54728
@NP	Fig. 9F	54728
@NP	FB 371 ¬ ± 161 vs FB+CSA 146 ¬ ± 84 ¬ µm , p = 0.0018	54737
@NP	FB 371 ¬ ± 161	54737
@NP	FB 371 ¬ ±	54737
@NP	161	54746
@NP	FB+CSA 146 ¬ ± 84 ¬ µm , p = 0.0018	54753
@NP	FB+CSA 146 ¬	54753
@NP	± 84 ¬ µm , p = 0.0018	54764
@NP	± 84 ¬ µm , p	54764
@NP	0.0018	54775
@NP	8 weeks	54791
@NP	5-HT-positive axons	54800
@NP	the lesion core of OEC + CSA than FB	54842
@NP	the lesion core of OEC	54842
@NP	the lesion core	54842
@NP	OEC	54861
@NP	CSA than FB	54866
@NP	CSA	54866
@NP	FB	54875
@NP	CSA-treated rats	54880
@NP	Fig. 9F ; FB + CSA -117 ¬ ± 166 vs OEC ¬ ± CSA 361 ¬ ± 137 ¬ µm , p = 0.0089	54898
@NP	Fig. 9F	54898
@NP	FB + CSA -117 ¬ ± 166 vs OEC ¬ ± CSA 361 ¬ ± 137 ¬ µm , p = 0.0089	54907
@NP	FB + CSA -117 ¬ ± 166	54907
@NP	FB	54907
@NP	CSA -117 ¬ ± 166	54912
@NP	CSA -117	54912
@NP	¬ ±	54922
@NP	166	54925
@NP	OEC ¬ ± CSA 361 ¬ ± 137 ¬ µm , p = 0.0089	54932
@NP	OEC	54932
@NP	± CSA 361 ¬ ± 137 ¬ µm , p = 0.0089	54937
@NP	± CSA 361 ¬ ± 137 ¬ µm	54937
@NP	± CSA 361	54937
@NP	¬ ± 137 ¬ µm	54947
@NP	¬ ±	54947
@NP	137 ¬ µm	54950
@NP	p = 0.0089	54959
@NP	p	54959
@NP	0.0089	54963
@NP	CSA treatment	54978
@NP	5-HT axon preservation	55001
@NP	FB-treated rats	55027
@NP	2 weeks postinjury	55051
@NP	these results	55081
@NP	OEC transplantation	55109
@NP	the extension of 5-HT axons	55138
@NP	the extension	55138
@NP	5-HT axons	55155
@NP	the scar border	55173
@NP	CSA-enhanced survival of OECs	55198
@NP	CSA-enhanced survival	55198
@NP	OECs	55223
@NP	these axons in the lesion core	55238
@NP	these axons	55238
@NP	the lesion core	55253
@NP	Enhanced-OEC and FB survival	55277
@NP	Enhanced-OEC	55277
@NP	FB survival	55294
@NP	inhibitory factors	55314
@NP	the injury site	55336
@NP	CSA-enhanced OEC survival	55368
@NP	inhibitory factors in the lesion site	55405
@NP	inhibitory factors	55405
@NP	the lesion site	55427
@NP	that observed with non-CSA-treated rats	55450
@NP	that	55450
@NP	non-CSA-treated rats	55469
@NP	we	55491
@NP	CSPG	55503
@NP	luminance levels in the lesion core and the rostral and caudal stumps	55508
@NP	luminance levels in the lesion core	55508
@NP	luminance levels	55508
@NP	the lesion core	55528
@NP	the rostral and caudal stumps	55548
@NP	the rostral	55548
@NP	caudal stumps	55564
@NP	We	55579
@NP	a time-dependent CSA treatment effect	55591
@NP	the levels of CSPG luminance	55632
@NP	the levels	55632
@NP	CSPG luminance	55646
@NP	the lesion core	55664
@NP	transplant groups	55685
@NP	2 week CSA 2.7 ¬ ± 0.3 vs no CSA 2.3 ¬ ± 0.2	55718
@NP	2 week CSA	55718
@NP	2.7 ¬ ± 0.3 vs no CSA 2.3 ¬ ± 0.2	55729
@NP	2.7 ¬ ± 0.3	55729
@NP	2.7 ¬	55729
@NP	± 0.3	55733
@NP	no CSA 2.3 ¬ ± 0.2	55741
@NP	no CSA 2.3 ¬	55741
@NP	± 0.2	55752
@NP	p = 0.0444 ; 8 week CSA 1.9 ¬ ± 0.2 vs no CSA 2.7 ¬ ± 0.5	55758
@NP	p = 0.0444	55758
@NP	p	55758
@NP	0.0444	55760
@NP	8 week CSA 1.9 ¬ ± 0.2 vs no CSA 2.7 ¬ ± 0.5	55768
@NP	8 week CSA	55768
@NP	1.9 ¬ ± 0.2 vs no CSA 2.7 ¬ ± 0.5	55779
@NP	1.9 ¬ ± 0.2	55779
@NP	1.9 ¬	55779
@NP	± 0.2	55783
@NP	no CSA 2.7 ¬ ± 0.5	55791
@NP	no CSA 2.7 ¬	55791
@NP	± 0.5	55802
@NP	p = 0.0156	55809
@NP	p	55809
@NP	0.0156	55813
@NP	the stumps	55833
@NP	the lesion core	55848
@NP	CSPG levels	55865
@NP	higher	55886
@NP	FB + CSA	55896
@NP	FB	55896
@NP	CSA	55901
@NP	OEC + CSA groups	55919
@NP	2 and 8 weeks -LRB- Fig. 9H ; 2 weeks , p = 0.0008 ; 8 weeks , p = 0.0438 -RRB-	55939
@NP	2 and 8 weeks	55939
@NP	Fig. 9H ; 2 weeks , p = 0.0008 ; 8 weeks , p = 0.0438	55954
@NP	Fig. 9H	55954
@NP	2 weeks , p = 0.0008 ; 8 weeks , p = 0.0438	55963
@NP	2 weeks	55963
@NP	p = 0.0008 ; 8 weeks , p = 0.0438	55972
@NP	p = 0.0008	55972
@NP	p	55972
@NP	0.0008	55974
@NP	8 weeks , p = 0.0438	55982
@NP	8 weeks	55982
@NP	p = 0.0438	55991
@NP	p	55991
@NP	0.0438	55994
@NP	2 weeks	56006
@NP	spinal rats treated with OEC ¬ ± CSA	56024
@NP	spinal rats	56024
@NP	OEC ¬ ± CSA	56049
@NP	OEC	56049
@NP	¬ ± CSA	56053
@NP	¬ ±	56053
@NP	CSA	56056
@NP	higher CSPG levels in the lesion core	56064
@NP	higher CSPG levels	56064
@NP	the lesion core	56086
@NP	those	56107
@NP	OECs alone	56126
@NP	OECs	56126
@NP	Fig. 9H ; OEC 1.2 ¬ ± 0.1 vs OEC+CSA 2.1 ¬ ± 0.3 , p = 0.0144	56138
@NP	Fig. 9H	56138
@NP	OEC 1.2 ¬ ± 0.1 vs OEC+CSA 2.1 ¬ ± 0.3 , p = 0.0144	56147
@NP	OEC 1.2 ¬ ± 0.1	56147
@NP	OEC 1.2 ¬	56147
@NP	± 0.1	56155
@NP	OEC+CSA 2.1 ¬ ± 0.3 , p = 0.0144	56163
@NP	OEC+CSA 2.1 ¬	56163
@NP	± 0.3 , p = 0.0144	56175
@NP	± 0.3	56175
@NP	p = 0.0144	56181
@NP	p	56181
@NP	0.0144	56184
@NP	CSPG levels in the lesion core	56193
@NP	CSPG levels	56193
@NP	the lesion core	56208
@NP	FB	56238
@NP	FB-treated rats	56260
@NP	8 weeks	56279
@NP	Fig. 9H ; FB 3.9 ¬ ± 0.5 vs FB + CSA 2.4 ¬ ± 0.1 , p = 0.0059	56288
@NP	Fig. 9H	56288
@NP	FB 3.9 ¬ ± 0.5 vs FB + CSA 2.4 ¬ ± 0.1 , p = 0.0059	56297
@NP	FB 3.9 ¬ ± 0.5	56297
@NP	FB 3.9 ¬	56297
@NP	± 0.5	56305
@NP	FB + CSA 2.4 ¬ ± 0.1 , p = 0.0059	56314
@NP	FB	56314
@NP	CSA 2.4 ¬ ± 0.1 , p = 0.0059	56319
@NP	CSA 2.4 ¬ ± 0.1	56319
@NP	CSA 2.4 ¬	56319
@NP	± 0.1	56327
@NP	p = 0.0059	56333
@NP	p	56333
@NP	0.0059	56335
@NP	CSPG levels in the stump borders	56344
@NP	CSPG levels	56344
@NP	the stump borders	56359
@NP	FB + CSA groups	56397
@NP	OEC + CSA groups	56427
@NP	both time points	56447
@NP	Fig. 9I ; 2 weeks , p = 0.0326 ; 8 weeks , p = 0.0460	56465
@NP	Fig. 9I	56465
@NP	2 weeks , p = 0.0326 ; 8 weeks , p = 0.0460	56474
@NP	2 weeks	56474
@NP	p = 0.0326 ; 8 weeks , p = 0.0460	56483
@NP	p = 0.0326	56483
@NP	p	56483
@NP	0.0326	56485
@NP	8 weeks , p = 0.0460	56493
@NP	8 weeks	56493
@NP	p = 0.0460	56502
@NP	p	56502
@NP	0.0460	56505
@NP	These findings	56514
@NP	OECs	56540
@NP	CSPG levels	56552
@NP	time at the lesion site regardless of CSA treatment	56569
@NP	time	56569
@NP	the lesion site regardless of CSA treatment	56577
@NP	the lesion site	56577
@NP	CSA treatment	56607
@NP	We	56622
@NP	levels of Oil Red O	56648
@NP	levels	56648
@NP	Oil Red O	56658
@NP	staining in FB	56668
@NP	staining	56668
@NP	FB	56680
@NP	¬ ±	56683
@NP	CSA - and OEC + CSA-treated injury sites	56686
@NP	CSA	56686
@NP	OEC + CSA-treated injury sites	56695
@NP	OEC	56695
@NP	CSA-treated injury sites	56701
@NP	immunosuppression	56741
@NP	the presence of myelin debris	56767
@NP	the presence	56767
@NP	myelin debris	56783
@NP	a reduction in myelin debris	56807
@NP	a reduction	56807
@NP	myelin debris	56822
@NP	CSA	56852
@NP	non-CSA-treated spinal cords	56870
@NP	the cell transplant type	56913
@NP	Figs. 10A ` ÄìD , 5A , B , E , F	56947
@NP	Figs. 10A	56947
@NP	ÄìD , 5A , B , E , F	56957
@NP	Punctate Oil Red O-stained debris	56973
@NP	8 week FB - and OEC-treated spinal cords -LRB- Fig. 10c , d -RRB-	57023
@NP	8 week FB	57023
@NP	OEC-treated spinal cords	57038
@NP	Fig. 10c	57064
@NP	d	57073
@NP	FB-treated rats	57084
@NP	myelin debris	57101
@NP	the lesion core	57128
@NP	the GFAP-positive stumps at 2 and 8 weeks -LRB- Fig. 10A , C -RRB-	57167
@NP	the GFAP-positive stumps	57167
@NP	2 and 8 weeks -LRB- Fig. 10A , C -RRB-	57195
@NP	2 and 8 weeks	57195
@NP	Fig. 10A , C	57210
@NP	Fig. 10A	57210
@NP	C	57219
@NP	contrast	57226
@NP	OEC + CSA-treated rats	57236
@NP	OEC	57236
@NP	CSA-treated rats	57242
@NP	minimal myelin debris	57269
@NP	the lesion core and stumps -LRB- Fig. 10B , D -RRB-	57294
@NP	the lesion core	57294
@NP	stumps -LRB- Fig. 10B , D -RRB-	57314
@NP	stumps	57314
@NP	Fig. 10B , D	57322
@NP	Fig. 10B	57322
@NP	D	57331
@NP	the greater reduction	57342
@NP	myelin debris in OEC - compared with FB-treated rats after immunosuppression	57367
@NP	myelin debris	57367
@NP	OEC	57384
@NP	FB-treated rats after immunosuppression	57403
@NP	FB-treated rats	57403
@NP	immunosuppression	57425
@NP	we	57444
@NP	OECs	57456
@NP	the clearance of myelin	57478
@NP	the clearance	57478
@NP	myelin	57495
@NP	OECs	57528
@NP	myelin particles	57546
@NP	we	57564
@NP	OECs	57601
@NP	Confocal images	57607
@NP	MBP-positive myelin fragments	57632
@NP	the cytoplasm of OECs -LRB- Fig. 10E -RRB-	57669
@NP	the cytoplasm	57669
@NP	OECs -LRB- Fig. 10E -RRB-	57686
@NP	OECs	57686
@NP	Fig. 10E	57692
@NP	This observation	57703
@NP	OEC phagocytic activity	57734
@NP	the removal of inhibitory myelin debris postinjury	57781
@NP	the removal	57781
@NP	inhibitory myelin debris postinjury	57796
@NP	Discussion Spinal cord injury	57834
@NP	Discussion	57834
@NP	Spinal cord injury	57845
@NP	a temporally regulated , pathological cascade	57873
@NP	cellular changes	57921
@NP	both central and peripheral cells	57951
@NP	a layered scar	57996
@NP	an inhibitory environment	58022
@NP	the lesion site	58051
@NP	Burda and Sofroniew , 2014 ; Cregg et al. , 2014	58068
@NP	Burda and Sofroniew	58068
@NP	2014 ; Cregg et al.	58089
@NP	2014	58089
@NP	Cregg et al.	58095
@NP	Cregg	58095
@NP	et al.	58101
@NP	2014	58109
@NP	The present study	58116
@NP	FBs andOECsdiffer in their modification of the lesion site	58145
@NP	FBs andOECsdiffer	58145
@NP	their modification of the lesion site	58166
@NP	their modification	58166
@NP	the lesion site	58188
@NP	complete spinal cord transection	58210
@NP	OECs , but not FBs ,	58244
@NP	OECs	58244
@NP	FBs	58258
@NP	neurons and 5-HT axons in the lesion core	58281
@NP	neurons	58281
@NP	5-HT axons in the lesion core	58293
@NP	5-HT axons	58293
@NP	the lesion core	58307
@NP	inhibitory CSPGs and myelin debris	58331
@NP	inhibitory CSPGs	58331
@NP	myelin debris	58352
@NP	immune cell infiltration to reduce secondary tissue damage	58377
@NP	secondary tissue damage	58412
@NP	CSA	58442
@NP	OEC survival	58466
@NP	the innate immune response and secondary tissue damage	58480
@NP	the innate immune response	58480
@NP	secondary tissue damage	58511
@NP	The prolonged presence of OECs	58549
@NP	The prolonged presence	58549
@NP	OECs	58575
@NP	the survival of neurons	58589
@NP	the survival	58589
@NP	neurons	58605
@NP	the regeneration of axons in the lesion site	58629
@NP	the regeneration	58629
@NP	axons in the lesion site	58649
@NP	axons	58649
@NP	the lesion site	58658
@NP	contact-mediated mechanisms	58677
@NP	Our results	58706
@NP	evidence	58726
@NP	OECs	58740
@NP	axon regeneration	58774
@NP	a growth	58805
@NP	permissive substrate	58814
@NP	the inhospitable lesion site environment	58847
@NP	OECs	58889
@NP	astroglial scar border formation	58905
@NP	injury astrocytes	58944
@NP	a protective barrier	58967
@NP	further cell loss	59020
@NP	the spread of inflammation	59048
@NP	the spread	59048
@NP	inflammation	59062
@NP	blood	59088
@NP	Äìbrain barrier repair -LRB- Bush et al. , 1999 ; Faulkner et al. , 2004 -RRB-	59094
@NP	Äìbrain barrier repair	59094
@NP	Bush	59118
@NP	et al. , 1999 ; Faulkner et al. , 2004	59123
@NP	et al.	59123
@NP	1999 ; Faulkner et al.	59131
@NP	1999	59131
@NP	Faulkner et al.	59137
@NP	Faulkner	59137
@NP	et al.	59146
@NP	2004	59154
@NP	We	59161
@NP	FBs , but not OECs ,	59174
@NP	FBs	59174
@NP	OECs	59187
@NP	astrocyte barrier formation	59199
@NP	FB-transplanted rats	59236
@NP	greater cell infiltration and overall tissue damage	59262
@NP	greater cell infiltration	59262
@NP	overall tissue damage	59292
@NP	rats transplanted with OECs	59319
@NP	rats	59319
@NP	OECs	59342
@NP	Reactive astrocyte processes in FB-treated rats	59348
@NP	Reactive astrocyte processes	59348
@NP	FB-treated rats	59380
@NP	immune cells	59438
@NP	fibroblasts , or CSPG-positive cells within the spinal cord stumps	59461
@NP	fibroblasts	59461
@NP	CSPG-positive cells within the spinal cord stumps	59477
@NP	CSPG-positive cells	59477
@NP	the spinal cord stumps	59504
@NP	transplantation of skin FBs into the injured spinal cord	59534
@NP	transplantation	59534
@NP	skin FBs into the injured spinal cord	59553
@NP	skin FBs	59553
@NP	the injured spinal cord	59567
@NP	the amount of cellular invasion	59603
@NP	the amount	59603
@NP	cellular invasion	59617
@NP	the astrocytic scar formation	59655
@NP	contrast to FBs	59689
@NP	contrast	59689
@NP	FBs	59701
@NP	OECs	59706
@NP	astrocytes	59729
@NP	sequestration of invading peripheral cells	59767
@NP	sequestration	59767
@NP	peripheral cells	59793
@NP	example	59815
@NP	immune cell infiltration	59824
@NP	2 weeks	59859
@NP	FB	59870
@NP	4 weeks	59888
@NP	OECtreated rats	59899
@NP	our findings	59932
@NP	OECs	59946
@NP	astrocytes in vivo	59982
@NP	astrocytes	59982
@NP	vivo	59996
@NP	astrocyte reactivity or an increase	60019
@NP	astrocyte reactivity	60019
@NP	an increase	60043
@NP	CSPG levels	60058
@NP	transplantation	60080
@NP	intact spinal cords -LRB- Lakatos et al. , 2000 , 2003 -RRB-	60101
@NP	intact spinal cords	60101
@NP	Lakatos	60122
@NP	et al. , 2000 , 2003	60130
@NP	et al.	60130
@NP	2000	60138
@NP	2003	60144
@NP	OECs	60170
@NP	an in vitro scar-like culture model	60189
@NP	an in vitro scar-like culture	60189
@NP	scar-like culture	60201
@NP	they	60225
@NP	astrocytic reactivity	60244
@NP	the boundary zones	60278
@NP	meningeal fibroblasts -LRB- Khankan et al. , 2015 -RRB-	60316
@NP	meningeal fibroblasts	60316
@NP	Khankan	60339
@NP	et al. , 2015	60347
@NP	et al.	60347
@NP	2015	60355
@NP	OECs	60373
@NP	scar-forming astrocytes	60393
@NP	the lesion core following spinal cord injury	60427
@NP	the lesion core	60427
@NP	spinal cord injury	60453
@NP	Thus OECs , compared with FBs ,	60473
@NP	Thus OECs	60473
@NP	FBs	60498
@NP	reactive astrocyte border formation	60514
@NP	the re-establishment of the glial limitans	60572
@NP	the re-establishment	60572
@NP	the glial limitans	60596
@NP	The STAT3-signaling pathway	60616
@NP	the organization of reactive astrocyte processes	60659
@NP	the organization	60659
@NP	reactive astrocyte processes	60679
@NP	cells -LRB- Herrmann et al. , 2008 -RRB-	60726
@NP	cells	60726
@NP	Herrmann	60733
@NP	et al. , 2008	60742
@NP	et al.	60742
@NP	2008	60750
@NP	STAT3-null mice	60757
@NP	a deficient astrocytic scar barrier	60778
@NP	spinal cord injury	60820
@NP	increased inflammation	60855
@NP	neuronal loss -LRB- Herrmann et al. , 2008 ; Wanner et al. , 2013 -RRB-	60882
@NP	neuronal loss	60882
@NP	Herrmann	60897
@NP	et al. , 2008 ; Wanner et al. , 2013	60906
@NP	et al.	60906
@NP	2008 ; Wanner et al.	60914
@NP	2008	60914
@NP	Wanner et al.	60920
@NP	Wanner	60920
@NP	et al.	60927
@NP	2013	60935
@NP	our FB-treated spinal cords	60964
@NP	Reactive astrocytes	60993
@NP	Iba-1-positive inflammatory cells and CSPG-positive meningeal fibroblasts	61031
@NP	Iba-1-positive inflammatory cells	61031
@NP	CSPG-positive meningeal fibroblasts	61069
@NP	FB	61108
@NP	OECtreated rats	61121
@NP	The cytokines	61138
@NP	the activation of the tripartite receptor complex involved in STAT3-signaling	61172
@NP	the activation	61172
@NP	the tripartite receptor complex involved in STAT3-signaling	61190
@NP	the tripartite receptor complex	61190
@NP	STAT3-signaling	61234
@NP	CNTF , LIF , and IL-6 -LRB- Stahl and Yancopoulos , 1994 -RRB-	61254
@NP	CNTF , LIF ,	61254
@NP	CNTF	61254
@NP	LIF	61260
@NP	IL-6 -LRB- Stahl and Yancopoulos , 1994 -RRB-	61269
@NP	IL-6	61269
@NP	Stahl and Yancopoulos	61275
@NP	1994	61298
@NP	OECs	61332
@NP	Wewetzer et al. , 2001 ; Asan et al. , 2003 ; Herbert et al. , 2012	61338
@NP	Wewetzer	61338
@NP	et al. , 2001 ; Asan et al. , 2003 ; Herbert et al. , 2012	61347
@NP	et al. , 2001	61347
@NP	et al.	61347
@NP	2001	61355
@NP	Asan et al. , 2003	61361
@NP	Asan	61361
@NP	et al. , 2003	61366
@NP	et al.	61366
@NP	2003	61374
@NP	Herbert et al. , 2012	61380
@NP	Herbert	61380
@NP	et al. , 2012	61388
@NP	et al.	61388
@NP	2012	61396
@NP	cytokine signaling	61418
@NP	olfactory bulbectomy -LRB- Nan et al. , 2001 -RRB-	61443
@NP	olfactory bulbectomy	61443
@NP	Nan	61465
@NP	et al. , 2001	61469
@NP	et al.	61469
@NP	2001	61477
@NP	The CNTF , LIF , and IL-6 receptors	61484
@NP	The CNTF	61484
@NP	LIF	61494
@NP	IL-6 receptors	61503
@NP	an OEC-mediated regulatory role	61539
@NP	cytokine secretion -LRB- Nan et al. , 2001 ; Wewetzer et al. , 2001 -RRB-	61574
@NP	cytokine secretion	61574
@NP	Nan	61594
@NP	et al. , 2001 ; Wewetzer et al. , 2001	61598
@NP	et al.	61598
@NP	2001 ; Wewetzer et al.	61606
@NP	2001	61606
@NP	Wewetzer et al.	61612
@NP	Wewetzer	61612
@NP	et al.	61621
@NP	2001	61629
@NP	OECs	61642
@NP	astrocytes	61681
@NP	immune cell infiltration and secondary tissue damage	61701
@NP	activation of the STAT3 pathway	61758
@NP	activation	61758
@NP	the STAT3 pathway	61772
@NP	OECs	61791
@NP	immunomodulatory and neuroprotective Beck	61800
@NP	et al. -LRB- 2010 -RRB-	61842
@NP	et al.	61842
@NP	2010	61850
@NP	flow cytometry	61861
@NP	there	61904
@NP	a time-dependent , multiphasic inflammatory response in which	61913
@NP	a time-dependent , multiphasic inflammatory response	61913
@NP	macrophages	61974
@NP	first peak at 7 d and then at 60 d	61986
@NP	first peak	61986
@NP	7 d	62000
@NP	60 d	62016
@NP	a spinal cord contusion	62027
@NP	complete spinal cord transection	62058
@NP	the activation and peak of immune response	62092
@NP	the activation and peak	62092
@NP	immune response	62119
@NP	OEC	62150
@NP	FB-treated rats	62162
@NP	This delay in immune activation	62179
@NP	This delay	62179
@NP	immune activation	62193
@NP	the prolonged survival of OECs	62235
@NP	the prolonged survival	62235
@NP	OECs	62261
@NP	FBs	62280
@NP	OECs	62291
@NP	inflammation	62315
@NP	the injury site	62331
@NP	macrophage infiltration	62359
@NP	myelin debris	62393
@NP	neurons	62423
@NP	the scar border	62440
@NP	It	62457
@NP	OECs	62475
@NP	neurons in the lesion core	62488
@NP	neurons	62488
@NP	the lesion core	62499
@NP	a contact-mediated mechanism	62520
@NP	these neurons	62568
@NP	OECs	62610
@NP	This	62616
@NP	OECs	62635
@NP	neurons	62661
@NP	the astrocyte scar border	62684
@NP	CSA	62711
@NP	a potent immunosuppressant	62716
@NP	T-cell activation	62755
@NP	other immune cells -LRB- Ho et al. , 1996 -RRB-	62787
@NP	other immune cells	62787
@NP	Ho	62807
@NP	et al. , 1996	62810
@NP	et al.	62810
@NP	1996	62818
@NP	Iba-1 infiltration	62833
@NP	FB - and OEC-treated rats	62855
@NP	equivalent levels and prolonged FB and OEC survival in the lesion core	62883
@NP	equivalent levels	62883
@NP	prolonged FB and OEC survival in the lesion core	62905
@NP	prolonged FB and OEC survival	62905
@NP	the lesion core	62938
@NP	neurons	62959
@NP	the lesion core of OEC CSA , but not FB CSA-treated rats	62981
@NP	the lesion core of OEC CSA	62981
@NP	the lesion core	62981
@NP	OEC CSA	63000
@NP	FB CSA-treated rats	63019
@NP	FB	63019
@NP	CSA-treated rats	63024
@NP	This	63042
@NP	OECs	63061
@NP	neurons	63075
@NP	a different mechanism than CSA	63086
@NP	a different mechanism	63086
@NP	CSA	63113
@NP	an additive neuroprotective effect	63134
@NP	the combined use of OEC transplantation and CSA treatment	63174
@NP	the combined use	63174
@NP	OEC transplantation and CSA treatment	63194
@NP	OEC transplantation	63194
@NP	CSA treatment	63218
@NP	the OEC-mediated delay and attenuation of immune infiltration	63244
@NP	the OEC-mediated delay and attenuation	63244
@NP	immune infiltration	63286
@NP	secondary tissue damage	63314
@NP	the direct presence of OECs	63362
@NP	the direct presence	63362
@NP	OECs	63385
@NP	neurons	63401
@NP	the lesion core	63412
@NP	OECs	63429
@NP	5-HT axonal loss	63440
@NP	Our data	63457
@NP	OEC-mediated immunomodulation and direct OEC-axon alignment	63474
@NP	potential mechanisms	63537
@NP	5-HT axons	63574
@NP	the lesion core	63588
@NP	Evans et al. -LRB- 2014 -RRB-	63605
@NP	Evans et al.	63605
@NP	Evans	63605
@NP	et al.	63611
@NP	2014	63619
@NP	blood-derived macrophages	63649
@NP	axonal dieback in a dorsal column crush model of spinal cord injury	63695
@NP	axonal dieback	63695
@NP	a dorsal column crush model of spinal cord injury	63713
@NP	a dorsal column crush model	63713
@NP	spinal cord injury	63744
@NP	we	63775
@NP	more 5-HT axonal dieback	63787
@NP	OEC-treated rats	63831
@NP	the peak time of immune infiltration	63851
@NP	the peak time	63851
@NP	immune infiltration	63868
@NP	CSA	63889
@NP	5-HT axonal preservation in FB-treated rats only at the 2 week time point	63917
@NP	5-HT axonal preservation	63917
@NP	FB-treated rats only at the 2 week time point	63945
@NP	FB-treated rats	63945
@NP	the 2 week time point	63969
@NP	the axonal dieback caused by immune infiltration	64003
@NP	the axonal dieback	64003
@NP	immune infiltration	64032
@NP	no 5-HT axonal dieback	64065
@NP	OEC-treated rats	64104
@NP	CSA treatment	64137
@NP	OECs in the lesion core	64168
@NP	OECs	64168
@NP	the lesion core	64176
@NP	5-HT axon preservation via contact-mediated mechanisms , independent of CSA	64203
@NP	5-HT axon preservation	64203
@NP	contact-mediated mechanisms , independent of CSA	64230
@NP	contact-mediated mechanisms	64230
@NP	independent of CSA	64259
@NP	independent	64259
@NP	CSA	64274
@NP	we	64290
@NP	alignment with OECs	64307
@NP	alignment	64307
@NP	OECs	64322
@NP	neurite outgrowth	64350
@NP	an in vitro scar-like culture model of spinal cord injury	64371
@NP	scar-like culture model of spinal cord injury	64383
@NP	scar-like culture model	64383
@NP	spinal cord injury	64410
@NP	Khankan	64430
@NP	et al. , 2015	64438
@NP	et al.	64438
@NP	2015	64446
@NP	OECs	64461
@NP	multiple axon guidance and adhesion molecules	64474
@NP	it	64521
@NP	these OEC-axonal interactions	64539
@NP	both orient axons	64573
@NP	their growth postinjury	64603
@NP	Both 5-HT and neurofilament-labeled axons	64628
@NP	Both 5-HT	64628
@NP	neurofilament-labeled axons	64642
@NP	palisading astrocytic processes	64683
@NP	the scar border	64735
@NP	OECs	64778
@NP	Interactions between transplanted OECs and scar-forming astrocytes	64784
@NP	Interactions	64784
@NP	transplanted OECs and scar-forming astrocytes	64805
@NP	transplanted OECs	64805
@NP	scar-forming astrocytes	64827
@NP	a surface	64867
@NP	axon regeneration	64891
@NP	an arrangement	64910
@NP	the ` Äúpathway	64938
@NP	hypothesis ` Äù	64953
@NP	neural repair -LRB- Li et al. , 2005b ; Raisman and Li , 2007 -RRB-	64970
@NP	neural repair	64970
@NP	Li	64985
@NP	et al. , 2005b ; Raisman and Li , 2007	64988
@NP	et al.	64988
@NP	2005b ; Raisman and Li	64996
@NP	2005b	64996
@NP	Raisman and Li	65003
@NP	2007	65019
@NP	the scar	65033
@NP	border OECs	65042
@NP	a trabecular network	65070
@NP	OEC-lined conduits surrounded by a fibronectin-rich matrix	65103
@NP	OEC-lined conduits	65103
@NP	a fibronectin-rich matrix	65136
@NP	OECs	65176
@NP	an olfactory nerve lesion -LRB- Li et al. , 2005a -RRB-	65187
@NP	an olfactory nerve lesion	65187
@NP	Li	65214
@NP	et al. , 2005a	65217
@NP	et al.	65217
@NP	2005a	65225
@NP	these conduits	65244
@NP	axons	65270
@NP	OEC transplantation	65299
@NP	structural scaffolds	65338
@NP	axon regeneration	65375
@NP	astrocyte bridges and OEC-lined conduits	65406
@NP	astrocyte bridges	65406
@NP	OEC-lined conduits	65428
@NP	OECs	65448
@NP	inhibitory CSPGs	65460
@NP	myelin debris postinjury A well known feature of the inhibitory glial scar	65481
@NP	myelin debris postinjury A	65481
@NP	feature of the inhibitory glial scar	65519
@NP	feature	65519
@NP	the inhibitory glial scar	65530
@NP	the upregulation and secretion	65559
@NP	CSPGs	65593
@NP	astrocytes and fibroblasts	65602
@NP	McKeon et al. , 1995 ; Morgenstern et al. , 2002 ; Fitch and Silver , 2008	65630
@NP	McKeon	65630
@NP	et al. , 1995 ; Morgenstern et al. , 2002 ; Fitch and Silver , 2008	65637
@NP	et al. , 1995	65637
@NP	et al.	65637
@NP	1995	65645
@NP	Morgenstern et al. , 2002	65651
@NP	Morgenstern	65651
@NP	et al. , 2002	65663
@NP	et al.	65663
@NP	2002	65671
@NP	Fitch and Silver , 2008	65677
@NP	Fitch and Silver	65677
@NP	2008	65695
@NP	Several studies	65702
@NP	OECs	65730
@NP	CSPG immunoreactivity	65742
@NP	the injured spinal cord	65767
@NP	Lakatos	65792
@NP	et al. , 2003 ; Barbour et al. , 2013	65800
@NP	et al.	65800
@NP	2003 ; Barbour et al.	65808
@NP	2003	65808
@NP	Barbour et al.	65814
@NP	Barbour	65814
@NP	et al.	65822
@NP	2013	65830
@NP	our 8 week data	65841
@NP	a direct correlation between the loss of OECs and the increase in CSPG density	65862
@NP	a direct correlation	65862
@NP	the loss of OECs and the increase in CSPG density	65891
@NP	the loss of OECs	65891
@NP	the loss	65891
@NP	OECs	65903
@NP	the increase in CSPG density	65912
@NP	the increase	65912
@NP	CSPG density	65928
@NP	addition to reducing inhibitory CSPGs	65945
@NP	addition	65945
@NP	inhibitory CSPGs	65966
@NP	OEC treatment	65984
@NP	the buildup of myelin debris	66006
@NP	the buildup	66006
@NP	myelin debris	66021
@NP	the lesion core and spinal cord stumps	66038
@NP	the lesion core	66038
@NP	spinal cord stumps	66058
@NP	The accumulation of myelin debris	66078
@NP	The accumulation	66078
@NP	myelin debris	66098
@NP	axon regeneration -LRB- Filbin , 2003 ; Yiu and He , 2006 -RRB-	66121
@NP	axon regeneration	66121
@NP	Filbin , 2003 ; Yiu and He , 2006	66140
@NP	Filbin	66140
@NP	2003 ; Yiu and He	66148
@NP	2003	66148
@NP	Yiu and He	66154
@NP	Yiu	66154
@NP	He	66162
@NP	2006	66166
@NP	secondary damage due to inflammation -LRB- Sun et al. , 2010 -RRB-	66187
@NP	secondary damage	66187
@NP	inflammation	66211
@NP	Sun	66225
@NP	et al. , 2010	66229
@NP	et al.	66229
@NP	2010	66237
@NP	OECs	66252
@NP	the inflammatory response , this reduction in myelin debris	66266
@NP	the inflammatory response	66266
@NP	this reduction in myelin debris	66293
@NP	this reduction	66293
@NP	myelin debris	66311
@NP	the decrease in inflammation	66339
@NP	the decrease	66339
@NP	inflammation	66355
@NP	OEC-treated rats	66378
@NP	lower levels of myelin debris	66405
@NP	lower levels	66405
@NP	myelin debris	66421
@NP	CSA administration	66441
@NP	OECs	66461
@NP	phagocytes	66470
@NP	apoptotic olfactory receptor axons	66497
@NP	Su et al. , 2013 ; Nazareth et al. , 2015	66533
@NP	Su et al.	66533
@NP	2013 ; Nazareth et al.	66544
@NP	2013	66544
@NP	Nazareth et al.	66550
@NP	Nazareth	66550
@NP	et al.	66559
@NP	2015	66567
@NP	We	66574
@NP	evidence	66589
@NP	OECs	66603
@NP	myelin particles	66619
@NP	myelin debris	66653
@NP	a complete spinal cord transection	66681
@NP	OECs likely	66734
@NP	OECs	66734
@NP	myelin debris	66769
@NP	Astrocytes and microglia/macrophages	66784
@NP	a traumatic injury	66832
@NP	complex molecular signaling cascades	66865
@NP	the responses of multiple neural and peripheral cells	66907
@NP	the responses	66907
@NP	multiple neural and peripheral cells	66924
@NP	both a chemical and mechanical barrier	66970
@NP	a chemical	66975
@NP	mechanical barrier	66990
@NP	regeneration	67017
@NP	OECs	67031
@NP	the astrocyte response	67047
@NP	astrocytic processes	67082
@NP	pathways that would enhance axon outgrowth	67114
@NP	pathways	67114
@NP	axon outgrowth	67142
@NP	Li	67158
@NP	et al. , 2005b ; current study	67161
@NP	et al.	67161
@NP	2005b	67169
@NP	current study	67176
@NP	the reduction in OEC survival	67200
@NP	the reduction	67200
@NP	OEC survival	67217
@NP	the number of 5-HT axons crossing the border	67231
@NP	the number	67231
@NP	5-HT axons crossing the border	67245
@NP	5-HT axons	67245
@NP	the border	67265
@NP	these axons	67300
@NP	the lesion core	67336
@NP	Such findings	67353
@NP	OECs	67390
@NP	the lesion microenvironment	67406
@NP	an early time point postinjury	67437
@NP	long lasting effects on axon regeneration	67484
@NP	long lasting effects	67484
@NP	axon regeneration	67508
@NP	survival of OECs	67536
@NP	survival	67536
@NP	OECs	67548
@NP	a bridge	67562
@NP	axons	67588
@NP	the scar border	67611
@NP	axons	67641
@NP	the lesion core	67650
@NP	later time points	67669
@NP	we	67702
@NP	OEC transplantation after a complete spinal cord transection	67718
@NP	OEC transplantation	67718
@NP	a complete spinal cord transection	67744
@NP	contact-associated mechanisms	67827
@NP	an environment that supports axonal regeneration	67867
@NP	an environment	67867
@NP	axonal regeneration	67896
@VP	to Facilitate Regeneration Multiple neural	145
@VP	Facilitate Regeneration Multiple neural	148
@VP	form a structurally and chemically inhibitory scar that limits axon regeneration	276
@VP	limits axon regeneration	332
@VP	form an astroglial scar	369
@VP	produce chondroitin sulfate proteoglycans -LRB- CSPGs -RRB-	397
@VP	activate microglia	448
@VP	recruit blood-derived immune cells to the lesion for debris removal	472
@VP	results in functional improvements	615
@VP	promotes axon regeneration after spinal cord injury	654
@VP	limited the investigation of mechanisms underlying their proregenerative effects	756
@VP	underlying their proregenerative effects	796
@VP	preserve axons and neurons , and reduce inhibitory molecules in the lesion core	1286
@VP	preserve axons and neurons	1286
@VP	reduce inhibitory molecules in the lesion core	1318
@VP	limit immune-cell activation and infiltration	1398
@VP	to enhance graft survival	1601
@VP	enhance graft survival	1604
@VP	intermingled with astrocytes	2242
@VP	invading peripheral cells	2333
@VP	attenuated immune cell infiltration	2365
@VP	reduced secondary tissue damage	2402
@VP	protected neurons and axons in the lesion core	2435
@VP	helped clear myelin debris	2487
@VP	enhanced survival of OECs and FBs	2533
@VP	facilitated axon regeneration and neuron preservation	2649
@VP	contribute to a nonpermissive environment and minimal functional recovery	2962
@VP	To facilitate axonal regeneration and subsequent synaptic connectivity	3141
@VP	facilitate axonal regeneration and subsequent synaptic connectivity	3144
@VP	overcome these post-traumatic growth-inhibitory factors	3228
@VP	promote tissue preservation	3288
@VP	provide neurotrophic factors to spared neurons and function in axonal guidance	3532
@VP	to regenerate functional synaptic connections and initiate recovery	3665
@VP	regenerate functional synaptic connections and initiate recovery	3668
@VP	regenerate functional synaptic connections	3668
@VP	initiate recovery	3715
@VP	facilitate the generation of new olfactory receptor neurons	3802
@VP	express adhesion molecules involved in axonal outgrowth	4009
@VP	involved in axonal outgrowth	4036
@VP	secrete trophic factors , such as brain derived	4066
@VP	derived	4105
@VP	growing axons to protect them from inhibitory molecules	4186
@VP	to protect them from inhibitory molecules	4200
@VP	protect them from inhibitory molecules	4203
@VP	supports the regeneration of corticospinal tract axons	4695
@VP	preserves neurons and axons near the lesion site	4751
@VP	increases the recovery of motor-evoked potentials in the hindlimb muscles	4801
@VP	facilitates stepping	4880
@VP	stepping	4892
@VP	may facilitate axon regeneration and functional recovery	5171
@VP	facilitate axon regeneration and functional recovery	5175
@VP	are unclear	5228
@VP	To better understand how acutely transplanted OECs interact with the glial scar	5241
@VP	better understand how acutely transplanted OECs interact with the glial scar	5244
@VP	interact with the glial scar	5292
@VP	surrounding inhibitory environment after a complete spinal cord transection	5325
@VP	derived from GFP-transgenic rats -LRB- Perry et al. , 1999 -RRB-	5494
@VP	To assess the survival and engraftment	5549
@VP	assess the survival and engraftment	5552
@VP	found that OECs survived more robustly than FBs	5692
@VP	survived more robustly than FBs	5708
@VP	asked whether the presence of OECs preserved neurons	5750
@VP	preserved neurons	5785
@VP	provided a permissive environment for axons postinjury	5807
@VP	determine whether FBs and OECs differed in their modification of the lesion site	5991
@VP	differed in their modification of the lesion site	6022
@VP	examined astroglial scar formation	6076
@VP	would enhance graft survival	6325
@VP	enhance graft survival	6331
@VP	augment the beneficial effects of OECs	6358
@VP	improved both FB and OEC survival , and confirmed that OECs are neuroprotective	6412
@VP	improved both FB and OEC survival	6412
@VP	confirmed that OECs are neuroprotective	6451
@VP	are neuroprotective	6471
@VP	modulate the inhibitory environment	6521
@VP	reduce secondary tissue damage , and promote axon regeneration	6558
@VP	reduce secondary tissue damage	6558
@VP	promote axon regeneration	6594
@VP	approved by the Chancellor ` Äôs Animal Research Committee at UCLA	6693
@VP	conducted in accordance with the National Institutes of Health guidelines	6762
@VP	were housed under standard conditions with ad libitum access to food	6845
@VP	housed under standard conditions with ad libitum access to food	6850
@VP	were used to obtain GFP-labeled FBs and OECs	7135
@VP	used to obtain GFP-labeled FBs and OECs	7140
@VP	to obtain GFP-labeled FBs and OECs	7145
@VP	obtain GFP-labeled FBs and OECs	7148
@VP	transplanted into rats	7191
@VP	were GFP-labeled , and will be referred to as FB or OEC throughout the paper	7214
@VP	were GFP-labeled	7214
@VP	will be referred to as FB or OEC throughout the paper	7236
@VP	be referred to as FB or OEC throughout the paper	7241
@VP	referred to as FB or OEC throughout the paper	7244
@VP	to as FB or OEC throughout the paper	7253
@VP	as FB or OEC throughout the paper	7256
@VP	were used in cortical neurite outgrowth experiments	7326
@VP	used in cortical neurite outgrowth experiments	7331
@VP	were maintained for 1 , 2 , 4 , or 8 weeks postinjury -LRB- Table 1 -RRB-	7713
@VP	maintained for 1 , 2 , 4 , or 8 weeks postinjury -LRB- Table 1 -RRB-	7718
@VP	to prepare all OEC primary and immunopurified cultures	7820
@VP	prepare all OEC primary and immunopurified cultures	7823
@VP	were removed to reduce fibroblast contamination	8091
@VP	removed to reduce fibroblast contamination	8096
@VP	to reduce fibroblast contamination	8104
@VP	reduce fibroblast contamination	8107
@VP	dissociated in 0.1 % trypsin -LRB- Invitrogen -RRB-	8151
@VP	was changed every 2 d.	8426
@VP	changed every 2 d.	8430
@VP	Dissociated	8449
@VP	were maintained in vitro for 5 d	8466
@VP	maintained in vitro for 5 d	8471
@VP	Purified	8618
@VP	were maintained in vitro for an additional 7 d	8632
@VP	maintained in vitro for an additional 7 d	8637
@VP	dissociated into fibroblast cultures as described by Takashima -LRB- 2001 -RRB-	9125
@VP	described by Takashima -LRB- 2001 -RRB-	9165
@VP	was separated mechanically from the epidermis and hypodermis	9207
@VP	separated mechanically from the epidermis and hypodermis	9211
@VP	trypsinized -LRB- 0.3 % -RRB- for 10 min at 37 ¬ ∞ C	9287
@VP	rinsed with D/F-FBS medium	9331
@VP	were centrifuged at 365µg for 5 min before the pellet	9365
@VP	centrifuged at 365µg for 5 min before the pellet	9370
@VP	filtered using a cell strainer	9539
@VP	using a cell strainer	9548
@VP	centrifuged	9571
@VP	supplemented with Primocin -LRB- 0.1 mg/ml ; InvivoGen -RRB-	9616
@VP	were plated on culture flasks , maintained at 37 ¬ ∞ C with 5 % CO2	9679
@VP	plated on culture flasks , maintained at 37 ¬ ∞ C with 5 % CO2	9684
@VP	plated on culture flasks	9684
@VP	maintained at 37 ¬	9710
@VP	was changed every 2 d.	9758
@VP	changed every 2 d.	9762
@VP	were isolated and pipetted into the center of each well	10183
@VP	isolated and pipetted into the center of each well	10188
@VP	were obtained from postnatal day 8 rat cerebral cortices	10257
@VP	obtained from postnatal day 8 rat cerebral cortices	10262
@VP	resuspended in Neurobasal medium -LRB- Invitrogen -RRB-	10681
@VP	plating the cortical neurons	10991
@VP	were maintained for an additional 24 h.	11030
@VP	maintained for an additional 24 h.	11035
@VP	were fixed in 4 % paraformaldehyde for 15 min , washed with buffer	11079
@VP	fixed in 4 % paraformaldehyde for 15 min , washed with buffer	11084
@VP	washed with buffer	11125
@VP	were visualized with anti- -3-tubulin -LRB- 1:1500 ; Covance -RRB-	11157
@VP	visualized with anti- -3-tubulin -LRB- 1:1500 ; Covance -RRB-	11162
@VP	were conducted	11252
@VP	conducted	11257
@VP	were analyzed	11310
@VP	analyzed	11315
@VP	selected 0.1296 mm2 fields	11351
@VP	using a Zeiss LSM 510 confocal microscope for neurite outgrowth analysis	11401
@VP	were traced using Neurolucida software -LRB- v10 .31 , MicroBrightField -RRB-	11513
@VP	traced using Neurolucida software -LRB- v10 .31 , MicroBrightField -RRB-	11518
@VP	using Neurolucida software -LRB- v10 .31 , MicroBrightField -RRB-	11525
@VP	were exported to Microsoft Excel using Neurolucida Explorer 10.31	11637
@VP	exported to Microsoft Excel using Neurolucida Explorer 10.31	11642
@VP	using Neurolucida Explorer 10.31	11670
@VP	administered via facemask	11878
@VP	was made at vertebral levels T6 to L1	11921
@VP	made at vertebral levels T6 to L1	11925
@VP	were retracted	11986
@VP	retracted	11991
@VP	were performed	12041
@VP	performed	12046
@VP	to expose the spinal cord	12132
@VP	expose the spinal cord	12135
@VP	maintaining most of the lateral and ventral dura intact	12165
@VP	was completely transected at spinal level T9 ` ÄìT10 with micro-scissors	12243
@VP	transected at spinal level T9 ` ÄìT10 with micro-scissors	12258
@VP	verified that the transection was complete.Atotal	12328
@VP	was complete.Atotal	12358
@VP	continued until the end of the study -LRB- Table 1 -RRB-	12508
@VP	were harvested after a total of 12 ` Äì14 d in vitro	12569
@VP	harvested after a total of 12 ` Äì14 d in vitro	12574
@VP	were rinsed with HBSS without Ca2	12627
@VP	rinsed with HBSS without Ca2	12632
@VP	+ and dissociated with 0.25 % trypsin-EDTA	12665
@VP	and dissociated with 0.25 % trypsin-EDTA	12667
@VP	resuspended at a concentration of 100,000 cells per microliter in serumfree DMEM	12764
@VP	was made for each FB and OEC transplantation	12871
@VP	made for each FB and OEC transplantation	12875
@VP	were placed in an incubator until fully responsive and then housed individually	13240
@VP	were placed in an incubator until fully responsive	13240
@VP	placed in an incubator until fully responsive	13245
@VP	then housed individually	13295
@VP	were inspected daily for weight loss and dehydration	13461
@VP	inspected daily for weight loss and dehydration	13466
@VP	were tested weekly using Multistix 10 SG reagent strips -LRB- Siemens -RRB-	13529
@VP	tested weekly using Multistix 10 SG reagent strips -LRB- Siemens -RRB-	13534
@VP	using Multistix 10 SG reagent strips -LRB- Siemens -RRB-	13548
@VP	intracardially perfused with 4 % paraformaldehyde	13774
@VP	postfixed for 2 h at 4 ¬ ∞	13827
@VP	washed	13872
@VP	dissected	13880
@VP	cryoprotected with 30 % sucrose	13891
@VP	embedded in OCT compound -LRB- Tissue-Tek -RRB-	13927
@VP	were cryosectioned sagittally at a thickness of 25 ¬ µm	14007
@VP	cryosectioned sagittally at a thickness of 25 ¬ µm	14012
@VP	were mounted in series onto 16 slides	14078
@VP	mounted in series onto 16 slides	14083
@VP	were stored at 4 ¬ ∞ C in Millonigs buffer with azide	14121
@VP	stored at 4 ¬ ∞ C in Millonigs buffer with azide	14126
@VP	To visualize immunostaining	15042
@VP	visualize immunostaining	15045
@VP	was used	15163
@VP	used	15167
@VP	were coverslipped with Fluorogel -LRB- Electron Microscopy Sciences -RRB-	15249
@VP	coverslipped with Fluorogel -LRB- Electron Microscopy Sciences -RRB-	15254
@VP	were washed with ddH2O for 5 min and rinsed with 70 % ethanol for 5 min	15377
@VP	washed with ddH2O for 5 min and rinsed with 70 % ethanol for 5 min	15382
@VP	washed with ddH2O for 5 min	15382
@VP	rinsed with 70 % ethanol for 5 min	15414
@VP	dissolved in 100 ml of 70 % ethanol , filtered twice , Sigma-Aldrich	15518
@VP	filtered twice , Sigma-Aldrich	15554
@VP	washed with ethanol for 1 min and ddH2Ofor 5 min -LRB- Ma et al. , 2002 -RRB-	15607
@VP	followed by 15 min in 0.1 % Triton detergent buffer	15746
@VP	containing 0.1 % Triton before incubation with anti-GFAP overnight	15841
@VP	amplified by incubation with avidin-biotin complex	15994
@VP	visualized using diaminobenzidine -LRB- Dojindo Laboratories -RRB-	16050
@VP	using diaminobenzidine -LRB- Dojindo Laboratories -RRB-	16061
@VP	were conducted blind to cell transplant type	16154
@VP	conducted blind to cell transplant type	16159
@VP	were obtained with a Zeiss LSM 510 or 800 microscope and 25 or 63 oil objective	16385
@VP	obtained with a Zeiss LSM 510 or 800 microscope and 25 or 63 oil objective	16390
@VP	To determine the survival and migration of transplanted FBs and OECs	16593
@VP	determine the survival and migration of transplanted FBs and OECs	16596
@VP	divided by the total volume of GFP within the lesion core plus stumps	16858
@VP	To determine FB and OEC filling of the lesion core	16929
@VP	determine FB and OEC filling of the lesion core	16932
@VP	to calculate volumes as described by Kubasak et al. -LRB- 2008 -RRB-	17132
@VP	calculate volumes as described by Kubasak et al. -LRB- 2008 -RRB-	17135
@VP	described by Kubasak et al. -LRB- 2008 -RRB-	17156
@VP	fill the GFAPnegative lesion volume	17244
@VP	To determine the extent of neuronal preservation	17281
@VP	determine the extent of neuronal preservation	17284
@VP	was quantified as by Takeoka et al. -LRB- 2011 -RRB-	17368
@VP	quantified as by Takeoka et al. -LRB- 2011 -RRB-	17372
@VP	To determine the preservation of axons postinjury	17612
@VP	determine the preservation of axons postinjury	17615
@VP	associated with the GFAP border in every 16th section	17723
@VP	sparing	17783
@VP	crossed the GFAP-positive border into the lesion core	17859
@VP	did not extend beyond the GFAP-positive border	18106
@VP	extend beyond the GFAP-positive border	18114
@VP	considered as zero	18154
@VP	were reported as negative lengths	18174
@VP	reported as negative lengths	18179
@VP	mean luminance measurements for Iba-1 , GFAP , and CS-56 immunoreactivity	18300
@VP	were acquired from images of every 16th section	18387
@VP	acquired from images of every 16th section	18392
@VP	gathered under identical exposure conditions	18448
@VP	using the Zen 2012 annotations/measurements feature	18564
@VP	marked by rectangles -LRB- 500,000 m2 -RRB- on the image	18657
@VP	follows	18720
@VP	were aligned with the GFAP-positive border	19136
@VP	aligned with the GFAP-positive border	19141
@VP	were avoided	19189
@VP	avoided	19194
@VP	was measured in the same Iba-1 and CS-56 zones	19241
@VP	measured in the same Iba-1 and CS-56 zones	19245
@VP	made for Iba-1 , GFAP , and CS-56 immunoreactivity	19327
@VP	were normalized to background auto-fluorescence of each sec - tion	19376
@VP	normalized to background auto-fluorescence of each sec - tion	19381
@VP	were averaged across zones for each animal	19526
@VP	averaged across zones for each animal	19531
@VP	Purified p75-NGFR-positive OECs	19597
@VP	plated at a concentration of 25,000 cells onto PLL-coated 15-mm-round coverslips	19634
@VP	left to adhere overnight	19719
@VP	to adhere overnight	19724
@VP	adhere overnight	19727
@VP	pretreated with Cell - Tracker Green CMFDA -LRB- 7 ¬ µM ; Invitrogen -RRB-	19755
@VP	allowed to recover for 24 h.	19821
@VP	to recover for 24 h.	19829
@VP	recover for 24 h.	19832
@VP	was mixed with D/F-FBS media	19969
@VP	added to OEC-coated coverslips at a final concentration of 0.1 mg/ml	19999
@VP	left to incubate at 37 ¬ ∞ C for 1 h.	20073
@VP	to incubate at 37 ¬ ∞ C for 1 h.	20078
@VP	incubate at 37 ¬ ∞ C for 1 h.	20081
@VP	rinsed with media to remove excess myelin	20124
@VP	to remove excess myelin	20142
@VP	remove excess myelin	20145
@VP	fixed with 4 % paraformaldehyde for 30 min	20167
@VP	washed three times with PBS before immunocytochemical staining	20214
@VP	blocked with normal donkey serum	20350
@VP	To visualize immunostaining	20464
@VP	visualize immunostaining	20467
@VP	were mounted onto glass slides with Fluorogel	20604
@VP	mounted onto glass slides with Fluorogel	20609
@VP	were obtained using a Zeiss LSM 510 confocal microscope and 63 objective	20658
@VP	obtained using a Zeiss LSM 510 confocal microscope and 63 objective	20663
@VP	using a Zeiss LSM 510 confocal microscope and 63 objective	20672
@VP	were averaged to obtain a mean for each animal	20787
@VP	averaged to obtain a mean for each animal	20792
@VP	to obtain a mean for each animal	20801
@VP	obtain a mean for each animal	20804
@VP	were combined into a group mean for each time point and reported as mean ¬ ± SEM	20864
@VP	were combined into a group mean for each time point	20864
@VP	combined into a group mean for each time point	20869
@VP	mean for each time point	20891
@VP	reported as mean ¬ ± SEM	20920
@VP	was conducted to compare the pooled effects of time and cell transplant groups	21098
@VP	conducted to compare the pooled effects of time and cell transplant groups	21102
@VP	to compare the pooled effects of time and cell transplant groups	21112
@VP	compare the pooled effects of time and cell transplant groups	21115
@VP	To compare group	21178
@VP	compare group	21181
@VP	means across time pointsMANOVAfollowed by a two-wayANOVAwas used	21195
@VP	pointsMANOVAfollowed by a two-wayANOVAwas used	21213
@VP	used	21255
@VP	were performed when interactions were observed	21298
@VP	performed when interactions were observed	21303
@VP	were observed	21331
@VP	observed	21336
@VP	was small	21380
@VP	was determined at * p < 0.05 , ** p < 0.01 , and *** p < 0.001	21589
@VP	determined at * p < 0.05 , ** p < 0.01 , and *** p < 0.001	21593
@VP	were present within the lesion core -LRB- asterisks -RRB-	21762
@VP	survived in the lesion core	22148
@VP	are present in the stumps -LRB- C , D , white arrows -RRB-	22200
@VP	survived at 8 weeks -LRB- data not shown -RRB-	22392
@VP	not shown	22418
@VP	formed thin tubular tracks of cells -LRB- yellow arrows -RRB-	22538
@VP	inset	22649
@VP	do not differ at other time points	22897
@VP	differ at other time points	22904
@VP	are shown in black for FBs and green for OECs in this and subsequent figures	22997
@VP	shown in black for FBs and green for OECs in this and subsequent figures	23001
@VP	shown in black for FBs	23001
@VP	green for OECs in this and subsequent figures	23028
@VP	are oriented with rostral to the left and dorsal to the top	23107
@VP	reduce neuronal degeneration	23233
@VP	identified with GFAP	23351
@VP	marked with NeuN	23407
@VP	were present in this section	23439
@VP	were measured.B	23618
@VP	were greater in FB	23904
@VP	reduce serotonergic axonal dieback	24023
@VP	cross the astroglial scar border -LRB- white arrowheads -RRB-	24384
@VP	align with OECs -LRB- white arrows -RRB-	24437
@VP	extend into the GFAP-negative lesion core -LRB- inset -RRB-	24473
@VP	to extend beyond the scar border -LRB- white arrowheads -RRB-	24664
@VP	extend beyond the scar border -LRB- white arrowheads -RRB-	24667
@VP	caudally extending 5-HT axon	24903
@VP	was greater in OEC - than FB-treated rats at 2 weeks -LRB- H -RRB-	24932
@VP	reduce inhibitory CSPGs in the lesion core	25048
@VP	facilitate astrocyte border formation	25095
@VP	show the inverse	25400
@VP	a function not found in FB-treated rats -LRB- A , white arrowheads -RRB-	25519
@VP	are displayed on the right to show distribution of each antibody	25622
@VP	displayed on the right to show distribution of each antibody	25626
@VP	to show distribution of each antibody	25649
@VP	show distribution of each antibody	25652
@VP	shown by combined Aquaporin 4 -LRB- AQP4 , cyan -RRB-	25937
@VP	interwoven with OECs -LRB- F , yellow arrowheads -RRB-	26145
@VP	appear compacted and disorganized with FBs -LRB- E , white arrowheads -RRB-	26194
@VP	-LRB- F , individual channels -RRB- by astrocytes -LRB- yellow arrowheads -RRB-	26394
@VP	reduce myelin debris at 2 , 4 , and 8 weeks postinjury	26522
@VP	is shown	26728
@VP	shown	26731
@VP	is marked with GFAP -LRB- brown -RRB- immunostaining	26765
@VP	marked with GFAP -LRB- brown -RRB- immunostaining	26768
@VP	was found in OEC-transplanted -LRB- B -RRB- rats	26957
@VP	found in OEC-transplanted -LRB- B -RRB- rats	26961
@VP	reduce immune cell activation during the first 2 weeks postinjury	27350
@VP	were not present in this section	27567
@VP	were measured	27688
@VP	measured	27693
@VP	were greater in FB - than OEC-treated spinal cords	27880
@VP	reduce immune cell infiltration into the spinal cord stumps	27969
@VP	are immunolabeled	28169
@VP	are stained -LRB- Hoechst , yellow -RRB-	28198
@VP	stained -LRB- Hoechst , yellow -RRB-	28202
@VP	are 2 -LRB- A , B -RRB- and 4 weeks -LRB- C , D -RRB- postinjury	28294
@VP	are displayed on the left	28378
@VP	displayed on the left	28382
@VP	is clearly defined -LRB- A ` ÄìD	28439
@VP	clearly defined -LRB- A ` ÄìD	28442
@VP	differs in the FB -LRB- A , C -RRB- versus OEC -LRB- B , D -RRB- sections	28589
@VP	bundle together tightly and are oriented	28857
@VP	bundle together tightly	28857
@VP	are oriented	28885
@VP	are organized more perpendicularly	28958
@VP	organized more perpendicularly	28962
@VP	shows an even -LRB- Figure legend continues . -RRB-	29074
@VP	shows an even	29074
@VP	continues	29103
@VP	improves graft survival at 2 and 8 weeks postinjury	29145
@VP	survived	29281
@VP	migrated into the lesion core -LRB- * -RRB- at 2 weeks -LRB- A , B -RRB-	29294
@VP	were maintained at 8 weeks -LRB- C , D -RRB-	29350
@VP	maintained at 8 weeks -LRB- C , D -RRB-	29355
@VP	treated rats without or with CSA -LRB- FB+CSA , orange ; OEC+CSA , purple -RRB-	29626
@VP	was larger with than without CSA administration	29740
@VP	was lower in 2 week CSA+FB	29911
@VP	means of Iba-l luminance in OEC-treated rats did not differ with CSA treatment	29982
@VP	did not differ with CSA treatment	30027
@VP	differ with CSA treatment	30035
@VP	reduces neuronal degeneration and enhances serotonergic axonal preservation	30131
@VP	reduces neuronal degeneration	30131
@VP	enhances serotonergic axonal preservation	30165
@VP	marked with white arrowheads	30473
@VP	survived in the lesion core -LRB- * -RRB-	30509
@VP	are surrounded by OECs -LRB- B , inset -RRB-	30545
@VP	surrounded by OECs -LRB- B , inset -RRB-	30549
@VP	B , inset	30569
@VP	Compared to non-CSA-treated rats	30831
@VP	crossing the scar border	30890
@VP	was greater	30915
@VP	increased in FB+CSA - and OEC+CSA	30967
@VP	treated rats at 2 weeks	31000
@VP	extending 5-HT axon and the scar border	31070
@VP	treated rats than any other treatment group -LRB- FB , FB+CSA , OEC -RRB-	31140
@VP	treated spinal cords at 2 and 8 weeks postinjury	31329
@VP	had lower levels of CSPGs than OEC+CSA	31527
@VP	treated rats at 2 weeks	31566
@VP	inset	31627
@VP	enhances OEC-mediated myelin uptake at 2 and 8 weeks postinjury	31676
@VP	treated spinal cords	31882
@VP	was present both in the stumps and lesion core of FB+CSA , but not in OEC	31946
@VP	CSA-treated spinal cords at 2 weeks postinjury	32020
@VP	treated with FB+CSA	32102
@VP	had more myelin debris present in the stumps than those treated with OEC+CSA	32122
@VP	treated with OEC+CSA	32178
@VP	show more red punctate Oil Red O-staining in FB+CSA than OEC+CSA	32260
@VP	treated	32325
@VP	engulfed MBP-positive myelin debris -LRB- red , white arrowheads -RRB- in vitro	32415
@VP	promoting abilities OECs are unique glia of the olfactory system	32578
@VP	are unique glia of the olfactory system	32603
@VP	express markers common to astrocytes , oligodendrocytes , and Schwann cells	32653
@VP	is currently available	32751
@VP	To identify transplanted cells in this study	32775
@VP	identify transplanted cells in this study	32778
@VP	generated by random transgene integration into the genome	32858
@VP	cultured from GFP-expressing rats	32940
@VP	differed from those derived from wild-type nontransgenic rats	32985
@VP	derived from wild-type nontransgenic rats	33005
@VP	examined GFP-OECs for expression of typical markers	33051
@VP	compared the growth promoting abilities of wild-type OECs with GFP-OECs	33199
@VP	promoting abilities of wild-type OECs with GFP-OECs	33219
@VP	grew long processes when cultured on laminin	33427
@VP	cultured on laminin	33452
@VP	limited outgrowth on the PLL substrate alone	33481
@VP	did not differ between OECs and GFP-OECs -LRB- p = 0.986 -RRB-	33797
@VP	differ between OECs and GFP-OECs -LRB- p = 0.986 -RRB-	33805
@VP	does not appear to alter the growth promoting effects of OECs	33880
@VP	appear to alter the growth promoting effects of OECs	33889
@VP	to alter the growth promoting effects of OECs	33896
@VP	alter the growth promoting effects of OECs	33899
@VP	promoting effects of OECs	33916
@VP	survived and migrated from the GFAP-positive rostral	34020
@VP	appeared healthy	34208
@VP	aligned into tubular networks	34419
@VP	survived primarily within the spinal cord stumps -LRB- Fig. 1C , D -RRB-	34541
@VP	transplanted with FBs	34772
@VP	survived in five of eight rats -LRB- Fig. 1E , F -RRB-	34830
@VP	had OECs in the rostral	34913
@VP	had the majority of OECs in the lesion core -LRB- Fig. 1F -RRB-	34965
@VP	compare D , F	35103
@VP	were found within the stumps	35138
@VP	found within the stumps	35143
@VP	remained in the lesion core at 8 weeks -LRB- data not shown -RRB-	35177
@VP	not shown	35222
@VP	suggest that OECs survive longer than FBs after transplantation	35245
@VP	survive longer than FBs after transplantation	35263
@VP	To estimate FB and OEC survival and migration	35310
@VP	estimate FB and OEC survival and migration	35313
@VP	divided by the total volume of GFP in the spinal cord	35408
@VP	was reported as a percentage	35462
@VP	reported as a percentage	35466
@VP	found in the lesion core -LRB- Fig. 1J ; FB 72 ¬ ± 5 % vs OEC 79 ¬ ± 4 % -RRB-	35551
@VP	was remarkable -LRB- Fig. 1J ; FB 3 ¬ ± 3 % vs OEC 14 ¬ ± 7 % -RRB-	35693
@VP	continue to migrate into the lesion core between 2 and 4 weeks	35911
@VP	to migrate into the lesion core between 2 and 4 weeks	35920
@VP	migrate into the lesion core between 2 and 4 weeks	35923
@VP	interacted in delicate trabecular-like networks -LRB- Fig. 1G ` ÄìI -RRB-	36053
@VP	To measure the extent that FBs and OECs filled the lesion core	36117
@VP	measure the extent that FBs and OECs filled the lesion core	36120
@VP	filled the lesion core	36157
@VP	reported as a percentage	36311
@VP	filled ` âà83 * 17 % of the lesion at 1 week	36341
@VP	remained -LRB- 3 * 3 % -RRB-	36408
@VP	* 3	36419
@VP	filled 34 * 6 % of the lesion volume at 1 week , and by 2 weeks	36431
@VP	contained OECs	36524
@VP	filled 8 ¬ ± 5 % of the lesion volume	36636
@VP	suggest that FBs initially fill more of the lesion core than OECs	36684
@VP	fill more of the lesion core than OECs	36711
@VP	is not maintained over time	36771
@VP	maintained over time	36778
@VP	asked whether OEC transplantation had long lasting effects on neuronal survival	36874
@VP	had long lasting effects on neuronal survival	36908
@VP	To determine whether OECs help preserve neurons	36955
@VP	determine whether OECs help preserve neurons	36958
@VP	help preserve neurons	36981
@VP	preserve neurons	36986
@VP	were combined to obtain the average neuron-free distance in the stumps	37304
@VP	combined to obtain the average neuron-free distance in the stumps	37309
@VP	to obtain the average neuron-free distance in the stumps	37318
@VP	obtain the average neuron-free distance in the stumps	37321
@VP	did not differ between transplant groups at 4 weeks	37941
@VP	differ between transplant groups at 4 weeks	37949
@VP	ensheathed by GFP-positive OECs	38026
@VP	promotes neuronal survival in the stumps	38126
@VP	protects the surviving neurons within the lesion core	38171
@VP	to seal off the lesion	38390
@VP	seal off the lesion	38393
@VP	could provide routes for regenerating axons	38468
@VP	provide routes for regenerating axons	38474
@VP	To assess whether or not OEC transplantation could preserve axons	38532
@VP	assess whether or not OEC transplantation could preserve axons	38535
@VP	could preserve axons	38577
@VP	preserve axons	38583
@VP	descending serotonergic -LRB- 5-HT -RRB- axons	38639
@VP	exhibiting rostrocaudally	39130
@VP	orientated processes that effectively provide ` Äúpathways ` Äù	39156
@VP	provide ` Äúpathways ` Äù	39194
@VP	oriented perpendicular to the rostrocaudal axis	39320
@VP	limit the extension of 5-HT axons into the lesion core -LRB- Fig. 3A , B -RRB-	39383
@VP	aligned with astrocytes and crossed the scar border	39501
@VP	aligned with astrocytes	39501
@VP	crossed the scar border	39529
@VP	crossed the rostral border in OEC - than FBtreated rats	39835
@VP	preserve 5-HT axons	39984
@VP	to promote the extension of 5-HT axons into the lesion core	40071
@VP	promote the extension of 5-HT axons into the lesion core	40074
@VP	crossed the astrocyte border	40177
@VP	were found in the lesion core of OEC - than FBtreated rats	40245
@VP	found in the lesion core of OEC - than FBtreated rats	40250
@VP	could not be clearly distinguished	40334
@VP	be clearly distinguished	40344
@VP	clearly distinguished	40347
@VP	measured the area of the lesion core that contained 5-HT axons	40373
@VP	contained 5-HT axons	40415
@VP	assessed how far into the lesion core the 5-HT axons persisted	40591
@VP	persisted	40644
@VP	indicated by a negative value	41010
@VP	extended beyond the astroglial scar border	41198
@VP	aligned with OECs -LRB- Fig. 3E -RRB-	41241
@VP	used anti-NF-H to identify axons in the injury site	41278
@VP	to identify axons in the injury site	41293
@VP	identify axons in the injury site	41296
@VP	extended past the rostral scar border at 4 weeks -LRB- Fig. 3F -RRB-	41399
@VP	projected into the lesion core -LRB- Fig. 3F -RRB-	41549
@VP	preserve axons in the lesion core	41633
@VP	reduce axonal dieback compared with FBs	41668
@VP	to provide pathways for axons to enter the lesion core	41762
@VP	provide pathways for axons to enter the lesion core	41765
@VP	to enter the lesion core	41792
@VP	enter the lesion core	41795
@VP	To determine whether OECs modify the inhibitory environment of the injury site	41868
@VP	determine whether OECs modify the inhibitory environment of the injury site	41871
@VP	modify the inhibitory environment of the injury site	41894
@VP	asked if they could reduce inhibitory factors , such as CSPGs and myelin debris	41951
@VP	could reduce inhibitory factors , such as CSPGs and myelin debris	41965
@VP	reduce inhibitory factors , such as CSPGs and myelin debris	41971
@VP	To examine the difference in CSPG expression over time	42501
@VP	examine the difference in CSPG expression over time	42504
@VP	compared CS-56 immunoreactivity at different time-points	42560
@VP	was measured from the same regions in each section	43273
@VP	measured from the same regions in each section	43277
@VP	did not differ between FB and OEC groups -LRB- data not shown -RRB-	43328
@VP	differ between FB and OEC groups -LRB- data not shown -RRB-	43336
@VP	not shown	43375
@VP	demonstrates differences in CSPG levels between FB and OEC transplanted rats	43456
@VP	assessed if the areas occupied by transplanted FBs or OECs	43542
@VP	showed different levels of CSPG luminance in the lesion core and stumps	43601
@VP	was disrupted in FB-transplanted rats	43972
@VP	disrupted in FB-transplanted rats	43976
@VP	overlapped with the presence of FBs than OECs -LRB- Fig. 4A , B -RRB-	44045
@VP	encircled	44167
@VP	reduce inhibitory CSPGs at the injury site compared with FBs	44269
@VP	seen in FB-treated rats	44370
@VP	identified with both AQP4 and GFAP -LRB- Wanner et al. , 2013 -RRB-	44526
@VP	have a palisading arrangement and intermingle with OECs -LRB- Fig. 4F -RRB-	44797
@VP	have a palisading arrangement	44797
@VP	intermingle with OECs -LRB- Fig. 4F -RRB-	44831
@VP	interact with FBs	44897
@VP	overlap with highly fibronectinpositive areas -LRB- Fig. 4E -RRB-	44915
@VP	imply that the astroglial scar border forms improperly after FB transplantation	45109
@VP	could alter the presence of myelin debris in and around the injury site	45216
@VP	alter the presence of myelin debris in and around the injury site	45222
@VP	stain that identifies neutral lipids including myelin debris	45323
@VP	identifies neutral lipids including myelin debris	45334
@VP	found more punctate Oil Red O-staining in FB - than OEC-treated rats	45402
@VP	appeared more abundant in the stumps	45621
@VP	mediate the survival of neurons and limit dieback of 5-HT axons	46178
@VP	survive 8 weeks after injury	46261
@VP	peaks at 1 and 8 weeks after a spinal cord injury -LRB- Beck et al. , 2010 -RRB-	46373
@VP	evaluate the interactions between transplant survival and activated microglial	46447
@VP	evaluate the interactions between transplant survival	46447
@VP	activated microglial	46505
@VP	were analyzed	46643
@VP	analyzed	46648
@VP	differ between FB	46838
@VP	OEC-transplanted rats at 1 , 2 , 4 , and 8 weeks -LRB- data not shown -RRB-	46861
@VP	not shown	46913
@VP	was delayed between 1 and 2 weeks in the rostral	47399
@VP	delayed between 1 and 2 weeks in the rostral	47403
@VP	compare slopes in B , D to C , E -RRB-	47494
@VP	were similar between the FB andOECgroups -LRB- Fig. 6B ` ÄìE -RRB-	47585
@VP	delineated in Figure 6A and never differed between FB and OEC groups	47708
@VP	delineated in Figure 6A	47708
@VP	never differed between FB and OEC groups	47736
@VP	not shown	47783
@VP	suggest that OECs delay	47808
@VP	reduce the initial activation of Iba-1-positive immune cells	47836
@VP	did not vary with FB or OEC transplantation	47935
@VP	vary with FB or OEC transplantation	47943
@VP	revealed differences	48020
@VP	was well defined by 2 weeks postinjury in all transplanted rats	48069
@VP	defined by 2 weeks postinjury in all transplanted rats	48078
@VP	varied by transplant group -LRB- Fig. 7A ` ÄìD -RRB-	48194
@VP	appeared disorganized	48277
@VP	encircled	48520
@VP	was disrupted in FB	48703
@VP	disrupted in FB	48707
@VP	varied by cell transplantation type	48850
@VP	had a greater difference in mean Iba-1 luminance than OEC-treated spinal cords	49034
@VP	To control for the Iba-1 luminance	49269
@VP	control for the Iba-1 luminance	49272
@VP	were measured	49340
@VP	measured	49345
@VP	again showed that FB - and OEC-treated rats did not differ -LRB- Fig. 7F -RRB-	49358
@VP	did not differ -LRB- Fig. 7F -RRB-	49401
@VP	differ -LRB- Fig. 7F -RRB-	49409
@VP	integrate well with the astroglial scar	49545
@VP	reduce immune cell activation and infiltration compared with FBs	49589
@VP	using cyclosporine-A	49673
@VP	is due to immune-mediated rejection of the transplanted cells	49845
@VP	To determine whether immunosuppression would enhance OEC survival	49908
@VP	determine whether immunosuppression would enhance OEC survival	49911
@VP	would enhance OEC survival	49947
@VP	enhance OEC survival	49953
@VP	was administered to the rats before and throughout the study	49979
@VP	administered to the rats before and throughout the study	49983
@VP	enhanced the survival of both FBs and OECs at 2 and 8 weeks -LRB- Table 1 -RRB-	50055
@VP	compare Figs. 8A , B , 1C , D	50268
@VP	migrated into the lesion core -LRB- Fig. 8E ; FB84 10 % , OEC75 4 % -RRB-	50358
@VP	was due to suppression of the innate immune response after CSA administration	51044
@VP	measured Iba-1 luminance levels as in Figure 6A	51126
@VP	reduced the innate immune response after spinal cord transection	51911
@VP	prolonged the survival of both FBs and OECs at the 2-week time point	51980
@VP	To determine whether CSA-enhanced OEC survival promotes a beneficial response	52115
@VP	determine whether CSA-enhanced OEC survival promotes a beneficial response	52118
@VP	promotes a beneficial response	52162
@VP	assessed neuronal preservation	52203
@VP	not shown	52519
@VP	did not differ with CSAenhanced OEC survival	52588
@VP	differ with CSAenhanced OEC survival	52596
@VP	compare Figs. 9B , 2B	52761
@VP	asked if axons were preserved in the lesion core	52792
@VP	were preserved in the lesion core	52807
@VP	preserved in the lesion core	52812
@VP	survived to 8 weeks after injury and CSA treatment	52855
@VP	reported in our 4-week observation -LRB- Fig. 3F -RRB-	53001
@VP	associated with OECs in the lesion core at 8 weeks -LRB- Fig. 9C -RRB-	53085
@VP	provide a bridge for axons to grow into the lesion core ,	53360
@VP	to grow into the lesion core	53387
@VP	grow into the lesion core	53390
@VP	also may play some functionally supportive role within the lesion core	53421
@VP	play some functionally supportive role within the lesion core	53430
@VP	could preserve axons and promote axon regeneration	53621
@VP	preserve axons and promote axon regeneration	53627
@VP	preserve axons	53627
@VP	promote axon regeneration	53646
@VP	identified raphespinal tract axons	53676
@VP	analyzed	53715
@VP	crossed the border	53754
@VP	contains 5-HT axons	53811
@VP	extending 5-HT axon	53893
@VP	crossed the border compared with OEC-treatment alone	54255
@VP	increased in the FB	54646
@VP	¬ ± CSA 361 ¬ ± 137 ¬ µm , p = 0.0089	54936
@VP	promoted 5-HT axon preservation in FB-treated rats only at 2 weeks postinjury	54992
@VP	Combined	55071
@VP	promotes the extension of 5-HT axons beyond the scar border	55129
@VP	preserves these axons in the lesion core longer	55228
@VP	observed with non-CSA-treated rats	55455
@VP	were combined	55703
@VP	combined	55708
@VP	treated with OEC ¬ ± CSA	56036
@VP	were lower in FB	56224
@VP	reduce CSPG levels over time at the lesion site regardless of CSA treatment	56545
@VP	assessed levels of Oil Red O staining in FB	56639
@VP	to see whether immunosuppression altered the presence of myelin debris	56726
@VP	see whether immunosuppression altered the presence of myelin debris	56729
@VP	altered the presence of myelin debris	56759
@VP	compare Figs. 10A ` ÄìD , 5A , B , E , F	56939
@VP	observed in 8 week FB - and OEC-treated spinal cords -LRB- Fig. 10c , d -RRB-	57011
@VP	was found in the lesion core	57115
@VP	found in the lesion core	57119
@VP	asked if OECs could facilitate the clearance of myelin in vitro	57447
@VP	could facilitate the clearance of myelin in vitro	57461
@VP	facilitate the clearance of myelin in vitro	57467
@VP	To test whether OECs could engulf myelin particles	57512
@VP	test whether OECs could engulf myelin particles	57515
@VP	could engulf myelin particles	57533
@VP	engulf myelin particles	57539
@VP	added isolated myelin to cultured OECs	57567
@VP	isolated myelin to cultured OECs	57573
@VP	to cultured OECs	57589
@VP	cultured OECs	57592
@VP	may be responsible for the removal of inhibitory myelin debris postinjury	57758
@VP	be responsible for the removal of inhibitory myelin debris postinjury	57762
@VP	form a layered scar and create an inhibitory environment at the lesion site	57991
@VP	form a layered scar	57991
@VP	create an inhibitory environment at the lesion site	58015
@VP	directly preserve neurons and 5-HT axons in the lesion core	58263
@VP	reduce inhibitory CSPGs and myelin debris	58324
@VP	limit immune cell infiltration to reduce secondary tissue damage	58371
@VP	to reduce secondary tissue damage	58402
@VP	reduce secondary tissue damage	58405
@VP	was used to enhance OEC survival	58446
@VP	used to enhance OEC survival	58450
@VP	to enhance OEC survival	58455
@VP	enhance OEC survival	58458
@VP	were reduced	58535
@VP	reduced	58540
@VP	enhanced the survival of neurons	58580
@VP	mediate axon regeneration by providing a growth permissive substrate	58766
@VP	providing a growth permissive substrate	58795
@VP	modify the inhospitable lesion site environment	58840
@VP	limit further cell loss	59014
@VP	restrict the spread of inflammation	59039
@VP	alter astrocyte barrier formation	59193
@VP	transplanted with OECs	59324
@VP	disorganized	59401
@VP	to sequester immune cells	59425
@VP	sequester immune cells	59428
@VP	invading fibroblasts , or CSPG-positive cells within the spinal cord stumps	59452
@VP	interfering with the astrocytic scar formation	59638
@VP	intermingled with astrocytes	59711
@VP	did not interfere with sequestration of invading peripheral cells	59744
@VP	interfere with sequestration of invading peripheral cells	59752
@VP	invading peripheral cells	59784
@VP	peaked at 2 weeks in FB	59849
@VP	can integrate and migrate with astrocytes in vivo	59951
@VP	integrate and migrate with astrocytes in vivo	59955
@VP	were added to an in vitro scar-like culture model	60175
@VP	added to an in vitro scar-like culture model	60180
@VP	did not alter astrocytic reactivity	60230
@VP	alter astrocytic reactivity	60238
@VP	formed around meningeal fibroblasts -LRB- Khankan et al. , 2015 -RRB-	60302
@VP	to bridge the lesion core following spinal cord injury	60417
@VP	bridge the lesion core following spinal cord injury	60420
@VP	facilitate reactive astrocyte border formation	60503
@VP	may contribute to the re-establishment of the glial limitans	60554
@VP	contribute to the re-establishment of the glial limitans	60558
@VP	to limit invading cells -LRB- Herrmann et al. , 2008 -RRB-	60708
@VP	limit invading cells -LRB- Herrmann et al. , 2008 -RRB-	60711
@VP	invading cells -LRB- Herrmann et al. , 2008 -RRB-	60717
@VP	is reminiscent of our FB-treated spinal cords	60946
@VP	involved in STAT3-signaling	61222
@VP	are CNTF , LIF , and IL-6 -LRB- Stahl and Yancopoulos , 1994 -RRB-	61250
@VP	is a time-dependent , multiphasic inflammatory response in which	61910
@VP	macrophages first peak at 7 d and then at 60 d after a spinal cord contusion	61974
@VP	was delayed in OEC - versus FB-treated rats	62135
@VP	delayed in OEC - versus FB-treated rats	62139
@VP	may have contributed to the prolonged survival of OECs compared with FBs	62211
@VP	have contributed to the prolonged survival of OECs compared with FBs	62215
@VP	contributed to the prolonged survival of OECs compared with FBs	62220
@VP	reducing macrophage infiltration	62350
@VP	limiting myelin debris	62384
@VP	preserving neurons close to the scar border	62412
@VP	is unclear how OECs support neurons in the lesion core	62460
@VP	support neurons in the lesion core	62480
@VP	is likely , because these neurons are completed surrounded by OECs	62549
@VP	are completed surrounded by OECs	62582
@VP	completed surrounded by OECs	62586
@VP	surrounded by OECs	62596
@VP	can directly protect neurons independent of the astrocyte scar border	62640
@VP	protect neurons independent of the astrocyte scar border	62653
@VP	blocks T-cell activation	62748
@VP	regulates other immune cells -LRB- Ho et al. , 1996 -RRB-	62777
@VP	were found in the lesion core of OEC CSA , but not FB CSA-treated rats	62967
@VP	found in the lesion core of OEC CSA , but not FB CSA-treated rats	62972
@VP	preserve neurons by a different mechanism than CSA	63066
@VP	combined with the direct presence of OECs	63348
@VP	protected neurons in the lesion core	63391
@VP	maintained 5-HT axons in the lesion core	63563
@VP	infiltrating blood-derived macrophages	63636
@VP	FBcompared with OEC-treated rats at the peak time of immune infiltration	63815
@VP	reducing the axonal dieback caused by immune infiltration	63994
@VP	caused by immune infiltration	64022
@VP	express multiple axon guidance and adhesion molecules	64466
@VP	is likely that these OEC-axonal interactions may both orient axons	64524
@VP	may both orient axons	64569
@VP	both orient axons	64573
@VP	enhance their growth postinjury	64595
@VP	aligned with palisading astrocytic processes	64670
@VP	extended beyond the scar border when directly aligned with OECs	64719
@VP	aligned with OECs	64765
@VP	formed OEC-lined conduits surrounded by a fibronectin-rich matrix	65096
@VP	surrounded by a fibronectin-rich matrix	65122
@VP	were ensheathed	65276
@VP	ensheathed	65281
@VP	promoting astrocyte bridges and OEC-lined conduits	65396
@VP	well known feature of the inhibitory glial scar	65508
@VP	reducing inhibitory CSPGs	65957
@VP	reduced the buildup of myelin debris in the lesion core and spinal cord stumps	65998
@VP	inhibits axon regeneration -LRB- Filbin , 2003 ; Yiu and He , 2006 -RRB-	66112
@VP	stimulates secondary damage due to inflammation -LRB- Sun et al. , 2010 -RRB-	66176
@VP	may be due to the decrease in inflammation , however	66325
@VP	be due to the decrease in inflammation , however	66329
@VP	had lower levels of myelin debris after CSA administration	66401
@VP	engulf myelin particles in vitro	66612
@VP	reduce myelin debris in vivo after a complete spinal cord transection	66646
@VP	suggest that OECs likely contribute to clearing myelin debris	66721
@VP	contribute to clearing myelin debris	66746
@VP	clearing myelin debris	66760
@VP	respond to a traumatic injury by activating complex molecular signaling cascades	66821
@VP	activating complex molecular signaling cascades	66854
@VP	generate both a chemical and mechanical barrier to axon regeneration	66961
@VP	to axon regeneration	67009
@VP	axon regeneration	67012
@VP	to provide pathways that would enhance axon outgrowth	67103
@VP	provide pathways that would enhance axon outgrowth	67106
@VP	would enhance axon outgrowth	67128
@VP	enhance axon outgrowth	67134
@VP	crossing the border	67256
@VP	was increased	67282
@VP	increased	67286
@VP	were found further into the lesion core	67312
@VP	found further into the lesion core	67317
@VP	had long lasting effects on axon regeneration	67480
@VP	Enhanced survival of OECs	67527
@VP	provided a bridge for regenerating axons to extend beyond the scar border	67553
@VP	regenerating axons to extend beyond the scar border	67575
@VP	to extend beyond the scar border	67594
@VP	extend beyond the scar border	67597
@VP	protected axons in the lesion core at later time points	67631
@VP	to create an environment that supports axonal regeneration	67857
@VP	create an environment that supports axonal regeneration	67860
@VP	supports axonal regeneration	67887
